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INTRODUCTION 
            Siddha system of medicine is the most primitive medical system which is flourished in 
the South India. This system was formulated and established about more than 25000 years 
back by the eminent persons called Siddhars and hence the name siddha medicine. 
            The fathers of siddha medicine are primordial Guru, Agathiyar. There are also 18 
prime siddhars who are the followers of the primordial Guru, contributed their valuable 
knowledge and experiences in this field. 
            Siddhars are considered as the great experts which they are highly intellectual & 
spiritual along with the supernatural person. Siddhars are well-versed in handling 4 different 
divisions which are related and inter-mingled with each other (Vadham, Vaidyam, Gnanam 
and Yogam). 
            In Siddha Chemistry had been found developed into a science auxiliary to 
MEDICINE (Vaidhiyam) and ALCHEM (Vadham).It was found usefull in the preparation of 
medicine for curing all sorts of sufferings, spiritual as well as corporeal and also in 
transmutation of basic Metals (copper) into Gold. 
           Siddha medical system doesn’t consider treatment and prevention separately. The 
main aim of this system is prevention of disease, as it is well said that “prevention is better 
than cure”.  
                                  “Medicine means the prevention of physical illness 
                                   Medicine means the prevention of mental illness 
                                   Prevention means to avert illness 
                                   Medicine therefore is the prevention of death”. 
                                                                                                    -Thirumoolar 
           Siddha medicine mostly works by revitalizing and rejuvenating the organ. This help to 
correct the dysfunctions responsible for causing the diseases. It restores the normal 
functioning of the organs and maintains the ratio of the Thodam (humours) there by 
providing a healthy state of equilibrium in the body.  
        In Siddha system of medicine, the disease “UTHIRAVADHA SURONITHAM”is 
brought under the types of vadha diseases. Here the clinical features of Rheumatoid arthritis 
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are correlated with “UTHIRAVADHA   SURONITHAM” according to the Siddhar YUGI 
MUNI classification. 
 
          Rheumatoid arthritis is an autoimmune disorder. It is a generalized chronic multi-system 
disease affecting the connective tissues of the whole body with focalized involvement of the 
musculoskeletal system. It is one among the important collagen disease. It is considered to be an auto 
immune response to an unknown antigen and antibody formed in rheumatoid factor which is 
identified as DR4. 
 
           Rheumatoid arthritis is widely prevalent throughout the world. The overall worldwide 
prevalence is 0.8%, in adult Indian population, prevalence rate is 0.75%. Occur most common in 
tropical areas. 80% women’s were affected. Women are 2 to 3 times more common than males. Male 
Female ratio - 1:3. About 25- 50years of age are affected.  
            Since RA is a chronic disease, NSAID drugs can reduce the pain and inflammation but do not 
slow down the progression of joint damage. In  modern  medicine, recently approved  DMARD 
Leflunomide an immunomodulator drug  which limits  irreversible joint damage by arresting the 
growth of activated lymphocytes(which induce inflammation in joints).Comparing with NSAID, the 
Leflunomide have high potential effect on managing the signs and symptoms of  RA but it shows 
some side effects also (Alopecia, Diarrhoea, Elevated liver enzymes and allergic rashes).  
             The medicine were prepared by the various research work done by the siddhars on herbs, 
minerals and animals.More than 80% of medicine formulated by herbal products but in certain life 
threatening diseases and in many chronic diseases, the herbal medicines alone have not been much 
effective. In such conditions, siddhars enumerated some herbo-mineral formulation. 
            For this reason I chosen the Siddha Herbo -mineral formulatory drug “RAJALOGA 
NAATHARASA PARPAM” (Internal) mentioned in “PRANARASHAMIRTHA SINDHU” Page 
no:185 which have  IMMUNOMODULATOR & ANTI - INFLAMMATORY ACTIVITY in its 
ingredients and PARUTHI THYLAM (External) mentioned in “NOI NEEKKUM THYLANGAL  
SEYMURAIGAL” Page no:87  along with MARIKOZHUNTHU OTTRADAM ( External 
Therapy) mentioned in “GUNAPADAM MOOLIGAI” Page no:733 for the study of 
‘UTHIRAVADHA SURONITHAM’. 
             So it is considered to evaluate a Siddha herbo- mineral formulation drug “RAJALOGA 
NAATHARASA PARPAM” (Internal) and “PARUTHI THYLAM” (External) and 
“MARIKOZHUNTHU OTTRADAM” (External Therapy) is efficacy and safety for the disease 
“UTHIRAVADHA SURONITHAM” (Rheumatoid arthritis). 
  
2. aim 
And 
objectives 
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AIM & OBJECTIVES 
 
AIM:  
To evaluate the therapeutic efficacy of siddha trail drugs “Rajaloga naatharasa parpam” 
(Internal), “Paruthi thylam” (External) and “Marikozhunthu Ottradam” (External 
Therapy) on Uthiravadha Suronitham [Rheumatoid arthritis] 
 
OBJECTIVES:  
PRIMARY OBJECTIVE:  
To  evaluate  the  therapeutic efficacy  of  Rajaloga naatharasa parpam [Internal], Paruthi 
thylam [External]  and  Marikozhunthu Ottradam [External therapy]  in Uthiravadha 
Suronitham [Rheumatoid arthritis] 
 
SECONDARY OBJECTIVE:  
 To Standardize the standard operating procedure for both siddha trail drugs. 
Standardization through both traditional modern analytical techniques  
 Evaluation of acute and sub- acute toxicity studies for the trail drug “Raajaloga 
naatharasa parpam” . 
 To evaluate the pharmacological activity Anti-inflammatory and 
Immunomodulatory of the trail drug Raajaloga naatharasa parpam in animal 
model.  
 To evaluate the safety of the trail drug Raajaloga naatharasa parpam in thiravadha 
Suronitham patients before and after treatment.  
 To have clinical trial drugs “Raajaloga naatharasa parpam” (int) and 
“Paruthithylam” (ext) in the treatment of “Uthiravadha Suronitham ”.  
 To demonstrate the methodology of Ottradam therapy in treating Uthiravadha 
Suronitham. 
 To create a knowledge about the siddha medicine and prove the efficacy of siddha 
drug for the disease of Uthiravadha Suronitham [Rheumatoid arthritis]. 
  
3. review 
of 
literature 
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3.REVIEW OFLITERATURE 
3.1.SIDDHA ASPECT 
 
         Man according to siddha system is production of divine mind and thought produced 
essence of the five elements, sole of the stars, and the spirit which is the stellar  and 
temporal sides of magnumlimbus from the matrix of nature formed of seven layers of 
tissues. 
         These five elements together constitute the human body and origin of other material 
objects are explained as Pancheekaranam (Mutual Intra Inclusion). None of these 
elements could act independently by themselves. They could act only in 
coordinationwithotherfourelements.Allthelivingcreaturesandthenon-livingthings are made 
up of these five basic elements. The five basic elements form the connecting link between 
the Microcosm (Man) and Macrocosm (World). Any change in the universe due to 
natural or unnatural causes will create changes in human systems. 
“                    
                ” 
        -                      
           Again it is said, like the universe man is composed of five elements such as earth, 
water, air, fire, ether. Therefore life force is the basis for man‟s mental and spiritual 
activities on that nature may evolve him towards perfection. 
 The earth gives shape to the body and release Sits energy, Bones, muscles, and 
tissues represent if in the body. 
 Water makes the earth supple and helps in the transmission of energy, serum, 
lymph, saliva etc. represent it in the body. 
 Fire makes the form of the body steady and gives vigour and stimulation. 
Digestion and circulation represent it in the body. Air ignites the fire and works 
as a life carrier and is the support of all contact and exchange. Respiration and 
Nervous system represent it in the body. 
 Ether is the creator of life itself in the body. A harmonious combination and 
function of these elements in the body produce a healthy and beautiful life. 
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THE 96 BASIC PRINCIPLES ( 96 Thathuvam ) 
 According to Siddha system of medicine, „Thathuvam‟ is considered as a 
science that deals with basic functions of the human body. Siddhars described 96 
principles as the basic constituent so human body that include physical, physiological, 
psychological and intellectual components of an individual. These 96Thathuvams are 
considered to be the cause and effect of our physical and mental well-being. The 
Thathuvam is the author of the conception of human embryo on which the theory of 
medicine is based. 
 There are in our body several supports to the soul for the existence and 
sustenance of life and they are the five elements (Earth, Water, Fire, Air, Ether), the six 
plexus, the three humors (mukkuttram), 72,000 blood vessels and nerves etc.. 
Constituting in all 96 thathuvas i.e constitute principles in nature. These three humours 
(vatham, pitham, kabham) plays a major role in the body and their function remain in 
the balanced state in a normal healthy person and disturbance in their equilibrium leads 
to the development of diseases in the body. 
 If the siddha medicine is to accomplish its real mission it must start a 
double movement of revival and reform. It must to revive its tridoshic theory on which 
the whole ancient medicine is based. 
“                          
                    
                      
                    
                          
                    
                      .” 
                                   -                             
  Man develops three distinct, personalities namely the mind and the vital or 
life force and the body. Through the mind he thinks and wills; through the vitalor life 
force he executes his thought and will; through the physical body he expresses what he 
thinks and wills. The mind is vatha, vital or life force is Pitha, and the body is kabha.  
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 Vatha, pitha, kabha have multiple significances and symbolical in terms. 
 Vatha represents Vayu, mind, dryness, pain, flatulence, sensitiveness, lightness, 
and also air. 
 Pitha represents gastric juice, bile energy heat, inflammation, anger and irritation, 
etc... 
 Kabha represents feeling of cold, heaviness, running of the nose, passing mucoid              
 Discharge and also the saliva. 
They are also formed by the combination of the five basic elements. 
 Accordingly Vali is formed by the combination of Vali (Air) and Aagayam 
(Space). This is the Creative force. Azhal is formed by Thee (Fire).This is the Force of 
Preservation. Iyyam is formed by Mann (Earth) and Neer (Water). This is the Destructive 
Force. These three humours are in the ratio 4:2:1 in equilibrium which is a healthy 
normal Condition. They are called as the life forces or humours. 
THE FORMATION OF UYIR THATHUKKAL: 
1.The Vali naadi is formed by the combination of Abanan and Idagalai. 
2.The Azhal naadi is formed by the combination of Piranan and Pinkalai.  
3.The Iyya naadi is formed by the combination of Samanan and 
Suzhumunai. 
 Vaatham – Ten types 
 Pitham- Five types 
 Kabam- Five types 
(a) Five forms of vadha: 
 These are the five main centres of the subtle physical body and correspond to the 
nervous plexuses of the gross physical body. 
 Matedial of muladhar centre (     ): This centre corresponds to the pelvic 
plexus and is the seat of kundalini or material energy and controls excretions 
 Navel centre(     ):This corresponds to the solar plexus in the 
navel region and controls digestion. 
 Heart centre (      ):This refers to the cardiac plexus in the Heart 
and circulation. 
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 Throat Centre (     ): This corresponds to the pharyngeal plexus in the 
throat region and control breathing and speech. 
 Forehead centre (     ): This corresponds to the Naso-ciliary plexus at the 
root-of the nose and base of the skull and control “will”. 
(b)Five forms of pitha: 
 Gastric juice (     ):This give appetie and helps Digestion. 
 Bile (       ):which gives complexion to the skin. 
 Haemoglobin (      ): which colours  the blood. 
 Aqueous Humour (       ):Which brightens the eyes 
 Lifeenergy (     ):Which controls the whole body. 
(c) Five form of kapha: 
 Saliva (      ): Which helps mastication 
 Cerebrospiral fluid (     ): Which keeps the head cool 
 Lymph (      ): Which gives taste 
  Serum (       ):Which helps the Heart in pumping 
 Synovial fluid (     ): Which lubricate and aids free movement of the joints 
The three humours of vatha, pitha and kapha which are absorbed and circulated in the 
blood have each certain definite qualities: What are they actually, 
1.VADHAM 
   (Ownqualities-6)                       (Oppositequalities-6) 
Vatha is dry-       Unctuous -      
Vatha is cold –           Hot-      
              Vatha is subtle-          Solid-      
Vatha is rough-          Soft -    
Vatha is unstable-           Stable -     
Vatha is lite-        Heavy -    
All this qualities are present in Air and hence air we inhale is Vadha 
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2.PITHAM 
      (Ownqualities-6)- (Oppositequalities-6)- 
Pitha is hot-      Cold-        
Pitha is acid-      Sweet -     
Pitha is mobile-      Immobile -         
Pitha isliquid-      Solid -       
Pitha is acute-     Mildorharmless-      
Pitha is pungent-     Bitter –     
 All this qualities are present in the gastric juice and hence the gastric juice is Pitha. 
3. KABAM 
         (Ownqualities-6)- (Oppositequalities-6)- 
    Kapha is cold-        Hot-      
    Kapha is heavy-    Lite –    
    Kapha is immobile -        Mobile –       
    Kapha is sweet-     Pungent-     
    Kapha is soft-    Rough-     
    Kapha is unctuous-    Dry –      
    Kapha is viscid-       Sandy -       
All this qualities are present in in Saliva so Saliva is Kapha. 
VADHAM: 
The term Vadham denotes Vayu, pain, dryness and flatulence. Vadham is responsible for 
respiration and control of all movements. 
Location -Abanan, Faeces, Idakalai, Pelvic bone, spermatic cord, skin, nerves, joints, 
hairs and muscles. 
 Character -It governs the other two basic elements and responsible for all physical 
process in general. For this reason, disturbance in vadha tend to have more severe 
implication than the other two humours and other affect the mind as well as entire 
physical body and also responsible for respiration. 
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Functions -Pain in the whole body, twitching, pricking pain, inflammation, reddish 
complexion, and roughness of skin, hardness of limbs, astringent sense of taste 
inthemouth,constipation,andoliguria,blackishdiscolorationofskin,stool,urineand muddy 
conjunctiva. 
So for 4448 diseases are classified by Agasthiyar rathina surukkam naadi and in this 
Vadha diseases are classified as 84 types 
“                    
                        
                      ” 
Vadham or vali is not mere wind, but also that causes motion, energy, and sensation of 
every cell in the body. Vali relates to the nerve force. It is responsible for all movements 
in the mind and the body. 
In human body the locomotors activity functions through voluntary muscles and its 
activities controlled by nerves system called Kanmendhriyam, likewise the sensation and 
its activities are known as Gnanendhriyam. These types of activities are governed by 
valikutram among the mukkutram. 
LOCATION OF VADHA HUMOUR: 
 Below the navel region(umbilicus) 
 Urinary bladder, motion, Spermatic cord, Umbilical cord, thigh, bone, skin, 
nerves, joints, muscles, hair follicles, pelvis, ear. 
               :        
NATURAL PROPERTIES OF VADHAM: 
“                           
                          
                         
                   .” 
            -            ,                   (    140) 
 
 Functioning of mind throughout the body 
 Giving briskness 
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 Making the uniform functioning of seven udal kattugal 
 Protection and strengthening of five sensory organs. 
 Regulation of fourteen physiological reflexes. 
 
QUALITIES OF VADHAM: 
“                         
                      
                          
            ”. 
                                     -        (    21) 
Own qualities-6 
Vadham is dry  -      
Vadham is cold  -        
Vadham is subtle  -       
Vadham is rough  -     
Vadham is unstable  -       
Vadham is lite  -    
            “                           
                                    
                                 
                      .” 
                                            -        (    22) 
Oppositequalities-6 
Unctuous –      
Hot         –      
Solid      –      
Soft        –     
Stable     –     
Heavy    –     
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VARIETIES OF VADHAM 
             “                            
                           
                            
                       ”. 
        -                       -142  
VAAYU – 10 (VITAL NERVE FORCE WHICH IS RESPONSIBLE FOR ALL 
KINDS OFMOVEMENTS) 
1.Uyirkaal (Piraanan) 
 This is responsible for the respiration of the tissues, controlling knowledge, mind and 
five sense organs and digestion of the food taken in. 
2.Keel nokkukaal (Abanan) 
It lies below the umbilicus. It is responsible for the downward expulsion of stools and 
urine, ejaculation of semen and menstruation. 
3.Paravukaal (Viyanan) 
This is responsible for the motor and sensory function of the entire body and the 
distribution of nutrients to various tissues. 
4.Maelnokkukaal (Uthanan) 
 ItoriginatesatUtharakini.Itisresponsiblefordigestion,absorptionanddistribution of food. It 
is responsible for all the upward movements. 
5.Samaanan (Nadukaal) 
This is responsible for the neutralization of the other 4Valis i.e. Piranan, Abanan, 
Viyanan and Uthanan. More over it is responsible for the nutrients and water balance of 
A the body. 
6.Naagan 
 It is a driving force of eye balls responsible for movements.     
7.Koorman 
It is responsible for the opening and closing of the eyelids and also vision. It is 
responsible for yawning. 
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8.Kirukaran 
It is responsible for the salivation of the tongue and also nasal secretion. Responsible for 
cough and sneezing and induces hunger. 
9. Devathathan 
This aggravates the emotional disturbances like anger, lust, frustration etc. As emotional 
disturbances influence to a great extent the physiological activities, it is responsible for 
the emotional upsets. 
10. Dhanancheyan 
Expelled three days after the death by bursting out of the cranium. It is responsible for 
edema, plethora and abnormal swelling in the body in the pathological state. 
As per yugi vaithiya cindhamani 
        “                    
                           
          …………………………………………. 
 
                           
                                        …………              ” 
AETIOLOGY OF VADHA DISEASES: 
According to yugi vaithya cindhamani 
“                      
                        
                           
                        
                          
                        
                         
                       ” 
 “                        
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                        ”. 
 
• Excessive sexual indulgence 
• Over consumption of bitters, astringents and rancid foods. 
• Drinking rainwater 
• Day time sleep 
• Night timework 
• Starvation 
• Lifting overweight 
• Will initiate and aggravate vali 
 
As per Konganavar Vadha Kaviyam 
“                             
                          
                           
                         
                          
                        
                          
                       ” 
 
            : 
“                                    
                                  
                                   ” 
• Excessive exposure to the sun 
• Excessive intake of water 
• Postponed of proper intake of food 
• Excessive intake of bitter gourd 
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According to Agathiyar Kanma Kaandam 
             “                         
                          
                       
                     
                     
                             
                                 ” 
• cutting trees and barks 
• Breaking the legs of living animals 
• cutting the leaves of living trees 
According to Agathiyar Gunavagadam, 
            “                          
                            
                          
                      
                       ” 
• Muscular diseases 
• Menorrhagia 
• Consumption of improper preparation of metallic compounds like mercury and 
lead will cause vadha diseases 
CHARACTERISTIC FEATURES OF VATHA DISEASE: 
1. As per Theraiyar Vaagadam: 
“                                  
                                        
                                     
                                         ”. 
  
• Loss of appetite 
• Pain and redness 
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• Fever and cough 
• Insomnia 
• Shivering 
• Hyperpyrexia 
 
              “                                         
                                          
                                       
                                    ” 
 
• Chillness of the body 
• Rigor and spasm 
• Pain and tenderness of joints 
• Swelling of the joints. 
             “                               
                         ” 
-                           
• Pain in the upper and lower limbs, pain in the costochondral junctions will be 
seen in vadham diseases. 
“                                  
............................                   ” 
-                           (1000) 
• When vadham increases it produce abdominal discomfort, pain in the hip joint 
and all the joints of upper and lower limbs, constipation and painful voiding of 
urine and stools will be seen. 
• The diseases will be precipitated in months from aani to karthigai. i.e., from June 
to December, (muthuvenil, kaar and koothirkaalam) 
“                        
                            
……………………………….                     ” 
-                       -285 
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• Indulging in sexual act during vitiation of vadham 
• Walking for long distance 
• Exposing to cold and dampness and harmful combinations like fruits vegetables 
and tubers with curd causes toxic factors which affects bones and joints 
In Aaviyalikkum Amutha murai Surukkam 
             “                       
                          
                        
                              
                           
                         
                              
                    ” 
• Fatigue, tiredness 
• Nausea 
• Loss of appetite 
• Pricking sensation all over the body 
• Pain all over the joints. 
• Diarrhoea 
• Azoospermia 
• Incontinence of urine 
• Difficulty in flexion and extension 
• Constipation 
Agathiyar 2000 
“                                    
                                     
                                     
                               ” 
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 Giddiness 
 Redness of eyes 
 Stabbing pain in the face 
 Abdominal distension 
 Joint pain in upper and lower limbs 
 Oliguria 
 Drowsiness 
 Chillness of the body 
    
                 
           “                                    
                                  
                                  
                                   ” 
 Pain in the joints 
 Headache 
 Excessive yawning 
 Constipation 
 Burning sensation of the body 
 Paralysis 
 Excessive salivation 
 Chillness and tremor 
 In kaaviyanaadi 
 “                                 ” 
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UTHIRAVADHA SURONITHAM 
“UTHIRAVADHA SURONITHAM” is one among the eighty types of vadha diseases 
described by the great siddha pathologist yugi munivar in the textbook of “YUGI 
VAIDHYA CHINDHAMANI”. 
  A form of arthritis of rheumatic origin marked by severe pain and the formation of 
inflammatory nodules in the region of the joints and especially in the limbs of the body. 
According to kathirai velpillai tamil mozhi agarathi 
        –     
         
According to sambasivam pillai dictionary 
        –     
           
           : 
A disorder of menstruation in women marked by affection in the chest and limbs extreme 
sensibility to pain, dryness in the dendrites nervous shock, accompanied by intense body 
pain. 
Therayar vaagadam: 
 “                                        
     ………………. 
(      -               ) 
The disease “suronithavatham” is occurs in the middle aged women. 
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“                                  
                                
                            
                              ” 
 Vitiation of vatha aggravates the signs and symptoms of “vatha suronitham”. 
Jeeva raksha mirtham classifies this disease into two types, 
 Pitha sonitha vatha rogam, which is soft and cause emaciation. 
 Slethuma sonitha vatha rogam has polyarthralgia and spindle shaped swelling in 
the phalanges. 
SIDDHA PATHOLOGY: 
 “                                   .............. 
                        
                           
                          
       …….………. ………….. …………….        ” 
      -        
 “                                
                     ” 
                                                                   -       
 “                         
                          ” 
                                   --                              
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NAADI PATHOLOGY: 
“                                   
                    ” 
                                                           -                   
AETIOLOGY OF SURONITHA VADHAM 
“                                       
                                 
                              
                             
                             
                             
                              
                                    ” 
 Intake of spicy food stuff 
 Intake of astringents 
 Daytime sleep Sedentary life 
 Food which decrease the absorption of iron 
 Foods which increases the body heat. 
 Riding over the elephant and horse 
All these factors will affect vatha which along with blood produces Suronitha 
vadham. 
According to para rasa sekaram: 
“                                          
                                  
                                  
                              ” 
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1.Over conception of bitters, astringents, savouries and rancid foods 
2.Intake of cold water 
3.Intake of varagu, thinai 
“                               
                                
                           
                                 ” 
 Eating of excessive intake of food 
 Starvation 
 Excessive sexual indulgence 
 Sleeping in the day time & not sleeping in the night 
 Not taking food at proper time, Decreased intake of sour and ghee 
diet increase the vadham 
“                                
                           
                                   
                            ” 
 Fear 
 Anger 
 Worry 
In textbook of siddha medicine (sabaa pathy kaiyedu) 
“                              
                                   
                                  ” 
 Intake of vadham containing food stuffs 
 Intake of cold items 
 Exposure to extreme cold air, rain and snow 
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 Hereditary 
 Stay in mountain 
CLINICAL FEATURES OF UTHIRAVADHA SURONITHAM: 
In yugi vaithiya chindhamani 
“                           
                      
                            
                       
                          
                      
                       ” 
 Swelling of the ankle and knee joints 
 Swelling of the foot 
 Pain in the fingers and toes 
 Confusion 
 Fatigue 
 Loss of appetite 
 
In Dhanvandhiri vaithiyam 
“                                  
                           
                                
                           
                                  
                                           
                                 ” 
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 Pyrexia and swelling of the body as in rat poison intoxication 
 Pain and tenderness 
 Twitching of muscles 
 Loss of sensation 
 Swelling of the wrist and phalanges 
 Black and redness of swelling due to vascular failure 
 Hyperaemia   
          : 
 “                              
                                
                             
                              ” 
According to Vaithiya Cindhamani by kannusamy 
                                  ,        , 
                                           .      
           ,    ,                         . 
 The disease name suronithavatham is also mentioned in Aaviyalikkum 
Amuthamurai Churukkam as painful and swollen joints. 
 Anubogavaithiya Deva Ragasiyam also deals with vatha diseases. Instead of 
“Uthiravaatha suronitham” it is mentioned as “Sonitha vatharogam”. 
 Jeevarakshamirtham also deals it as sonitha vaatharogam in Vaatharo gapadalam  
and the symptoms are polyarthralgia, swelling, anaemia, spindle shap1ed swelling 
in the joints. 
In pararaasasekaram 
“                                   
                                  
                                   ” 
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 Decrease in the haemoglobin level 
 Pain in the upper and lower limbs 
 Swelling especially in the peripheral joint and deformities 
 Morning stiffness present more than 1 hr. 
 
“                                 
                               
                                 
                           ” 
 
“                                
                                  
…………………..                    ” 
• Swelling of the ankle and knee joint 
• Swelling of hind foot 
• Pain in the distal interphalangeal joint 
       According to Agathiyar Ayulvedham– 1200 
 “                                        
                                    
                                       
                                  ” 
• Pain in the upper and lower limbs, forehead and cervical region. 
• Restricted joint movements. 
DIFFERENTIAL DIAGNOSIS: 
Among the 80 types of vatdha diseases mentioned in “yugi vaithiya cindhamani” the 
“Uthira vadha suronitham” is differentiated from the following types of suronitham. 
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  1.              : 
“                         
                             
…………………………………………………………… 
                        ” 
 Swelling with hyperaemia 
 Soft on touch 
 Cough 
 Pyrexia 
 Irritability 
   2.          : 
“                        
                       
      ………………………………………………………… 
                        ” 
 Emaciation 
 Swelling of joints 
 Restriction of movements 
 Anorexia 
 Excessive salivation 
 Discomfort 
3.              : 
              “                         
                           
 …………………………………………………….. 
                      ” 
 Anasarca 
 Reduced haemoglobin level 
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 Wrinkles 
 Neural pain 
 Bullous eruption as in palms 
 Glossy tongue 
 Sialorrhoea 
 Exfoliation 
 swelling 
 Warmness. 
       4.               : 
“                               
                           
 ………………………………………………………… 
                            ” 
 Hyperaemia 
 Tenderness in knee, elbow and smaller joints 
 Polyarthralgia 
 Pyrexia 
 Anaemia 
 
  5.                : 
“                         
                               
 ………………………………………………………………….. 
                            ” 
 Chillness with abdominal distension 
 Severe pain 
 Headache 
 Bronchitis with dyspnoea 
 Giddiness 
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 Dryness of mouth 
 Tachycardia 
 Syncope and Hallucination 
 Anorexia 
6.             : 
“                       
                           
 ………………………………………………………………….. 
                         ” 
 Fever with rigor 
 Dryness of mouth 
 Diarrhoea 
 Headache 
 giddiness 
 Excessive thirst 
 Loss of appetite 
 Pain all over the body 
 
IN SIDDHA - MODE OF PATHOLOGY 
VADHAM: 
 Vadham is said to be phenomenon responsible for the movements of the parts 
involved in locomotor system, hence it is responsible for the articulation of 
thejoints, tendons and muscles. 
 Bone and lower abdomen is considered to be the place for vadham. 
 Santhiga kabam is said to be the phenomenon which is responsible for the normal 
maintenance of synovial fluid. 
 Synovial fluid provides nutrition for the articular cartilages, disc, meniscus and 
there by avoids friction of the bones and erosion of the bones, it helps the 
smootharticulation. 
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 In Uthiravadha suronitham due to factors related to diet, habit, environment etc, 
adversely influence of vali and azhal mainly in mukkutram. 
 The involvement of viyanavayu and abanavayu plays a major role in the 
manifestations of signs & symptoms. Viyana is responsible for all the motor and 
sensory functions of the body and the nutrition of tissues. 
 Abananvayu is responsible for the assimilation of the nutritional factors from the 
gastro intestinal tract distribution between various thathus and expulsion of waste 
product through faeces, urination etc... 
AZHAL: 
 The azhal is responsible for the healthy maintenance of every tissue of the body 
and its variation results in inflammatory changes in the bone and other accessory 
structures like tendons, cartilage and synovial membrane which helps in perfect 
articulation of joints. 
IYAM : 
 The deterioration of iya humour leads to structural changes in the bones and the 
fluids in the joints which are mainly controlled by the factors of santhigam. 
 Disturbance in humours it produces different clinical manifestations. They Include, 
• Swelling of the joints, Pain 
• Stiffness 
• Restricted movements of the joints due to disturbed vali. 
• Inflammatory changes of the joints like redness hyperaemia, and warmness 
due to disturbed azhal and erosion of bone margin, increased synovial fluid 
due to disturbed iyam. 
• The tridosha phenomenon and the functioning of the joints. 
“                           
                                  
                               
                                ” 
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                           -             (          ,     603) 
     UYIRTHAATHUKKAL: 
These are the fundamentals and essential factors in the composition and 
constitution of the human body. 
 Vaatham(vali) 
 Pitham(azhal) 
 Kabam(iyyam) 
PINIYARI MURAIMAI (DIAGNOSIS): 
The methodology of diagnosing in siddha science is very unique and solely based on the 
clinical acumen of the physician. It is based on the three main principles, 
 PORIYAL THERTHAL 
 PULANAL THERTHAL 
 VINATHAL 
 
1. PORIYAL THERTHAL: 
Pori means sense of perception. Poriyal therthal understands by the five sense 
organs such as nose, tongue, eyes, skin, and ear. 
2. PULANAL THERTHAL: 
Pulan means objects of senses. Pulanal therthal understands by the sense objects. 
1. Smell (Manam) 
2. Taste (suvai) 
3. Vision (oli) 
4. Somatic sense (ooru) 
5. Sound (oosai) 
  In both of the above said methods, physician, pori and pulan are used as tools for 
examine the pori and pulan of the patients. 
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3. VINATHAL: 
 Vinathal is the process of obtaining the detailed history of the disease by interrogation 
the patient. By this gathering the history of disease, complaints, and duration, personal 
history, family history, clinical features, where an accurate history, is available, a disease 
can be easily diagnosed ever before clinical examinations carried out. It is the focal point 
of the “physician –patient” relationship and established the bonding necessary for patient 
cure. 
 The classified method of clinical examinations is known as ENVAGAI THERVU, 
Siddhars have devolved a unique method of diagnosing the diseases by “ENVAGAI 
THERVU” eight basic diagnostic parameters namely, 
1. Sparism 
2. Naa 
3. Niram 
4. Mozhi 
5. Vizhi 
6. Malam 
7. Moothiram 
8. Naadi 
NAADI NADAI IN UTHIRA VATHA SURONITHAM: 
Naadi diagnosis is the confirmatory diagnosis, Naadi is the inherent seat anchor of energy 
on which vibration the entire thathus of the body are functioning. 
1. Vathakapham 
2. Kaphavatham. 
        
“                        
                                
………………………………………………………………………… 
        ……………………………                    ” 
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“                          
                             
…………………………………………………………………… 
        …………………………                 ” 
DERANGEMENTS OF VATHAM IN UTHIRAVATHASURONITHAM: 
ABHANAN: Constipation, Polyuria, Menstrual disturbance 
VIYANAN: Pain and tenderness in the affected joints 
SAMANAN: Affected due to the derangements 
KOORMAN: Extra articular features 
KIRUKIRAN: Loss of appetite 
DERANGEMENTS OF PITHAM  IN UTHIRAVATHASURONITHAM 
ANALAGAM: Loss of appetite 
RANJAGAM: Anaemia 
SAADHAGAM: Disturbance in regular activities 
AALOSAGAM: Disturbance in vision 
PRASAGAM: Redness 
DERANGEMENTS OF KABHAM  IN UTHIRAVATHASURONITHAM 
AVALAMBAGAM: Dyspnoea (due to anaemia) 
KILEDHAGAM: Loss of appetite 
SANDHIGAM: Restriction of joint movements 
UDALTHATHUKKAL: 
In uthiravathasuronitham cases, 
Saaram 
        Seneer 
        Oon 
        Kozhuppu 
        Enbu 
       Moolai 
   Are the most affected 
REVIEW OF LITERATURE – SIDDHA ASPECT /2019                                                                              
32 
 
GNANENDHIRIYAM: 
In uthiravathasuronitham cases, 
      MEI: Pain 
      KAN: Disturbances of vision 
KANMENDHIRIYAM 
 In uthiravathasuronitham cases, 
      KAI: Difficulty to use the upper limbs 
      KAAL: Difficulty to use the lower limbs 
      ERUVAI: Constipation in some cases 
      KARUVAI: Irregular menstrual cycle in some cases 
PININEEKAM: 
 Siddha system of medicine is a unique system of medicine in which treatment   is given 
both for the body and mind. Thiruvalluvar in his thirukural under the heading 
“MARUNDHU” mentions about the diseases and its prevention, they are, So in Siddha 
system, treatment is not only for the removal of diseases, but for prevention and 
improving the body condition-Rejuvenation. 
1. Prevention 
2. Treatment-curative 
3. Restoration-promotive 
1.PREVENTION: 
 It is very much, essential and stressed in all siddha literature. Body and mind 
should be very clean and free from evil thoughts and deeds. 
2.TREATMENT: 
A Good physician should know about the derangements of humours and should  
treat the patients on the basis of altered humours. 
Treatment is based on, 
To bring the tridosham tonormal 
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To treat the disease according to its symptoms through 
medicines, To increase the natural immunity 
To normalize the tridosham, 
“                   ” 
Vatha disease can be brought down by vireasanam(purgation),by giving the      laxatives 
and purgatives according to the patient conditions, Four requisites of  successful 
treatment are explained by “THIRUVALLUVAR” 
             “                               
                ”. 
 
3.RESTORATION 
 Reassurance is given to all the patients for fast recovery 
 Not to be anxious 
 Not to be depressive 
 Avoid exposure to cold 
 Avoid excessive workload 
   To advice the patients to do asanas regularly 
MANEGEMENT OFUTHIRAVATHASURONITHAM: 
 The treatment of siddha medicine is aimed at keeping the three humours in equilibrium 
and maintenance of seven elements. So proper diet, medicine and disciplined regimen of 
life are advised for the healthy living and to restore equilibrium of humours in diseased 
condition. 
 INTERNAL MEDICINE: RAJALOGA NAATHARASA PARPAM    
    60mg with ghee twice daily, after food for the period of 21 days. 
 EXTERNAL MEDICINE: PARUTHI THYLAM 
 MARIKOZHUNTHU OTTRADAM (THERAPY) 
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REVIEW OF LITERATURE –  3.2. MODERN ASPECT JOINT 
        A joint, also called an articulation, is any place where adjacent bones or bone and 
cartilage come together (articulate with each other) to form a connection. 
        Joints are mainly classified structurally and functionally. Structural 
classification is determined by how the bones connect to each other, while 
functional classification is determined by the degree of movement between the 
articulating bones. 
 
Structural joints are, 
1.SYNOVIAL JOINT - the articulating surfaces of the bones are not directly connected, 
but instead come into contact with each other within a joint cavity that is filled with a 
lubricating fluid .This joint allow for free movement between the bones and are the most 
common joints of the body. 
2.FIBROUS JOINT - is where the adjacent bones are united by fibrous connective tissue. 
3.CARTILAGINOUS JOINT – the bones joined by hyaline cartilage or fibro cartilage. 
Functionally classified are, 
1.Diarthrodial  or synovial joint – which articulate with free movement, have a synovial 
membrane lining the joint cavity and contain synovial fluid 
2.Amphiarthroses – in which adjacent bones are separated by articular cartilage or a 
fibrocartilage disc and bound by firm ligaments permited motion . 
3.Immovable or synarthroses – which are found only in the skull, where thin fibrous 
tissue separates adjoining cranial plates that interlock to prevent detectable motion 
before the end of normal growth, yet permit growth in childhood and adolescence. 
 
Synarthroses (solid joints) are commonly grouped according to the principle 
type of interosseous connective tissue into fibrous joint and cartilaginous joints. 
Disarthrosis (cavitated joints) between the ends of other circumscribed 
surface of endochondrial bones. 
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 Most of the diseases of joints affect diarthrodial or synovial joints. In 
diarthrodial joints, the ends of two bones are held together by joint capsule with 
ligaments and tendons inserted at the outer surface of the capsule. The joint space is 
lined by synovial membrane or synovium which forms synovial fluid that lubricates 
the joint during movement. 
           There basic structures of synovial joints are followed, 
1. Capsule- It is made of tough membrane enclosing the joint. It connects the bone 
and holding them firmly inplace. 
2.Articularcartilage- It is composed of collagen and proteoglycans and 65.80% 
water which forms the cartilage matrix. And it is covering the end of the bones, 
absorbing the shock while providing as lick surface so that the bone end scan easily 
glide across each other during movement. 
3. Synovium-It secretes the synovial fluid to lubricate and nourish the cartilage. 
4. Muscles-It act as a shock absorber and contracts to provide a movement. 
5. Ligaments- It attaches bone to bone and provide stability. 
6. Tendons- It attaches muscles to bones and acts as a secondary joint stabilizer and 
also allow for free movements. 
7. Bursae- It is sac like cavity situated in places in tissues to facilitate the gliding of 
muscles or tendons over bony or ligamentous surfaces and protecting them against 
friction, wear and tear. 
CLASSIFICATION OF SYNOVIAL JOINTS: 
1.Plane joints 
2.Hinge joints  
3.Pivot joints 
4.Bicondylar 
5.Ellipsoid joints 
6.Saddle joints 
7.Ball and socket joints 
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Syndesmosis: 
The articulating bones are kept at a distance but united by a strong 
ligaments.e.gvertebral arches, coracoids process and clavicle. 
Nerve supply: 
The sources of nerve fibers to a joint conform well to Hilton’s law- the 
nerves to the muscles acting on a joint as well as to the skin over the area of action 
of these muscles. The capsule and ligaments receive an abundant sensory nerve 
supply. 
Blood supply. 
The articular and epiphyseal branches of neighboring arteries form a 
periarticular arterial plexes. The articular capsule is highly innervated but avascular 
(lacking blood and lymph vessels), and receives nutrition from the surrounding 
blood supply. The synovial membrane is highly vascular and lymphatic. 
Diseases of joints and their classification: 
1.Infectivearthritis: 
Bacterial, viral and parasite  
a. Acute infection: 
• Acute pyogenic arthritis 
• Acute gonococcal arthritis 
• Acute rheumatic arthritis 
• Small pox arthritis 
 b. Chronicinfection: 
• Non-specific: Pyogenic arthritis 
• Specific: Tuberculous arthritis, syphilitic arthritis, gonococcal arthritis 
• Parasitic: Guinea worm arthritis 
 
2.Rheumatoidarthropathy 
• Rheumatoid arthritis 
• Ankylosing spondylitis 
• Reiter’s disease 
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• Psoriatic arthritis 
• nteropathic arthritis 
• Juvenile rheumatoid arthritis 
• Sero negative spondylo arthropathy 
 
3.Degenerative arthrosis (orteoarthritis) 
• Primary orteoarthritis 
• Secondary orteoarthritis 
4.Neuropathicarthrosis 
• Charcot’s arthropathy 
• Syringo myelia 
• Leprosy 
• Diabetes mellitus 
 
5. Metabolicarthritis 
• Gout 
• Pseudo-gout 
• Alkaptonuric arthritis 
6. Arthritis in systemdisorders 
• Haemophilic arthritis 
• Reactive arthritis 
7. Miscellaneousconditions 
•  Villonodular synovitis 
•   Synovial chondromatosis 
 
8.Hystericaljoints.  
Arthritis is a generic term for inflammatory joint disease. With the 
involvement of synovium, articular surfaces and capsule. The inflammation may be 
such a severity as to destroy the joint cartilage. 
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RHEUMATOID ARTHRITIS: 
It is generalized chronic multi system disease affecting the connective 
tissues of the whole body with focalized involvement of musculoskeletal system. 
Though the most prominent manifestation of RA is inflammatory arthritis of the 
peripheral joints usually with symmetrical distribution followed by pain, swelling, 
stiffness, of the joints especially involving joints of hands, wrists and feet and later 
on spread to the proximal joints such as the knee, hips, elbow, shoulder. It is 
considered to be an auto immune response to an unknown antigen and the anti body 
formed is the rheumatoid factor which is identified as immunoglobulinM 
autoantibody is directed against the Fc portion of IgG antibodies. 
Epidemiology of Rheumatoid arthritis: 
  RA is a common chronic disease that affects about 1% of the world 
population. The prevalence of RA in the United States based on rates of RA from 
1995 minnesota study and 2005 census data is currently estimated at approximately 
1.3 million people or 0.6% of the population according to current census data. In 
India the prevalence of the disease 0.75% projected to the whole population, this 
would give a total of about seven million patients in India. 
  The diseases is 3-5 times highly preponderance in females than in males. 
The disease can begin at any age and even affects children (juvenile idiopathic 
arthritis), but it most often starts after 40 years of age and before 60 years of age. 
The courses and severity of the illness can vary considerably. Around 80% 
moderately to severely disable within 20 years, around 40%of RA patients 
registered disabled within 3 years and 25%will require a large joint replacement. 
The risk of RA may be highest when people with these genes HLA DR1, DR4 and 
MHC class 2 familial aggregation. Cigarette smoking increases a person’s risk of 
developing RA and can make the disease worse. 
  Women who have never given birth may be at greater risk of developing 
RA. Obesity also increase the risk of developing RA. But the women who have 
breast feed their infants have a decreased risk of developing RA. 
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ETIOLOGY 
No single factor had been identified to data 
1. Host genetic factor 
2. Immuno regulatory abnormalities and auto immunity 
3. A triggering or persisting microbial infection 
Genetic factor 
 Evidence for the importance of genetic susceptibility comes from higher 
concordance rates in monozygotic (12 – 15%) than in dizygotic twins (30%). 
 Severe Rheumatoid Arthritis is found at approximately 4 times the expected rate in 
first degree relatives of individuals with disease associated with the presence of the 
auto antibody, rheumatoid factor. 
 One of the major genetic factors in the aetiology of Rheumatoid  Arthritis is the 
class II major his to compatibility complex (MHC) gene product HLA-DR4. 
 HLA-DR4 is the major susceptibility halotype in most ethnic groups, DR1 is more 
important in Indian and Israelis DW15 in Japanese. 
 Genetic factor influence both susceptibility and severity with DR4 positivity more 
common in those with severe erosive disease. 
Environmental factors 
1.Infectious agent 
 It has been suggested that Rheumatoid Arthritis might be a manifestation of the 
response to an infectious agent in a genetically susceptible host. 
 The organism that have been implicated are Epstein- Bar virus, cytomegalo virus, 
parvo virus, rubella virus and mycoplasma. 
 The microorganism or response to microorganism might induce an immune 
response to components of the joints by altering its integrity and revealing 
antigenic peptides. 
 Another possibility is that the infecting microorganism might prime the host to 
cross – reactive determinants expressed with in the joint as a result of “molecular 
mimicry”.  
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 Super antigens are proteins with the capacity bind to HLA –  DR molecules and 
patients Vβ gene products and stimulate specific T-cell expressing the Vβ gene 
products. “Super antigens” produced by a number microorganism including 
Staphylococci, Streptococci and M.arthritidis. The sole of super antigens in the 
etiology of Rheumatoid Arthritis remains speculative. 
 Recently scientists have reported that smoking tobacco increases the risk of 
developing rheumatoid arthritis. 
2.Trauma  
     Many patients have mentioned traumatic incidents as a precipitating 
cause. 
3.Psychological Stress 
      The study of identical twins in one of whom rheumatoid arthritis developed tends 
to support this concept. 
4.Vascular Changes 
       Alteration of the normal, peripheral vascular bed perhaps by autonomic influence 
has been suggested as the primary abnormality. 
 5. Neurogenic 
 Neuropeptides can cause inflammation. Reflex sympathetic areas through the 
spinal cord could account for the contralateral distribution. Rheumatoid Arthritis affects 
the non – paralysed side much more severely in a hemiplegic patient. 
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PATHOLOGY 
Pathology of Rheumatoid Arthritis is divided in two major parts. 
I. Pathology of joint and tendons 
II. Pathology of extra articular tissues 
I.PATHOLOGY OF JOINT AND TENDONS 
  It can  be explained in three stages. 
1.Synovitis 
2.Destruction 
3.Deformity 
1.SYNOVITIS 
In this stage the following early changes are seen: 
 Vascular congestion 
 Proliferation of synoviocytes 
 Infiltration of synovial layers by polymorphus, lymphocytes, plasma cells. 
 Thickening of capsular structure 
 Villous formation of synovium 
 Cell-rich effusion into joints and tendon sheaths 
Though this stage was painful, swollen and tender, their structures are still intact and 
mobile. So, these disorders are reversible potentially. 
2. DESTRUCTION: 
Articular cartilage: 
Articular cartilage is eroded partly by proteolytic enzymes and partly by vascular 
tissue in folds of synovial reflection. 
Direct invasion of cartilage by pannus of granulation tissue creeping over 
particular surfaces. 
Margins of joints: 
Bone is eroded by granulation tissue invasion and osteoclastic resorption. In recent 
thoughts there is Synovial Hyperplasia rather than inflammation. 
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Tendons: 
Tenosynovitis 
Invasion of collagen bundles 
Partial or complete rupture of tendons 
Other changes: 
Synovial effusion-contains copious amount of fibrinoid materials that produces 
swelling of joints, tendons and bursae. 
3.DEFORMITY 
In this stage, combination of articular destruction, capsular stretching and tendon 
rupture that produces instability and then deformity. 
By this time, inflammation process may have subsided. 
The emphasis may be on the mechanical and functional effects of joint and tendons 
disruptions. 
II. PATHOLOGY OF EXTRA ARTICULAR TISSUES 
Inflammatory reactions 
Collagen bundles are disturbed 
                                                                               ↓ 
Hyperaemia devolps 
↓ 
Aggregation of leucocytes into joint space 
↓ 
Leucocytes organised in to granulation tissue 
                                                                                ↓ 
Granulation tissues matures and to form granular pannus 
                                                                             ↓ 
Granular pannus produce one enzymes called lysozymes 
  ↓ 
Lysozyme enzymes destroy the articular & peri-articular cartilage 
   ↓ 
The process is end with Ankylosis. 
 
 Rheumatoid nodule 
 Lymphadenopathy, splenomegaly 
 Vasculitis 
 Muscle weakness 
 In the sclera 
 Visceral disease 
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Rheumatoid nodule is a small granulomatous lesion consisting of central necrotic zone, 
surrounded by a radially disposed palisade of local histocytes and beyond that by 
inflammatory granulation tissues. 
Nodule occur,  
 Under the skin especially over subcutaneous of  bony prominence,  
 In the synovium 
 on the tendons 
 In many of the viscera 
 
AUTOIMMUNITY 
The antigens are the substance, which induce specific immune reactions in the 
body. 
Types 
1. Auto antigens - the antigens present on the body’s own cells like ‘A’ antigen and ‘B’ 
antigen on the RBC’s. 
2. Foreign antigens - the antigens entering the body from outside. 
Antibodies 
Antibodies or immunoglobulins (Ig) are produced by plasma cells in response to 
the presence of antigens. 
Immunoglobulins are circulating antibodies synthesized in B lymphocytes and 
plasma cells in response to the invasion of foreign compounds. 
Classes and Subclasses 
There are five major classes of immunoglobulins present in humans. 
They are IgG, IgA, IgM, IgD and IgE. 
 
The differentiation of the classes is based on their molecular weight, structure, 
electrophoretic mobility, ultra centrifugal properties and immunological properties. IgG 
and IgA are further subdivided into subclasses such as G1,G2 and G3 for IgG and A1 and 
A2 for IgA. 
Auto immune disease 
Normally the body has the tolerance against the self antigen . 
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However, in some occasions, the tolerance fails or becomes incomplete against 
the self antigen. This state is called auto immunity. 
Types 
 Organ Specific 
 Organ non specific or multi systemic diseases 
Rheumatoid Arthritis was classified as an autoimmune disease, following the discovery 
of IgM Rheumatoid factor in the blood of the patients. 
The Rheumatoid factor – secreting plasma cells have been demonstrated in the 
Rheumatoid synovium. Other auto antibodies that occur in the rheumatoid arthritis 
patients include natural antibodies, anti nuclear antibodies, anti collegen antibodies, anti 
keratin antibodies and an IgG perinuclear factor. They are considered as associated with 
the disease process but not directly involved in the pathogenesis. 
Another set antibodies identified in Rheumatoid Arthritis patients are directed against 
antigens present on cartilage such as collagen type II, IX and XI and chondrocyte – 
specific antigens. The popular hypothesis for induction of autoimmunity is that of 
“antigenic mimicry”. 
CLINICAL FEATURES: 
• Morning stiffness is very characteristics sign of rheumatoid arthritis. 
• It usually involves small joints of the hands and feet and then symmetrically 
affects the joints of wrists, elbows, ankles andknees. 
• The proximal inter phalangeal and metacarpo phalangeal joints are affected 
most severely. 
• It is a chronic disease with periodic acute exacerbations andremissions. 
• Bilateral symmetric polyarthritis is also a characteristicfeature. 
• There is joint line tenderness and the movements are painful and limited. 
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HISTOPATHOLOGY 
SYNOVIUM: 
The synovium serves as an important source of nutrients for cartilage. Since   
cartilage itself is avascular. 
Synovial cells synthesis joint lubricates such as,  
  Hyaluronicacid 
  Collagens Fibronectin 
1.Synovial lining or intimal layer-greatlyhypertrophied 
2.Sub intimal area of synovium-the sub intimal area is heavily infiltered with 
inflammatory cells, including T and B lymphocytes, macrophages, mast cells, and 
mononuclear cells that differentiate into multinucleated osteoclasts. 
3. Cartilage:-In RA , type II collagen, proteoglycans its integrity, resilience and water 
content all are impaired. 
BONE: 
Composed, primarilyoftypeIcollagen, bonydestructionisacharacteristics ofRA 
Hand and wrist deformity: 
Rheumatoid nodules are particularly found in the subcutaneous tissue over the 
pressure points such as elbow hand, occiput, sacrum .The centre of these nodules 
consists of an area of fibrinoid necrosis and cellular debris surrounded by radially 
dispersed palisade of local histiocytes. 
• Ulnardrift 
• Intrinsic plus deformity 
• Boutonniere or button hole deformity 
• Swan neck deformity 
• Elbow flexion deformity 
• Z deformity orhitch 
• Morrants bakers cyst 
• Trigger finger 
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CHART NO.3.1 : DEFORMITIES OF RA 
 
CHART NO. 3.2 : PAIN AND SWELLING IN MCP JOINTS 
Ankle and toe’s deformity: 
• Atrophy of plantar metatarsal fatpad 
• Achillestendinitis 
• Clawtoes 
• Calcanealerosions 
• Callosity underpressure 
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• Bunion 
• Hallusvalgus 
• Hammertoes 
• Plantarcallosity 
• Excessive plantar tilt of metatarsals 
• Flattening of longitudinalarch 
• Prominent meta tarsalhead 
• Over riding of 2 and3toes 
CHART NO.3.3: DEFORMITIES OF RA 
Non specific inflammatory changes are seen in the blood vessels (acute 
vasculitis), lungs pleura, pericardium, myocardium, lymphnodes, peripheral nerves 
and eyes.  
The combination of bone deformity and swallon inflammatory tissue can 
pries on the spinal cord, leading to ischeamia and wide spread neurological 
consequences affecting all four limbs, bowel ,bladder function , or the respiratory 
muscles and centres in the brain stem that control respiration, potentially resulting 
in death. 
\ 
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Extra articular manifestation: 
Skin: 
• Palmar erythema 
• Pyoderma gangrenosum 
• Hyperhidrosis in extremities 
• Raynaud’sphenomenon 
• Painless non-tender sub cutaneous nodules 
• Non healing ulcers in the fingers 
• Vasculitis of nail beds and tip of the finger 
Eyes: 
• Scleritis due to the granuloma formation 
• Sclero malacia perforans 
• Aneamia 
• Cornea band keratopathy 
 
Ineffective production of erythropoiesis and the RBC is reduced due to the 
production of hemosiderin in the reticulo endothelial system. 
Respiratory system: 
• Recurrent pleural effusion 
• Intersitial fibrosis 
• Caplan’s syndrome 
• Crico arytenoid arthritis is seen–dyspnoea,  stridor. 
• Pneumonia 
• Pneumothorax 
Cardio vascular system: 
• Pericarditis 
• Aortic regurgitation and conductiondefect. 
• Myocardial infarction (due to coronary vasculitis) 
• Endocarditis 
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Nervous system: 
•   Symmetrical polyneuropathy 
•   Carpel tunnel syndrome 
•   Tarsal tunnel syndrome 
•   Wrist drop 
•   Foot drop 
 
Orthopaedics: 
•   Juxta articular osteoporosis is seen 
•   Osteo malacia 
 
Sjogren’s syndrome: 
• Xerostomia 
• Kerato conjunctivitis in association with connective tissue disorder. 
 
Felty ‘s syndrome: 
•   Rheumatoid arthritis 
•   Spleenomegaly 
•   Leucopenia 
 
Gastrointestinal system: 
•   Dysphagia 
•  Parotid enlargement  
 
Muscles: 
•   Myopathy (steroid, chloroquine) 
•   Tenosynovitis 
•   Weakness andatrophy 
 
Rheumatoid vasculitis: 
•   Mono neuritis multiplex 
•   Cutaneous ulceration 
•   Visceral infarction 
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Still’s disease: 
         RA is occurring in children it is characterized by mono or poly arthritis, fever, 
maculapapular rash, hepatosplenomegaly, lymphadenopathy, leucocytosis. The 
joint deformity is rare but growth retardation ispresent. 
DIAGNOSIS: 
 
The essential criteria laid down by the American Rheumatism Association         
(ARA) for the diagnosis of RA are as follows; 
1.  Morning stiffness more than 1hour 
2.  Arthritis of three or more joints areas observed by physician simultaneously have soft 
tissue swelling or joint effusion not just bony over growth. 
3.  Arthritis of hand joints: Wrist, metacarpo phalangeal joints, proximal   
interphalangeal joints.   
4.  Symmetric arthritis 
5.  Rheumatoid nodules: Subcutaneous nodules over bony prominences, extens or 
surfaces, or juxta articular surfaces observed byphysician. 
6.  Serum rheumatoid factor demonstration by any method for which the result has 
been positive in less than 5% of normal control subjects.  
7.  Radio graphic changes: Typical changes of RA on postero anterior band and wrist 
radiographs which will show erosions or unequivocal bony decalcification localized 
in or most marked adjacent to the involved joints. 
DIFFERENTIAL DIAGNOSIS: 
•   Ankylosing spondylitis 
•   Systemic lupus erythematosus 
•   Reiter’s disease 
•   Osteoarthritis 
•   Gout and pseudo-gout 
•   Tuberculous arthritis 
•   Pyogenic arthritis 
•   Psoriatic arthritis 
•   Gonorrheal arthritis 
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•   Haemophilic arthritis 
LABORATORY INVESTIGATION  
1.Complete blood count: 
•   Aneamia 
•   Thrombocytosis 
•   Increased ESR  
2. Increased acute phase proteins (CRP)  
3. Increased plasma visciosity 
4. Serum protreins 
• Decreased albumin 
• Increased gamma globulins 
5. Increased IgG, IgM, IgA Serological tests: 
Rheumatoid factor-It is detected IgM by, 
Rose Waaler test- It is more specific and is said to be positive when more than1:32 
Latex test: It is sensitive and less specific and said to be positive when more 
than1:20. 
6. Synovial fluid analysis: 
•  Turbidity 
•  Reduced viscosity 
•  Increased proteins 
•  Normal or decrease glucose concentration 
•  Increased polymorph count 
 
7. Synovial biopsy and histological examination 
8. Arthroscopic examinations to evaluate damage to articular cartilage.  
9. Antinuclear antibodies are positive in 20 to50%. 
10. Antibodies to CCP (cyclic citrullinated polypeptide). This test has similar 
sensitivity and better specificity for RA. 
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11. Radiological features of early RA 
• Soft tissue swelling 
• Periarticular osteopenia 
• Periosteitis 
Erosions-periarticular and articular Later: 
• Narrowed joint spaces is caused by loss of cartilage 
• Juxta –articular erosion 
• Articular surface irregularity 
• Subluxation 
• Large cystic erosions of bone 
• Ankylosis 
 
Ultrasound and MRI imaging has improved the sensitivity of detecting joint damage 
earlier in diseases. 
Ultrasound may detect synovitis, effusions, and erosions, in addition to Doppler 
providing estimates of ongoinginflammation. 
MRI may show inflammatory synovitis that enhances with Gadolinium and shows 
early erosions. 
Arthroscopy-Synovium oedematous, diffusely erythematous, and friable and later the 
synovium becomes thickened. 
Computerised tomography 
Scintigraphy. 
Renal biopsy-reduced tubular or glomerular filteration rate. 
Pulmonary biopsy-to distinguish rheumatoid nodules from carcinoma or to find out 
the diagnosis of fibrosing alveolitis. 
 
MANAGEMENT 
The treatment of this chronic crippling condition needs the team work of 
rheumatologist, ortho-paedic surgeon, physiotherapist, occupational therapist and social 
worker to provide comprehensive management. The patient and his relatives must 
understand the condition fully and be well motivated to cooperate with the 
treatment which has to be prolonged. 
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The aim of the treatment is to 
•    Relieve pain 
•    Keep the inflammatory process down to aminimum, 
•    Preserve joint motion 
•    Maintain the tone of muscles, 
•    Prevent deformities and stiffness of joint, 
•    Correct deformities 
General treatment 
It is important to correct anaemia by haematinics and even blood transfusion 
may be neccessary. A nutritious diet with a high intake of vitaminc is very essential 
for these patients. 
Conservative Treatment 
 
The inflamed joint is kept at absolute rest by splinting the joint in the 
position of function. Physiotherapy is given during the acute phase. Active joint 
mobilization and muscle strenthening exercise are also prescribed. 
Drug Therapy 
 
The drug used are as follows: 
•    Non-steroidal anti-inflammatory drug 
•    Disease modifying anti rheumatoid drug 
•   Steroids 
•   Cytotoxic drug 
•     Newer drug 
Sugical Treatment: 
•    The role of surgery is mainly reconstructive orrehabilitative. 
•    Synovectomy 
•    Osteotomy 
•    Arthroplasty 
•    Excision arthroplasty  
• Replacement arthoplasty 
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Foods that may worsen RA symptoms: 
Red meat – contain high level of saturated fat and omega – 6 fatty acids which 
can exacerbate inflammation. 
Sugarandre fined flour: Sugary snacks and drinks, white flour  bread and pasta, 
white rice. 
Fried foods and gluten, a protein found in grains such as wheat, rye and barley 
and alchohol. 
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3.3.DRUG REVIEW  
INTERNAL MEDICINE 
1.HYDRAGYRUM: 
Mercury is a heavy silver metallic element that exists as a liquid at room temperature. 
ATOMIC SYMBOL   : Hg 
ATOMIC NUMBER  : 80 
ATOMICWEIGHT    : 200.592g/ml 
ODOUR                        : Odourless 
BOILING POINT        : 356.7
O
C 
MELTING POINT      : -38.83
O
C 
SOLUBILITY              : Insoluble 
DENSITY                    :13.55 at 68◦F 
BLOCK-d-block 
 Mercury occurs in deposits throughout the world mostly as cinnabar(mercuric 
sulphide), 
 The red pigment vermilion is obtained by grinding natural cinnabar or synthetic 
mercuric sulphide.  
 Mercury does not react with most acids, such as dilute sulphuric acid and it 
reacts with solid sulphur flakes, which are used in mercury spill kits to absorb 
mercury. 
Amalgams: 
 Mercury dissolves many other metals such as gold and silver to form amalgams. 
 Mercury readily combines with aluminium to form a mercury-aluminium 
amalgam. Mercury can be absorbed through the skin and mucous membrane and 
mercury vapors can be inhaled, so containers of mercury are securely sealed to 
avoid spills and evaporation. 
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 The tobacco plant readily absorbs and accumulates heavy metals such as 
mercury from the surrounding soil into itsleaves. 
Effects of mercury poisoning: 
Symptoms typically include sensory impairment,disturbed sensation and a lack of 
coordination 
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2.SULPHUR: 
 
 Sulphur is a chemical element with symbol of “S” and atomic number16. 
 It is an abundant multivalent non–metal 
 Sulphur is the third most abundant mineral in the body about half 
concentrated in our muscles, skin, and bones and is essential forlife. 
 It is widely distributed in close proximity to hot springs andvolcanoes. 
 It is an essential nutrient and therefore cannot be synthesized by the human 
body and instead must be obtained from thediet. 
 Sulphur is not present as an isolated element in the body, the primary 
placement of sulphur in the human body is in the sulphur containing amino 
acids.(SSA) 
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 Methionine , cysteine, and taurine are the sulphur containing amino acids. 
 The human body composed of 0.2-0.3% sulphur 
 Sulphur is the sixth most abundant macro-mineral in human breast milk. 
 Generally, proteins contain about 1% sulphur by weigh. 
Physical properties: 
Color:  Pale yello ,non metallic 
Phase : Solid 
Crystalline structure &forms: Rhombic, Amorphous and prismatic 
Odour: Odourless 
Taste: Tasteless 
Solubility: Insoluble in water 
Boiling point: 444.6 
Conductivity: A poor conductor of heat and electricity. 
Viscosity: Upon melting, sulphur is converted into a mobile Yellow liquid 
Chemical properties: 
Chemical formula: S 
Compounds: Hydrogen sulphide, sodium sulphide 
Oxidation : Sulphur dioxide, sulphur trioxide 
Reactivity: It is a chemically reactive especially upon heating, sulphur reacts with meals. 
Bio chemical functions: 
 Cellular energyproduction&metabolism. 
 Maintainingblood glucose levels. 
 Protects nerve tissue-Synthesis neurotransmitters,improvesmemory 
 Antioxidant protection-scavenges or neutralizes free radicals and recycles 
oxidized Anti oxidant. 
 Blood flow: Produces both blood clotting factors as well as anti coagulant. 
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 Joint health: 
Production of glycosamineglycan’s( GAGS) 
Chondroitin sulphate and hyaluronic acid 
 Detoxification: By means of conjugation and  chelation 
 Digestion: Production of hydrochloricacid 
 Regulation of DNA replication and transcription 
 Formation of skin hair and nails.  
Proper immune response: 
Enhancing proliferation of lymphocytes, cytotoxic T cell and NK Cells.  
Supports healthy lipoprotein balance: Cholesterol, HDL, LDL  
Lungs: Protects against mucous formation in lungs. 
Eyes: Decrease cataract development. 
Dietary requirements and sources: 
There are no specific dietary requirements for sulphur. Adequate intake of sulphur 
containing essential amino acid methionine will meets the body needs. Food proteins rich 
in methionine and cystiene are the sources of sulphur. 
Metabolism of sulphur: 
 Sulphur is metabolized by all organisms, from bacteria plants and animals. 
 Sulphur is reduced or oxidized by organisms in a variety forms. 
 The element is present in proteins, nucleic acid, sulfates, esters of 
polysacchrides, steroids, phenols, sulphur containing co-enzymes. 
Role of sulphur in Rheumatoid arthritis: 
 Sulfasalazine is a drug used in the treatment of rheumatoid arthritis and some 
other auto immuneconditions. 
 It helps with pain and swelling and also slow the progression of arthritis over 
time. 
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 Sulfasalazine is also known as a disease modifying anti rheumatic drug 
(DMARDs), because it not only decrease the pain and swelling of arthritis,but 
also prevent damage to joints. 
 It may reduce the risk of long term loss offunction. 
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          :    ,      ,      
KINGDOM                : Animalia 
PHYLUM                  : Mollusca 
CLASS                      : Gastropoda 
ORDER                     : Littorinimorpha 
SUPERFAMILY       : Cypraeoidea  
FAMILY                    : Cypraeidae 
GENUS                      : Cypraea 
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SPECIES                    : C.moneta 
SCIENTIFIC NAME :Cypraeamoneta 
ENGLISH NAME     : Marine shell 
CHEMICAL CONSTITUENTS: Protein component 
ACTION: Febrifuge, Expectorant, Sedative, Rubefacient 
       : 
 “                               
                   -    
                            
                  .” 
    :      
MEDICINAL USES: 
1. It is used in indigestion, colic, peptic ulcer, eye disease, dysentery, ear ache, 
ulcer. 
2. It is diuretic, anti-diarrheal and of value in eye disease if used in the form of 
anjanam. 
3. It is externally used as caustic in various skin disorders. 
4.        
         :        ,       ,          ,      ,           
ATOMIC NUMBER  : 11 
MELTING POINT      : 743
O
C 
BOILING POINT       : 1.575
O
C 
PH                              : 9.13 
MOLECULAR WEIGHT : 381.37214 
MOLECULAR FORMULA : B4Na2O7 
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SOLUBILITY                         : Water soluble 
DENSITY                               : 1.7 g/cm
3 
ODOR                                    : Odorless 
VANDERWAAꞌS RADIUS     : 0.196 nm 
IONIC RADIUS                         : 0095(+1) nm 
CHEMICAL NAME                   : Sodium biborate 
ENGLISH NAME                      :  Borax 
        
                             
                     –        
                          
                   .” 
           :                 
     :       
MEDICINAL USES: 
1. It is  used to  treat rheumatoid arthritis. 
2. Its supplement for sports and bone-related conditions. 
3. It is used in small quantities to prevent or treat osteoporosis or osteoarthritis. 
5.    
           :    ,     ,    ,    ,    ,     ,      ,      ,    ,  
                     ,     ,         
KINGDOM                : Animalia 
PHYLUM                  : Mollusca 
SUB CLASS              : Caenogastropoda 
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CLASS                      : Gastropoda 
ORDER                     : Neogastropoda 
SUPERFAMILY        : Turbinelloidea 
FAMILY                    : Turbinellidae 
SUB FAMILY            : Turbinellinae 
GENUS                      : Turbinella 
SPECIES                    : T.rapa 
SCIENTIFIC NAME   : Turbinellarapa 
ENGLISH NAME       : Gastropoda, Conch shell 
ACTION: Febrifuge, Expectorant, Stomachic, Astringent, Anodyne,                                             
Carminative, Tonic   
            
                                       
                     –        
                                 
                    .” 
     :      
MEDICINAL USES: 
1. Internally given to the acute form of dyspepsia.  
2. Given for asthuma, cough, constipation, shooting pain and  inflammatory 
conditions in joints. 
3. A remedy for blotches, pimples and other skin troubles on the face and body. 
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DRUG REVIEW- EXTERNAL 
1.            
         :        ,          ,   ,     ,      
GENERAL PROPERTIES OF PARUTHI KOTTAI 
KINGDOM                                  : Plantae 
DIVISION                                   : Angiosperm 
CLASS                                         : Dicotledons 
SUBCLASS                                 : Polypetalae 
SERIES                                        : Thalamiflorae 
ORDER                                        : Malvales 
FAMILY                                      : Malvaceae 
GENUS                                        : Gossypium 
SPECIES                                      : G.herbaceum 
BOTANICAL NAME                   : Gossypiumherbaceum 
ENGLISH NAME                         : Indian cotton plant 
USED PART                                 : Seed, Leaf, Flower, Bark 
CHEMICAL CONSTITUENTS     : Gossypol, glycosides, saponins, phenolic  
                                                       compounds 
ACTION     : Laxative, Expectorant 
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      :      ,      
     :      
      :       
MEDICINAL USES: 
1. Seeds are used internally in the  dysentery, intermittent fever and fibroids. 
2. Externally the seeds are used to treat herpes, scabies, wounds, reduces swelling, 
inflammation and orchitis. 
2.       
        :        ,            
GENERAL PROPERTIES OF SITRAMUTTIVER 
KINGDOM                                  : Plantae 
DIVISION                                   : Angiosperms 
CLASS                                        : Dicotyledons 
SUBCLASS                                : Polypetalae 
SERIES                                       : Thalamiflorae 
ORDER                                      :  Malvales 
FAMILY                                     : Malvaceae 
GENUS                                       : Pavonia 
SPECIES                                     : P.zylanica 
BOTANICAL NAME                 :  Pavoniazylanica 
ENGLISH NAME                       : Yellow sticky root 
USED PART                               : Whole plant 
CHEMICAL CONSTITUENTS   : Ephedrine alkaloid 
ACTION                 : Emollient, Astringent, Aphrodiasiac 
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MEDICINAL USES: 
1. It is used for arthritis and joint pain. It also helps to reduce the stiffness of 
joints. 
2. It is used nerve tonic and rejuvenate for all kinds of vatha disease. 
3.     
        :    ,      
GENERAL PROPERTIES OF ULUNTHU 
KINGDOM                                 : Plantae 
DIVISION                                   : Angiosperms 
CLASS                                        : Dicotyledons 
SUBCLASS                                 : Polypetalae 
SERIES                                        : Calyciflorae 
ORDER                                        : Fabales 
FAMILY                                       : Fabaceae 
GENUS                                         : Vigna 
SPECIES                                       : V.mungo 
BOTANICAL NAME                    : Vignamungo 
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ENGLISH NAME                       : Black gram 
USED PART                               : Seeds, Root 
CHEMICAL CONSTITUENTS   : Saponin 
ACTION                    : Demulcent, Refrigerant, Nervine tonic, Nutritive 
        
                              
                       -         
                         
                . 
      :      
     :     
      :      
MEDICINAL USES: 
1. The seeds is used for its suppurative, cooling and astringent properties. 
2. Seeds flour is rich saponins and can be used as soap substitute. It makes the 
skin smooth and soft. 
4.       
          :    ,      
GENERAL PROPERTIES OF KOLLU 
KINGDOM                                  : Plantae 
DIVISION                                   :  Angiosperms 
CLASS                                         : Dicotyledons 
SUBCLASS                                 :  Polypetalae 
SERIES                                        : Calyciflorae 
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ORDER                                       : Rosales 
FAMILY                                     : Rosaceae 
GENUS                                       : Macrotyloma 
SPECIES                                     : M.uniflorum 
BOTANICAL NAME                 : Macrotylomauniflorum 
ENGLISH NAME                       : Horse gram 
USED PART                               : Seed, Whole plant 
CHEMICAL CONSTITUENTS    : Polyphenols, flavonoids and proteins 
ACTION               : Astringent, Tonic, Diuretic 
        
                                  
               -       
                                  
                   . 
      :      ,        
     :      
      :       
MEDICINAL USES: 
1. It helps to regulate cholesterol level. 
2. It is externally used to treatment for swelling and boils. 
5.    
         :      
GENERAL PROPERTIES OFKADUGU  
KINGDOM                                  :  Plantae 
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DIVISION                                    :  Angiosperms 
CLASS                                         : Dicotyledons 
SUBCLASS                                  : Polypetalae 
SERIES                                        : Thalamiflorae 
ORDER                                        :  Parietales 
FAMILY                                      :  Brassicaceae 
GENUS                                        :  Brassica 
SPECIES                                      :  B.juncea 
BOTANICAL NAME                   : Brassica juncea 
ENGLISH NAME                         : Indian mustard 
USED PART                                : Seed 
CHEMICAL CONSTITUENTS    : Polyphenols, flavonoids, proteins 
ACTION             : Rubefacient, Diuretic, Digestive, Stimulant, Emetic, antioxidant 
        
                            
                  -      
    !                           
               . 
      :      
     :      
      :       
MEDICINAL USES: 
1. Mustard seeds are used externally relieves congestion, neuralgia and spasms. 
2. Decoction of the mustard seeds is used in the treatment of induration of the 
liver and spleen. 
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6.    
         :           ,        ,          ,       , 
       ,       ,     
GENERAL PROPERTIES OF CHUKKU 
KINGDOM                                 : Plantae 
DIVISION        : Angiosperms 
CLASS                                        : Monocotyledons  
SERIES                                       : Epigynae 
FAMILY                                     : Zingiberaceae 
GENUS                                       : Zingiber 
SPECIES                                     : Z.officinale 
BOTANICAL NAME                  : Zingiberofficinale 
ENGLISH NAME                        : Dried ginger 
USED PART                                : Dried tuber 
CHEMICAL CONSTITUENTS    : Phellandrene, Gingerol, Gingerin 
ACTION                        : Stimulant, Stomachic, Carminative 
        
                                
                   -       
                             
                   . 
      :       
     :      
      :       
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MEDICINAL USES: 
1. Dried ginger is used in imbalance of vadha and kabhadhosa as in rheumatoid    
arthritis and osteoarthritis. 
2. It helps to relieve weakness of heart, sharp pain due to cardiac condition. 
7.       
         :        ,       
GENERAL PROPERTIES OF SATHAKUPPAI 
KINGDOM                                 :Plantae 
DIVISION                                  : Angiosperms 
CLASS                                        : Dicotyledons 
SUBCLASS                                : Polypetalae 
SERIES                                       : Calyciflorae 
ORDER                                       : Umbellales 
FAMILY                                     : Apiaceae 
GENUS                                       : Anethum 
SPECIES                                     : A.graveolens 
BOTANICAL NAME                 : Anethumgraveolens 
ENGLISH NAME                       : Gardendill, Anet 
USED PART                               : Seed, Leaf, flower 
CHEMICAL CONSTITUENTS    : Anethine, Phellandrene, Apiol 
ACTION                        : Antispasmodic, Deobstruent, Stimulant, Diuretic 
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                          -       
                       
               . 
      :     ,      
     :      
      :       
MEDICINAL USES: 
1. Dill seeds are used to treatment for arthritis and it is mainly used digestive 
disorders. 
2. It is also used to cures urinary complaints, piles, mental disorders. 
8.          
          :    ,        ,         
GENERAL PROPERTIES OF  THIPPILIVER 
KINGDOM                                  : Plantae 
DIVISION                                    : Angiosperms 
CLASS                                         : Dicotyledons 
SUBCLASS                                  : Monochlamydeae 
SERIES                                         : Microembryeae 
FAMILY                                       : Piperaceae 
GENUS                                         : Piper 
SPECIES                                       : P.longum 
BOTANICAL NAME                    : Piper longum 
ENGLISH NAME                         : Long pepper root 
REVIEW OF LITERATURE – DRUG REVIEW / 2019 
74 
 
USED PART                                 : root 
CHEMICAL CONSTITUENTS : Piperlongumine, Sesamine, Piperine, 
Monoterpene 
ACTION                        :  Stomachic 
        
                           
                      -       
                            
                       . 
    :      -    ,     -    ,    -     
       -     ,     -     ,    -      
MEDICINAL USES: 
1. Root decoction used in sciatica, hemiplegia, arthritis. 
2. Root and fruit decoction used for treating gonorrhoea, menstrual pain, RTI, 
TB. 
9.            
         :     ,            
GENERAL PROPERTIES OF MOOKIRATTAIVER 
KINGDOM                                  :Plantae 
DIVISION                                   : Angiosperms 
CLASS                                         : Dicotyledons 
SUBCLASS                                  : Monochlamydeae 
SERIES                                         : Curvembryeae 
FAMILY                                       : Nyctaginaceae 
GENUS                                         : Boerhaavia 
REVIEW OF LITERATURE – DRUG REVIEW / 2019 
75 
 
SPECIES                                       : B.diffusa 
BOTANICAL NAME                   : Boerhaaviadiffusa 
ENGLISH NAME                         : Hog weed, Pig weed 
USED PART                                 : Root, Whole plant 
CHEMICAL CONSTITUENTS: Uridine triacetate, eupalitin 3-O-β-D-
galactopyranoside, β amyrin,3-O-β-D-glucopyranosylsitosterol, boeravinone 
ACTION             : Diuretic, Anthelmintic, Laxative, Expectorant 
        
                         
                   –     
                          !      
                  . 
      :      
     :      
     :      
MEDICINAL USES: 
1. Decoction of its hog weed plant for treating inflammation and pain. 
2. It is used to treat various liver disorders including jaundice and kidney 
disorders. 
10.          
          :         ,              
GENERAL PROPERTIES OF MURUNKAI PATTAI 
KINGDOM                                  :Plantae 
DIVISION                                   :Angiosperms 
CLASS                                         : Dicotyledons 
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SUBCLASS                                : Polypetalae 
ORDER                                       : Brassicales 
FAMILY                                     : Moringaceae 
GENUS                                       : Moringa 
SPECIES                                     : M.oleifera 
BOTANICAL NAME                 : Moringaoleifera 
ENGLISH NAME                       : Drum stick, Horse radish 
USED PART                               : Bark, Leaf, Flower, Seed, Root,Wood 
CHEMICAL CONSTITUENTS : Beta-sitosterol, zeatin, quercetin, kaemopferol,       
                                                       caffeoylguinic acid 
ACTION                : Antispasmodic, Diuretic, Abortifacient, Expectorant, Tonic 
        
                           
                    -       
                !                   
                  . 
      :     ,     ,     
     :     
      :        -     ,   -     
MEDICINAL USES: 
1. Drumstick bark is used to treatment for sexually transmitted diseases, gout 
and arthritis. 
2. Its bark powder is used in treatment of epilepsy. 
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11.         
         :      ,      ,     ,      
GENERAL PROPERTIES OF MILAGIN VER 
KINGDOM   :  Plantae 
DIVISION    :  Angiosperms 
CLASS    :  Dicotyledons 
SUBCLASS    :  Monochlamydeae 
SERIES     : Microembryeae 
FAMILY   :  Piperaceae 
GENUS    :  Piper 
SPECIES    :  P.nigrum 
BOTANICAL NAME    : Piper nigrum 
ENGLISH NAME                       :  Black pepper root 
USED PART                               :  Root 
CHEMICAL CONSTITUENTS :Piperine, piperine, piperanine, pipernonaline 
ACTION                    : Anti vadha, Antidote, Antiperiodic, Resolvent, Carminative 
        
                             
                       -      
                        
                   . 
      :     ,      
     :      
      :       
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MEDICINAL USES  : 
1. Black pepper is used in the treatment of pain relief, chills, rheumatism, flu, 
muscular aches, cold. 
2. It is used externally to treat nasal congestion, sinusitis, epilepsy and skin 
inflammations. 
12.       
          :    ,     ,          ,            
GENERAL PROPERTIES OF DEVADARU 
KINGDOM                                 :  Plantae 
DIVISION                                   : Gymnosperm 
CLASS                                        : Pinopsida 
ORDER                                       : Pinales 
FAMILY                                     : Pinaceae 
GENUS                                       : Cedrus 
SPECIES                                     : C.deodara 
BOTANICAL NAME                 : Cedrusdeodara 
ENGLISH NAME                       : Himalayan cedar, Deodar 
USED PART                               :  Bark, Wood 
         CHEMICAL CONSTITUENTS :  Cholesterin 
ACTION                    : Astringent, Febrifuge, Carminative 
        
                                
                      –        
                            
                . 
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      :     -     ,    -       
     :      
      :       
MEDICINAL USES: 
1. Deodar wood is used to treatment for inflammations and rheumatoid 
arthritis. 
2. Deodar oil is also used in arthritis and headache. 
3. It is extremely useful in neurological disorders,asthma, pruritus, fever, 
infested wound. 
13.        
GENERAL PROPERTIES OF SITRARATHAI 
KINGDOM                                 : Plantae 
DIVISION                                   :Angiosperms 
CLASS                                        : Monocotyledons 
SERIES                                       : Epigynae 
FAMILY                                     : Zingiberaceae 
GENUS                                       : Alpinia 
SPECIES                                     : A.officinarum 
BOTANICAL NAME                 : Alpiniaofficinarum 
ENGLISH NAME                       : Lesser galangal 
USED PART                               : Root 
CHEMICAL CONSTITUENTS : Galangol, Galangin 
ACTION                    : Expectorant, Febrifuge, Stomachic 
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                     -        
    !                         
                   . 
      :      , 
     :      
      :       
MEDICINAL USES: 
1. Lesser galangal root is used to treat anorexia, indigestion, colic, stomach 
ache. 
2. It is used to remedy for rheumatic pain and arthritis. 
14.       
          :        ,    ,    
GENERAL PROPERTIES OF KOTTAM 
KINGDOM                                 : Plantae 
DIVISION                                   : Angiosperms 
CLASS                                        : Monocotyledons 
SERIES                                       : Epigynae 
FAMILY                                     : Zingiberaceae 
GENUS                                       : Costus 
SPECIES                                     : C.speciosus 
BOTANICAL NAME                 : Costusspeciosus 
ENGLISH NAME                       : Costus root 
USED PART                               : Root 
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CHEMICAL CONSTITUENTS : Starch 
ACTION                    :  Tonic, Diaphoretic, Stomachic, Expectorant 
        
                            
                          -     
                              
                 . 
      :     ,        
     :       
      :       
MEDICINAL USES: 
1. Costus root is used in the treatment of skin diseases, gout, respiratory 
disorders and rheumatism. 
2. The root is used for treating worm infections. 
15.         
          :     
GENERAL PROPERTIES OF EL 
KINGDOM                                : Plantae 
DIVISION                                  : Angiosperms 
CLASS                                        : Dicotyledons 
SUBCLASS                                :Gamopetalae 
SERIES                                       :Bicarpellatae 
ORDER                                       : Lamiales 
FAMILY                                     : Pedaliaceae 
GENUS                                       : Sesamum 
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SPECIES                                     : S.indicum 
BOTANICAL NAME                 : Sesamumindicum 
ENGLISH NAME                       : Gingeli oil plant 
USED PART                               : seed oil 
CHEMICAL CONSTITUENTS : Lignanssesamolin, Pinoresinol, Lariciresinol 
ACTION                    : Demulcent, Emollient, Laxative,Nutritive 
        
                                          
                        –           
                                       
                                .” 
      :      
     :      
      :      
MEDICINAL USES: 
1.Calcium, zinc, copper minerals in oil plays an important role in growth of bone,    
healing, regrowth of bone and prevent osteoporosis. 
2. Externally it can increase skin elasticity, smoothness and reduce the appearance    of 
age spots. 
3. It can help to reduce the inflammation and discomfort of various conditions such as 
gout and arthritis by reducing the swelling. 
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16.        
        :   ,    ,    ,    ,    ,     ,    ,     
KINGDOM                : Animalia 
PHYLUM                   :  Chordata 
CLASS                       : Mammalia 
ORDER                      : Artiodactyla 
FAMILY                    : Bovidae 
GENUS                      : Capra 
SCIENTIFIC NAME  : Capra AegagrusHircus 
ENGLISH NAME     : Goat 
CHEMICAL CONSTITUENTS: Calcium, iron, magnesium and phosphorus 
ACTION  :  Immuno-modulatory, anti-inflammatory 
        
                             
                      -          
                          
                    . 
MEDICINAL USES: 
1. Goat’s milk can help to build bone density, boost immunity against diseases and 
protect against allergies. 
2. It help support healthy digestion, lower risk of diabetes, support weight, prevent fat 
loss and reduce high blood pressure. 
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DRUG REVIEW-EXTERNAL THERAPY 
          
          :        ,    
GENERAL PROPERTIES OFMARUKOZHUNTHU 
KINGDOM                                 : Plantae 
DIVISION                                   : Angiosperms 
         CLASS                                         :  Dicotyledons 
SUBCLASS                                 :  Gamopetalae 
SERIES                                        :  Bicarpellatae 
ORDER                                       : Lamiales 
FAMILY                                     : Lamiaceae 
GENUS                                       : Majorana 
SPECIES                                     : M.hortensis 
BOTANICAL NAME                 : Majoranahortensis 
ENGLISH NAME                       : Southern wood 
USED PART                               : Leaf 
CHEMICAL CONSTITUENTS : Borneol, Camphor, Pinene 
ACTION                    : Tonic, Stomachic, Anodyne, Antispasmodic 
        
                                  
                              –      
                                        
                            .” 
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      :     ,       
     :      
      :       
MEDICINAL USES: 
1. Marjoram is commonly used for runny nose, coughs, colds, infections and 
various  digestion problems. 
         2. It is externally used for scabies, wound and joint swelling. 
         3. In foods, marjoram herb and oil used as flavourings. 
      
         :     ,      ,       
GENERAL PROPERTIES OFAAMANAKKU 
KINGDOM                                :  Plantae 
DIVISION                                  :  Angiosperms 
CLASS                                       :  Dicotyledons 
SUBCLASS                                :  Monopetalae 
SERIES                                       : Unisexuales 
FAMILY                                     : Euphorbiaceae 
GENUS                                       : Ricinus 
SPECIES                                     : R.communis 
BOTANICAL NAME                 :  Ricinuscommunis 
ENGLISH NAME                       : Castor- oil plant 
USED PART                               : leaves, seeds, root 
CHEMICAL CONSTITUENTS :  Recinolein 
ACTION                    : Anti vatha, Galactagogue 
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                 -          
                             
                   ”. 
                          -               
      :      
     :      
      :       
MEDICINL USES 
1. Castor oil is applied topically,it reduced inflammation and relieves pain. 
2. It is commonly used to relieve temporary constipation. 
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MATERIALS AND METHODS 
I had chosen siddha trial drug RAJALOGA NAATHARASA PARPAM 
(Internal) for this study from classical siddha literature pranarashamirtha sindhu, 
PARUTHI THYLAM (External) from noi neekkum thylangal seymuraigal and 
MARIKOZHUNTHU OTTRADAM (Externa therapy)  from textbook of Gunapadam 
mooligai. 
The raw drugs were purchased from the raw drug shop R.N.RAJAN & CO Paris. 
After getting proper authentication from the Head of the Department of Pharmacology 
(Gunapadam) and Medicinal Botany, GSMC, Chennai-106 the medicines were prepared. 
 
INTERNAL MEDICINE 
RAJALOGA NAATHA RASA PARPAM 
INGREDIENTS: 
1.Purified Rasam (Mercury)                            -35gm  
2.Purified Kanthagam (Sulphur)                     -35gm  
3.Purified Palagarai (Cypraea Moneta)           -140gm  
4.Purified Venkaram (Sodium Biborate)         -35gm  
5.Purified Sangu (Turbinella Rapa)                 -280gm  
 
METHODS OF PURIFICATION & MATERIALS REQUIRED 
Purification of Mercury: 
Mercury is grinded along with brick powder and turmeric powder each for about one 
hour and is washed with pure water and mixed with the juice of Acalypha indica and 
ignited well until itdetoxify. 
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                     Before Purification                              Brick With Turmeric Powder  
    Grinding  And Purification 
 
                         Squeezing Method                                    After Purification 
            
           Purification of sulphur: 
Sulphur is placed in an iron spoon (their on spoonislined) with cow’s 
butter and the spoon is heated till the sulphur melts, this mixure is immersed 
in inclined position in cow’s milk. This procedure is repeated for 30 times to 
get purified sulphur. Eachtime fresh milk is to be used. 
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              Before Purification                            Melting Sulphur 
 
                   Gandhagam Poured Into Milk                   After Purification  
 
Purification of Cypraea Moneta: 
Cypraea moneta is boiled with lime water. 
  Before Purification   Cypraea Moneta Boil     After Purification 
                                          With Lime Water                 
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Purification of Sodium Biborate: 
Sodium Biborate were purified by fry. 
   Before Purification                               After Purification 
                                   
Purification of Turbinella Rapa: 
Turbinella rapa is grinded and boiled with milk. 
Before Purification / Turbinella Rapa Boil With Milk / After Purification  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS  / 2019 
91 
 
METHODS OF PREPARATION    
Grounded Rasam & Gandhagam             Grounded Rasam & Gandhagam 
                                                                                insidepalagarai 
                                         
Vengararam grounded with cow’s milk          Palagarai is sealed with 
                                                                                    Vengararam paste 
        
Plagarai is placed in the mid of Sangu                 Sealed with clay smeared cloth 
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Incenerated by using 1000 cow dung cakes                After Incenerated drug 
                                  
            Grounded end product                                           Collected parpam 
                                            
 Purified Rasam & Gandhagam are grounded using a stone mortar and place inside 
the Palagarai. 
 This palagarai is sealed with the mixture of vengaram grounded with cow’s milk. 
Then a mud plate is coated with limestone powder. 
 The purified half amount of Sangu is placed in the centre of the mud plate. 
 Plagarai is placed in the mid of Sangu .The remaining purified Sangu pieces are 
placed above the palagarai 
 It is closed with another suitable mud plate and sealed it with clay smeared cloth. 
 It is incenerated by using 1000 cow dung cakes (Kajapudam) 
 Then it is allowed to cool and parpam is collected in clean, dry, airtight container. 
 DOSAGE         : 60mg  -twice daily 
ADJUVENT     : Milaguchooranam 
INDICATION  : 80 VagaiVaatham (neyyil), 40 VagaiPiththam, 96 VagaiKabam,    
                                     Athisaaram, Kiraani, Shayam, Irumal, Suvaasam, Kunmam. 
REFERENCE             : “Pranarashamirtha sindhu” pg.no.185 
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EXTERNAL MEDICINE 
PARUTHI THYLAM 
INGREDIENTS: 
PART I  
 1. PARUTHI KOTTAI [Gossypium herbaceum]      -10gm                                                               
 2. SITRAMUTTIVER [Sida cordifolia]                   -10gm                                                                                         
PART II 
 3. ULUNTHU [Vigna mungo]                                  -10gm                                                                                                        
 4. KOLLU [Macrotyloma uniflorum]                       -10gm                                                                                                    
PART III 
1.GINGELY OIL (Sesamum indicum)                     -800gms 
2.GOAT‘S  MILK                                                   -800gms 
PART IV 
1. KADUGU [Brassica juncea]                                -1gm                                                                                                          
 2. CHUKKU [Zingiber officinale]                              -1gm                                                                                            
 3. SATHAKUPPAI [Anethum graveolens]                 -1gm                                                                                               
 4. THIPPILI VER [Piper longum]                              -1gm                                                                                                                              
 5. MOOKIRETTAI  VER [Boerhaavia diffusa]         -1gm                                                           
 6. MURUNKAI PATTAI [Moringa oleifera]             -1gm                                                                                   
 7. SEVVIYAM  [Piper nigrum]                                  -1gm                                                                                                   
 8. DEVADARU [Cedrus deodora]                             -1gm                                                                                              
 9. SITRAMUTTI  VER [Sida cordifolia]                   -1gm 
10. SITRARATHAI [Alpinia officinarum]                  -1gm                                                                           
11. KOSTAM [Costus speciousus]                              -1gm  
 
METHODS OF PURIFICATION 
Purified and dried under classical text. 
MATERIALS REQUIRED 
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PART I DRUGS 
GOSSYPIUM HERBACEUM                             SIDA CORDIFOLIA 
                           
PART II DRUG 
      VIGNA MUNGO                               MACROTYLOMA UNIFLORUM 
                               
PART III DRUGS 
SESAMUM INDICUM  OIL                                  GOAT‘S  MILK 
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PART IV DRUGS 
        BRASSICA JUNCEA                           ZINGIBER OFFICINALE 
                        
 
ANETHUM GRAVEOLENS                         PIPER LONGUM  ROOT 
                              
BOERHAAVIA DIFFUSA                                  MORINGA OLEIFERA 
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PIPER NIGRUM ROOT                                        CEDRUS DEODORA 
                         
 
   ALPINIA OFFICINARUM                              COSTUS SPECIOUSUS 
                             
METHODS OF PREPARATION 
GINGELY OIL,GOATS MILK&CHOORANAMADDED TO THE DECOCTION 
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ABOVE OIL CONTENT HEATED,FILTRED AND COLLECTED 
                 
Part I, Part II drugs  grounded separately in a stone mortar. Then 2 liters of water will be 
added in part I drugs and boiled, till it is reduced  to ¼ part as decoction.Likewise 
decoction will be made using part II drugs. Then gingely oil, goats milk added to the 
decoctions. Other raw drugs(part IV)  powdered in a stone mortar. The powdered drugs 
added to the above decoctions and boiled till it attains a waxy consistency. 
INDICATION: vadharogam
 
REFERENCE: NoiNeekkum Thylangal Seymuraigal (page no :87 ) 
 
                              THERAPY (MARIKOZHUNTHU OTTRADAM) 
INGREDIENTS: 
1. Marikozhunthu leaf (majorana hortensis) 
2. Castor oil(Ricinus communis) 
METHODS OF PURIFICATION 
                Purified and dried under classical text. 
MATERIALS REQUIRED 
     MAJORANA HORTENSIS                           RICINUS COMMUNIS 
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METHODS OF PREPARATION 
Marikozhunthu  leaves are sauted with castor oil and It is tied in an cotton cloth 
and given as ottradam in affected areas. 
INDICATION : Swelling 
REFERENCE : Gunapadam - Mooligai(page  no:733) 
 
STANDARDIZATION PARAMETERS 
ORGANOLEPTIC CHARACTERS: 
State  : Solid 
Appearance : Greenish white in color 
Nature : Very fine in nature 
Odor  : Very mild 
Flow property:Free flowing 
 
PHYSICOCHEMICAL EVALUATION: 
Percentage Loss on Drying 
Test drug was accurately weighed in evaporating dish .The sample was dried at 
105oC for 5 hours and then weighed. 
Determination of Total Ash 
Test drug was accurately weighed in silica dish and incinerated at the furnace a 
temperature 400 ºC until it turns white in color which indicates absence of carbon. 
Percentage of total ash will be calculated with reference to the weight of air-dried drug. 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute hydrochloric 
acid for 6mins. Then the insoluble matter is collected in crucible and will be washed with 
hot water and ignited to constant weight. Percentage of acid insoluble ash will be 
calculated with reference to the weight of air-dried ash. 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. 
The insoluble matter is collected in crucible and will be washed with hot water, and ignite 
for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter will be 
subtracted from the weight of the ash; the difference in weight represents the water 
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soluble ash. Calculate the percentage of water-soluble ash with reference to the air-dried 
drug. 
Determination of Alcohol Soluble Extractive 
Test sample was macerated with 100 ml of Alcohol in a closed flask for twenty-
four hours, shaking frequently during six hours and allowing to stand for eighteen hours. 
Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml of the filtrate to 
dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to constant weight and 
weigh. Calculate the percentage of alcohol-soluble extractive with reference to the air-
dried drug. 
Determination of Water Soluble Extractive 
             Test sample was macerated with 100 ml of chloroform water in a closed flask for 
twenty-four hours, shaking frequently during six hours and allowing to stand and for 
eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml 
of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to 
constant weight and weigh. Calculate the percentage of water-soluble extractive with 
reference to the air-dried drug.  
                Water soluble extract = Weight of Extract/ Wt of the Sample taken X 100 
Determination of pH 
                 About 5 g of test sample will be dissolved in 25ml of distilled water and 
filteredthe resultant solution is allowed to stand for 30 mins and the subjected to pH 
evaluation. 
HEAVY METAL ANALYSIS BY AAS 
                Standard: Hg, As, Pb and Cd – Sigma 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for 
detecting metals and metalloids in environmental samples. The total heavy metal content 
of the sample was performed by Atomic Absorption Spectrometry (AAS) Model AA 240 
Series. In order to determination the heavy metals such as mercury, arsenic, lead and 
cadmium concentrations in the test item. 
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Sample Digestion 
 Test sample was digested with 1mol/L HCl for determination of arsenic and 
mercury.Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L ofHNO3. 
Standard reparation 
             As & Hg- 100 ppm sample in 1mol/L HCl 
Cd &Pb- 100 ppm sample in 1mol/L HNO3 
PHYTOCHEMICAL ANALYSIS  
Extraction 
Sample Extraction were carried out with water and the resulting extract was utilized 
forthe phytochemical analysis 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
 
Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
Test for saponins:  
To the test sample, 5 ml of water was added and the tube was shaken vigorously. Copious 
lather formation indicates the presence of Saponins. 
Test for tannins:  
 To the test sample, ferric chloride was added, formation of a dark blue or greenish black 
color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water bath, 
filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered 
hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is separated and 
10% ammomia solution is added to it. Pink colour indicates presence of glycosides. 
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Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added followed by 
addition of few drops of conc. Sulfuric acid. Appearance of yellow color indicates the 
presence of Flavonoids. 
 
Test for phenols: 
Lead acetate test:  
To the test sample; 3 ml of 10% lead acetate solution was added.  A bulky white 
precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. Sulphuric acid 
(3ml), and shaken well. The upper layer in the test tube was turns into red and sulphuric 
acid layer showed yellow with green fluorescence. It showed the presence of steroids. 
 
Triterpenoids 
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
Test for Cyanins 
A. Aanthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min 
at 100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Proteins (Biuret Test) 
To extracts 1% solution of copper sulphate was added followed by 5% solution of 
sodium hydroxide, formation of violet purple colour indicates the presence of proteins. 
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TOXICOLOGICAL STUDY ACUTE ORAL TOXICITY STUDY OF RAJALOGA 
NAATHARASA PARPAM 
                                (OECD GUIDELINE – 423)     
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals of 
a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on average 
2-4 steps may be necessary to allow judgement on the acute toxicity of the test 
substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification 
purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least two 
doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of a 
minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. Absence 
or presence of compound-related mortality of the animals dosed at one step will 
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determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance to 
one of a series of toxicity classes. 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent species 
may be used. Healthy young adult animals are commonly used laboratory strains should 
be employed. Females should be nulliparous and non-pregnant. Each animal, at the 
commencement of its dosing, should be between 6 to 8 weeks old and the weight (150-
200gm) should fall in an interval within±20 % of the mean weight of any previously 
dosed animals.  
Housing and Feeding Conditions 
The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be artificial, 
the sequence being 12 hours light, 12 hours dark. For feeding, conventional laboratory 
diets may be used with an unlimited supply of drinking water. Animals may be group-
caged by dose, but the number of animals per cage must not interfere with clear 
observations of each animal. 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
Test Animals and Test Conditions:  
Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
Kings institute, Guindy, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Saimeera foods, Bangalore). 
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Preparation of animals:   
   The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, RAJALOGA NAATHARASA PARPAM. 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC No: LV/07/CLBMCP/2018 
Test Substance  : RAJALOGA NAATHARASA PARPAM 
Animal Source  : Kings institute, Guindy, Chennai. 
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual    
                  marking by using Picric acid. 
Number of animals               : 3 Female/group,  
Route of administration       :   Oral  
Diet    : Pellet feed supplied by Saimeera foods Pvt Ltd, Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
                  provided with bedding of husk. 
Housing temperature :  between 22ºC +3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
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Administration of Doses:  
 RAJALOGA NAATHARASA PARPAM was suspended in water and 
administered to the groups of wistar albino rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the vehicle. Animals were 
fasted 12 hours prior to dosing. Following the period of fasting, the animals were 
weighed and then the test substance was administered. Three Female animals are used for 
each group. The dose level of 5, 50, 300 and 2000 mg/kg body weight was administered 
stepwise. After the substance has been administered, food was withheld for a further 3-4 
hours. The principle of laboratory animal care was followed. Observations were made 
and recorded systematically and continuously as per the guideline after substance 
administration. The visual observations included skin changes, mobility, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. Finally, the number of 
survivors was noted after 24 hrs and these animals were then monitered for a further 14 
days and observations made daily. The toxicological effect was assessed on the basis of 
mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of recovery 
period, and may thus be extended when considered necessary. The times at which signs 
of toxicity appear and disappear are important, especially if there is a tendency for toxic 
signs to be delayed. All observations are systematically recorded with individual records 
being maintained for each animal. 
            Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
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signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
 
          REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
                            RAJALOGA NAATHARASA PARPAM 
 
Test Substance  : RAJALOGA NAATHARASA PARPAM 
Animal Source  : Kings institute, Guindy, Chennai 
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
    marking by using    Picric acid 
Diet    : Pellet feed supplied by SaiMeera Foods Pvt Ltd,                
                                                   Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
       provided with bedding of husk. 
Housing temperature :  between 22ºC±3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
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Table 5  
 
RAJALOGA NAATHARASA PARPAM 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for 28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior to 
the initiation of treatment. Each animal was marked with picric acid. The females were 
nulliparous and non-pregnant. 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are low 
dose (X), mid dose (10X), high dose (20X). X is calculated by multiplying the acute 
toxicity dose (2000mg)   i.e X dose is (20mg/kg), 10X dose is (200mg/kg), 20X dose is 
(400mg/kg).  
Preparation and Administration of  Dose: 
RAJALOGA NAATHARASA PARPAM suspended in with water, It was 
administered to animals at the dose levels of X, 10X, 20X. The test substance 
suspensions were freshly prepared every two days once for 28 days. The control animals 
were administered vehicle only. The drug was administered orally by using oral gavage 
once daily for 28 consecutive days. 
 
 
 
 
 
 
Groups No of Rats 
Group I Vehicle control (Water) 12(6male,6 female) 
Group II  low dose X (20mg) 12 (6male,6 female) 
Group III Mid dose 10X (200mg) 12 (6male,6female) 
Group IV High dose 20X(400mg) 12(6male,6female) 
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Observations: 
Experimental animals were kept under observation throughout the course of study 
for the following: 
 
Body Weight: 
  Weight of each rat was recorded on day 0, at weekly intervals throughout the 
course of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated 
dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
 
Mortality: 
All animals were observed twice daily for mortality during entire course of      
study. 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy of all 
animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
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Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group than 
the low, then the mid dose group will also be examined. Organs will be collected from all 
animals and preserved in 10% buffered neutral formalin for 24 h and washed in running 
water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto 
technicon and then cleared in benzene to remove absolute alcohol. Embedding was done 
by passing the cleared samples through three cups containing molten paraffin at 50°C and 
then in a cubical block of paraffin made by the “L” moulds. It was followed by 
microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, hematology 
and blood chemistry were subjected to One-way ANOVA followed by dunnet t test using 
a computer software programme – Graph pad version 7. All data were summarized in 
tabular form, (Table-6 to 12) 
 
                                  PHARMACOLOGICAL STUDY 
 
1. IMMUNOMODULATOR ACTIVITY - CELL LINE STUDY 
             The evaluation of the immunomodulatory activity of was Rajaloga naatharasa 
parpam carried out in cultured raw cell line in Biogenix Research Center. 
DETERMINATION OF INVITRO IMMUNOMODULATORY EFFECT OF 
EXTRACTS ON CULTURED RAW CELL LINES 
            RAW 264.7 cells was initially procured from National Centre for Cell Sciences 
(NCCS), Pune, India and maintained Dulbecco’s modified Eagles medium, DMEM ( 
Sigma aldrich, USA). 
The cell line was cultured in 25 cm2 tissue culture flask with DMEM 
supplemented with 10% FBS, L-glutamine, sodium bicarbonate (Merck, Germany) and 
antibiotic solution containing: Penicillin (100U/ml), Streptomycin (100µg/ml), and 
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Amphoteracin B (2.5µg/ml). Cultured cell lines were kept at 37ºC in a humidified 5% 
CO2 incubator (NBS Eppendorf, Germany).  
           The cells were grown to 60% confluency followed by activation with 1 µL 
lipopolysaccharide (LPS: 1µg/mL). LPS stimulated RAW cells were exposed with 
different concentration (25,50, 100 µg/mL) of sample solution  and Diclofenac sodium, a 
standard anti-inflammatory drug in varying concentration corresponding to the sample 
was added and incubated for 24 hours. After incubation the anti-inflammatory assays 
were performed using the cell lysate. 
Estimation of Cellular Nitrite Levels  
              The level of nitrite level was estimated by the method of Lepoivre et al. 
(Lepoivre et. al. 1990) To 0.5 mL of cell lysate, 0.1 mL of sulphosalicylic acid was added 
and vortexed well for 30 minutes. The samples were then centrifuged at 5,000 rpm for 15 
minutes. The protein-free supernatant was used for the estimation of nitrite levels. To 200 
μL of the supernatant, 30 μL of 10% NaOH was added, followed by 300 μL of Tris-HCl 
buffer and mixed well. To this, 530 μL of Griess reagent was added and incubated in the 
dark for 10–15 minutes, and the absorbance was read at 540 nm against a Griess reagent 
blank. Sodium nitrite solution was used as the standard. The amount of nitrite present in 
the samples was estimated from the standard curves obtained.  
2. ANTI-INFLAMMATORY STUDIES USING RAJALOGA NAATHARASA 
PARPAM (RNP) 
For the experiment, the animals were divided into 5 groups with 6 animals in each group. 
• Group-I (control) received 3% gum acacia 10 ml/kg p.o. 
• Group-II (Carageenan) received 0.1ml of 1% w/v suspension of carrageenan S.C 
• Group-III (standard) received Indomethacin 40 mg/kg p.o. 
• Group-IV(Test-1) received RNP 200mg/kg p.o. 
• Group-V(Test-2) received RNP 400mg/kg p.o. 
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All the drugs were administered orally and the volume of medicaments kept 
constant at 10 ml/kg body weight of the animals it was administered orally to rats 1 
hrbefore subcutaneous injection of carrageenan. After 1 hr 0.1ml of 1% w/v suspension 
of carrageenan was injected into sub-plantar region of the left hind paw to all the groups. 
The paw volume was measured at 1, 2, 3, 4, and 5 hr using plethysmometer (Model 7150 
UGO Basile, Italy) Edema was expressed as the mean increase in paw volume relative to 
control animals. 
 
 
CLINICAL STUDY 
This study was conducted after getting approval from IEC (Institutional Ethical 
Committee), GSMC Chennai. IEC No: GSMC-CH-ME-21/014/2017. This study was 
also registered in Clinical Trail Registry of India CTRI/REF/2018/05/013640, this was 
done in Post graduate department Sirappu Maruthuvam, Government Siddha Medical 
College and Hospital, Arignar Anna Hospital Campus, Arumbakkam, Chennai-106 under 
the observation and guidance of Head of the department. In this clinical study totally 40 
cases were enrolled out of which 20 cases were treated with Internal medicine alone, 20 
cases were treated with Internal , External medicines & Ottradam therapy. 
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STUDY CENTER 
OPD of Arignaranna Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam, Chennai-106. 
TRAIL DRUG: 
Internal  : Rajaloga naatharasa parpam 
External  : Paruthi thylam 
External therapy : Marikozhunthu Ottradam 
Study period  : 21days 
Sample Size  : 40 cases 
20 cases treated with Internal drug alone 
20 cases treated with Internal, External drug and Ottradam (Therapy) 
SUBJECT SELECTION: 
There is considerable number of patients reporting of  PG Sirappu Maruthuvam 
OPD, Aringar anna govt. hospital, GSMC, with the symptom of  inclusion criteria will be 
subjected to screening test and documented using screening proforma. 40 Patients who 
fulfilled the inclusion criteria were included for the study. Patients criteria, clinical 
assessment, siddha assessment, laboratory investigations, diagnosis and treatment aspect 
in patients after the degree of palliation is achieved they were advised to visit OPD for 
further follow up selection were strictly subjected to protocol comprising selection. 
INCLUSION CRITERIA 
 Age : 18-60 years 
 Sex : both male & female 
 Low grade fever 
 Morning stiffness>1hours 
 Arthritis of ≥3 joint area of the possible 28 joints 
 Arthritis of  hand joints[MCPs , PIPs , WRISTs] 
 Symmetric swelling –same joints on both sides 
 Redness of joints 
 Rheumatoid nodules 
 Serum rheumatoid factor [RA factor] +ve or -ve 
 Anti ccp  +ve 
MATERIALS AND METHODS  / 2019 
113 
 
 
EXCLUSION CRITERIA 
 Systemic lupus erythematosis 
 Sub acute  bacterial endocarditis 
 Rheumatic fever 
 Gouty arthritis 
 Carries spine 
 Ankylosing spondylitis 
 Psoriatic arthritis 
 Osteomyelitis 
 Renal failure 
 Tumours 
 History of long term intake of steroid 
 HIV 
 Progressive systemic sclerosis 
 Pregnancy&lactation 
 Chickungunya 
 
WITH DRAWAL CRITERIA 
 Intolerance to the drug and development of any serious adverse effect during the 
period of drug trial 
 Patients turned unwilling to continue in the  course of clinical trial with any other 
systemic illness.  
ADR REPORTING: 
 If ADR is reported patients will be referred to SCRI [Peripheral 
pharmacovigilance center]  
 Patient is directed to nearest Government Hospital. 
CLINICAL ASSESSMENT 
BLOOD : 
HB, Total WBC Count, Polymorphs, Lymphocytes, Eosinophil, Monocytes, 
Basophils, Total RBC Count, ESR, Blood sugar, Serum cholesterol. 
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RENAL FUNCTION TESTS : 
      Blood urea, Serum  creatinine. 
LIVER FUNCTION TESTS : 
      Total bilirubin, Serum Alkaline Phosphatase, SGOT, SGPT. 
SPECIFIC INVESTIGATION: 
RA Factor, Anti-CCP, CRP. 
URINE : 
Albumin, Sugar, Deposits 
PAIN  ASSESSMENT VISUAL   ANALOGUE SCALE 
 
 
STUDY ENROLMENT: 
Patient reporting at the OPD with symptoms of Anti CCP  +ve, RA factor +ve/ -
ve, CRP, Arthritis of  more than 3 joints, Pain and swelling in inter phalangeal joints, 
Spindle shape swelling , rheumatoid nodules are chosen for enrolment based on this 
inclusion criteria. The patient who are enrolled are informed about the trial drug, possible 
outcomes and objective of the study in the language and terms understandable to them 
and the informed consent would be obtained in the consent form. 
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CONDUCT OF THE STUDY: 
Patients satisfying the inclusion and exclusion criteria will be included in the trial. 
Modern investigations will be carried out before treatment and at the end of the 
treatment. At the end of the study the trial patients are advised to report when there is 
recurrence. 
DATA  COLLECTION FORMS: 
Required information will be collected from each patient by using following forms. 
Form I : Screening and selection proforma 
Form II    : History taking proforma 
Form III : Clinical assessment proforma 
Form IV   : Clinical assessment during and after trial 
Form V : Laboratory investigation proforma 
Form VI : Informed consent form 
Form VII   : Withdrawal form 
Form VIII : Patients information sheet 
From IX         :Diet sheet 
DATA ANALYSIS: 
After enrolling the patients in the study, a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patients visits OPD during 
the study period necessary entries will be made in the assessment forms. The data entries 
and adverse events if any will be monitored by the head of the department. 
OUTCOME OF TREATMENT 
  PRIMARY OUTCOME 
 Primary outcome is mainly assessed by reduction in pain and inflammation of 
joints 
 Reduction of morning stiffness 
 Pain is assessed by universal pain assessment scale 
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 By comparing the any two parameters before and after treatment      ESR, Hb, 
Anti-CCP, RA factor 
 SECONDARY OUTCOME 
 Secondary outcome is assessed by comparing the safety parameter before and 
after treatment. 
ETHICAL  ISSUES 
 Informed consent will be obtained from the patients after explaining about the 
clinical trial in regional tongue. 
 After the consent of the patient (through consent form) if they are in the  inclusion 
criteria they will be enrolled in the study. 
 Treatment will be provided free of cost. 
 Concomitant medications will be given when required. 
 Rescue medications will be given when needed. 
 The patients who withdrawn from the trial  are given proper treatment with full 
care at OPD & IPD. 
 
 
  
 
5. result 
and  
observations 
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RESULTS AND OBSERVATIONS 
 
ORGANOLEPTIC CHARACTERS 
Table –5.1: Organoleptic character of RAJALOGA NAATHARASA PARPAM      
State Solid 
Appearance Greyish White 
Nature Very Fine 
Odor Very Mild 
Flow Property Free flowing 
 
PHYSICOCHEMICAL EVALUATION  
Table – 5.2: Physicochemical evaluation of RAJALOGA NAATHARASA PARPAM      
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 
1.36  ±  0.64 
2.  Total Ash (%)  
93.7  ± 1.66 
3.  Acid insoluble Ash (%) 
12.8  ± 0.72 
4.  Water Soluble Ash (%) 
7.73 ± 0.70 
5.  Alcohol Soluble Extractive (%) 
0.15  ±  0.04 
6.  Water soluble Extractive (%) 
0.33  ± 0.08 
7.  Ph 
10.5 
 
HEAVY METAL ANALYSIS 
Table –5.3: Heavy Metal Analysis of RAJALOGA NAATHARASA PARPAM      
Name of the Heavy 
Metal 
Absorption Max 
Λ max 
Result Analysis Maximum Limit 
 
Mercury 253.7 nm 1.04 ppm 1 ppm 
Lead 217.0 nm 5.11 pm 10 ppm 
Arsenic 193.7 nm 0.04 ppm 3 ppm 
Cadmium 228.8 nm BDL 0.3 ppm 
  Cadmium BDL- Below Detection Limit 
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Report and Inference 
Results of the present investigation have clearly shows that the sample has traces of 
heavy metals such as Mercury, Arsenic and lead. Further there is no trace of cadmium 
in the sample presented for analysis. 
 
PHYTOCHEMICAL ANALYSIS  
 
 Table – 5.4: Phytochemical analysis of RAJALOGA NAATHARASA PARPAM      
 
S.NO              TEST  OBSERVATION 
1 ALKALOIDS - 
 
2 FLAVANOIDS - 
 
3 GLYCOSIDES - 
 
4 STEROIDS - 
 
5 TRITERPENOIDS - 
 
6 COUMARIN - 
 
7 PHENOL + 
 
8 TANIN + 
 
9 PROTEIN + 
 
10 SAPONINS + 
 
11 SUGAR - 
 
12 ANTHOCYANIN - 
 
13 BETACYNIN - 
 
+ -> Indicates Positive and - -> Indicates Negative 
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TEST DONE FOR 
 
          Test for Alkaloids, Flavonoids, Glycosides, Steroids and Triterpenoids 
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                              Test for AnthoCyanin and carbohydrates 
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TOXICOLOGICAL STUDY 
Acute oral toxicity study of RAJALOGA NAATHARASA PARPAM 
Observation done: 
Table – 5.5: Dose finding experiment and its behavioral Signs of acute oral 
Toxicity 
SL Group 
CONTROL 
Observation SL Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of posture Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color 
Change 
7 Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 
10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
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Behaviour: 
 The animals will be observed closely for behaviour in the first four hours 
which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, 
catalepsy, convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, 
loss of traction, piloerection  reactivity of touch, salivation, scratching, sedation, 
chewing,  head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, 
sleep and coma. 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intake 
No of animals in each group:3 
                         Table – 5.6: Observational study Results 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
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1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhea 18. Writhing 19. Respiration 20. Mortality. 
(+  Present, -  Absent) 
        Table – 5.7: Body weight Observation 
 
Table – 5.8: Water intake (ml/day) of Wistar albino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
DOSE 
 
DAYS 
1 6 14 
CONTROL 58 ± 1.02 58±9.20 59.4±1.04 
HIGH DOSE 60.4±1.20 60.8±1.40       59.9±6.24 
P value (p)* NS NS NS 
 
N.S- Not Significant,**(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One-
way ANOVA followed by Dunnett’s test) 
 
Table -5.9: Food intake (gm/day) of Wistar albino rats group exposed 
toRAJALOGA NAATHARASA PARPAM      
DOSE 
 
DAYS 
1 7 14 
CONTROL 61.04±2.62 62.2±4.76 64.3±6.26 
High DOSE 62.4±4.23 62.4±6.22 62.6±4.18 
 
 
                               
DOSE 
 
DAYS 
1 7 14 
CONTROL 229.2±12.30 229.4 ± 10.10 232.2 ±12.10 
HIGH DOSE 310.4± 1.01 310 ± 2.04 314.2 ± 2.10 
P value (p)* NS NS NS 
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SUB ACUTE TOXICITY 
Repeated Dose 28- day oral toxic study of RAJALOGA NAATHARASA  
PARPAM 
 
Table – 5.10: Body weight of wistar albino rats group exposed to RAJALOGA 
NAATHARASA PARPAM      
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table – 5.11: Water intake (ml/day) of Wistar albino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 60.1 ± 8.72      60±1.52 60.2±1.40 61±1.32 61.4±1.62 
LOW DOSE 63.1±1.21 63.6±4.22 63.6±1.02 63.2±2.06 64.4±1.20 
MID DOSE 66.1±1.02 66.3±1.21 66.1±2.62 66.4±4.32 65.4±1.64 
HIGH 
DOSE 
61.1±1.81 61.2±1.32 61.4±1.14 61.6±1.62 61.8±2.02 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 235.2±18.46 236.5 ± 35.10 236.6 ± 45.60 
238.7± 
56.16 
238.4 ± 66.15 
LOW DOSE 284.2 ± 65.24 284.7 ± 66.28 285.6± 55.34 286 ±56.34 286.8± 35.36 
MID DOSE 242.4± 16.34 243.3 ± 16.24 243.4 ± 14.12 
245.2 ± 
15.20 
246.4 ± 54.10 
HIGH DOSE 251.6± 62.24 251.4±42.22 252.4 ± 52.24 253 ± 54.28 254 ± 74.60 
P value (p)* NS NS NS NS NS 
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Table -5.12: Food intake (gm/day) of Wistaralbino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 34±4.14 34.2±6.12 34.3±2.18 34.2±1.14 34±5.62 
LOW DOSE 36.3±1.64 36.3±1.51 36.2±1.51 36.5±1.62 36.5±1.22 
MID DOSE 34.1±2.12 34.2±3.50 34.2±2.14 34.2±2.16 35.2±1.64 
HIGH DOSE 32.4±1.62 32.1±1.64 32.6±2.36 32.6±1.20 36.4±2.32 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’stest 
 
Table – 5.13: Haematological parameters of Wistaralbino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 11.4±0.71 11.60±0.14 11.7±0.13 11.82±0.13 N.S 
Total WBC (×10
3   
l) 10.31±0.22 10.42±0.22 10.34±0.22 10.29±1.10 N.S 
Neutrophils (%) 21.13±0.60 21.02±0.52 21.11±1.42 22.02±2.71 N.S 
lymphocyte (%) 82.10±1.26 82.12±1.42 83.10±2.44 83.20±2.54 N.S 
Monocyte (%) 1.1±0.03 1.1±0.01 1.2±0.04 1.1±0.03 N.S 
Eosinophil (%) 0.8±0.03 0.8±0.04 0.9±0.05 0.9±0.08 N.S 
Platelets cells10
3
/µl 900.17±3.18 901.11±4.02 901.1±2.20 901.2±2.64 N.S 
Total RBC 10
6
/µl 9.32±0.11 9.33±0.33 9.35±0.64 9.36±0.46 N.S 
PCV% 44.10±0.2 44.12±5.30 45.8±4.70 46.4±.62 N.S 
MCHC g/Dl 36.5±1.61 36.2±1.51 36.8±1.30 36.3±1.60 N.S 
MCV fL(µm
3
) 58.2±2.02 58.2±1.80 58.7±1.10 59.7±1.30 N.S 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One-
way ANOVA followed by Dunnett’s test) 
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Table – 5.14: Biochemical Parameters of Wistaralbino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 138.10±2.02 139.12±2.10 
140.9±12.0
6 
141.12±5.25 N.S 
T.CHOLESTEROL(mg/dl) 140.14±5.10 141.15±5.20 
141.40±1.6
8 
142.21±1.10 N.S 
TRIGLY(mg/dl) 74.15±1.82 74.11±1.32 75.15±1.22 77.16±1.21 N.S 
LDL 78.6±2.13 78.7±2.05 79.10±1.03 
    
79.40±01.32 
NS 
VLDL 14.2±1.52 14.20±2.41 15.02±1.32 15.04±12.15 NS 
HDL 28.12±4.32 27.32±2.50 29.46±1.20 29.51±1.23 NS 
Ratio 1 
(T.CHO/HDL) 
3.73±1.16 3.72±1.80 3.73±1.32 3.74±2.33 NS 
Ratio 2 (LDL/HDL) 
 
1.92±1.22 1.92±1.20 1.93±2.20 1.94±06.02 NS 
Albumin(g/dL) 
6.21±0.22 6.22±0.52 6.±7.20 
6.55±6.48 
NS 
  
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table – 5.15: Renal function test of Wistaralbino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 14.50±0.29 14.50±0.29 14.46±1.18 14.42±1.22 N.S 
CREATININE(mg/dl) 0.42±0.02 0.41±0.04 0.43±0.03 0.42±0.09 N.S 
BUN(mg/dL) 19.1±0.02 19.2±0.34 19.3±0.42 19.2±1.02 NS 
URIC ACID(mg/dl) 4.02±0.04 4.06±0.21 4.4±0.12 4.20±0.10 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Table 16: Liver Function Test of ofWistar albino rats group exposed to 
RAJALOGA NAATHARASA PARPAM      
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)*  
T BILIRUBIN(mg/dl). 0.08±0.01 0.08±0.03 0.08±0.03 0.08±0.01 N.S 
SGOT/AST(U/L) 64.11±1.53 64.12±0.22 64.24±1.54 65.74±1.53 N.S 
SGPT/ALT(U/L) 79.21±1.02 79.24±1.04 79.24±1.16 79.28±0.21 N.S 
ALP(U/L) 137.11±2.21 138±2.20 138±1.24 139.03±6.02 N.S 
T.PROTEIN(g/dL) 7.2.40±0.14 7.2±0.41 7.2±0.60 7.3±0.61 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test. 
 
HISTO PATHOLOGY 
CONTROL GROUP 
          KIDNEY                          LIVER                      SPLEEN 
 
High dose 
 
               KIDNEY                      LIVER                  SPLEEN      
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PHARMACOLOGICAL STUDY 
SAMPLE:RAJALOGA NAATHA RASA PARPAM 
                  Table – 5.17: Immunomodulator activity of RNP 
 
Sample concentration(µg/ml) OD at 540nm Concentration(µg) 
Control 0.1162 575.19 
25 0.0902 446.49 
50 0.0733 362.835 
100 0.0421 208.395 
 
                                     Chart – 1:Sample concentration 
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Standard-Nitrate level 
Table –5.18: Standard nitrate level for Immunomodulatory activity 
              Concentration(µg)         OD (540nm) 
100 0.021 
200 0.042 
300 0.063 
400 0.080 
500 0.170 
RESULT AND INFERENCE: 
While the concentration level is decreased, nitrate level increased. Hence 
25µg/ml of RLNRP has rich level of nitrate and thus proven to be an 
immunomodulator 
[[PAW EDEMA VOLUME 
Table –5.19: Paw edema volume of anti-inflammatory studies by using RNP 
Group  Dose Initial paw volume Change in paw edema mm at 
different time intervals 
  0hr 1 hr 2hr 3hr 4hr 5hr 
I Control 1.20 ±0.14 1.20±0.14 1.20±0.14 1.20±0.14 1.20±.14 1.20±0.14 
 
II Carrageenan 1.21±0.17 
1.91 ±0.21 2.27 ± 0.02 2.37 ± 0.14 2.48 ± 0.18 
2.62 ± 0.17** 
 
III Indomethacin 1.01±0.06 
2.10±0.26 1.56±0.15 1.47±0.05 1.34±0.18 
1.15±0.16** 
 
IV Low dose 1.38 ±0.21 1.43 ±0.20 1.49 ± 0.42 1.58 ± 0.14 
 
1.51 ± 0.33 1.50 ± 0.32** 
V High dose  1.20±0.24 1.32 ±0.22 1.52 ± 0.33 
 
1.56 ± 0.52 1.42 ± 0.51 
 
1.30 ± 0.62** 
The paw volume up to the tribiotural articulation was measured at 0, 1, 2, 3, 4, 5 hrs 
Each value represents the mean ± SEM of results from six rats. ∗∗ p < 0.01 compared to 
control 
Table –5.20:Percentage protection anti-inflammation 
Group Initial paw 
volume 
5 hr in mm Difference in 
paw volume 
Percentage 
protection  
I 1.20 ± 0.14 1.20±0.14 0.00 100 
II 1.21± 0.17 2.82 ± 0.17 1.61 15.62 
III 1.01± 0.06 1.15 ± 0.16 
 
0.14 96.68 
IV 1.38 ± 0.13 1.69 ± 0.32 0.25 41.42 
V 1.20 ±0.44 1.46 ± 0.12 0.14 75.45 
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Percentage protection is calculated by the formulae:  (T2---T1/T2 )  x 100 
T 1----normal control 
T2 ----drug treated test  
Chart -2 
 
 
 
 
 
 
 
 
 
 
 
Results of the study were observed with respect to the following criteria 
1. Selection of case 
2. Age distribution 
3. Gender distribution   
4. Occupational distribution  
5. Socio-economic status 
6. Diet  
7. Duration of illness 
8. Distribution Paruvakalangal 
9. Distribution Kaalam (Season)  
10. Distribution of Vatham 
11. Distribution of Pitham 
12. Distribution of Kabam 
13. Distribution of Envagaithervugal 
14. Neerkuri/Neikkuri 
15. Clinical Prognosis 
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SELECTION OF CASE 
 
Table –5.21: Selection of case 
 
S.NO SELECTION OF CASE NO OF 
PATIENTS 
PERCENTAGE 
(%) 
1 INTERNAL             20            50 
2 INTERNAL, 
EXTERNAL 
& OTTRADAM 
            20            50 
 
 
Chart – 3:Selection of case 
 
 
 
Inference: 
Among 40 cases, 20 cases (50%) were treated with internal drug alone, 20 cases 
(50%) were treated with internal, external ottradam. 
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GENDER DISTRIBUTION 
 
                                             Table –5.22: Gender distribution 
 
S.NO GENDER DISTRIBUTION  NO OF PATIENTS PERCENTAGE(%) 
1 MALE               9            22.5 
2 FEMALE              31            77.5 
 
Chart -4: Gender distribution 
 
 
 
 
 
Inference: 
Among 40 cases, 9 cases (22.5%) were male and 31 cases (77.5%) were female. 
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AGE DISTRIBUTION 
 
Table –5.23:Age distribution 
 
S.NO AGE DISTRIBUTION NO OF CASE PERCENTAGE(%) 
1 18-20 1 2.5 
2 21-30 2 5 
3 31-40 13 32.5 
4 41-50 17 42.5 
5 51-60 7 17.5 
 
 
Chart –5:Age distribution 
 
 
 
 
Inference: 
Among 40 cases, high age incidence is between 41-50 (42.5%) and 31-40 
(32.5%). 
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FAMILY HISTORY: 
 
Table –5.24: Family history 
  
S.NO FAMILY HISTORY NO OF CASES PERCENTAGE(%) 
1. PRESENT 2 5 
2. ABSENT 38 95 
 
 
 
Chart – 6: Family history 
 
 
 
 
Inference: 
         Among 40 cases, only 2 cases(5%) had positive family history of  Rheumatoid 
arthritis. 
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OCCUPATIONAL HISTORY 
 
                                               Table -5.25: Occupational status 
  
 
S.NO 
OCCUPATIONAL 
STATUS 
 
NO OF CASES 
 
PERCENTAGE(%) 
1. ENGINEER 1 2.5 
2. TEACHER 3 7.5 
3. DRIVER 1 2.5 
4. EMPLOYEE 6 15 
5. BUSINESS 1 2.5 
6. LABOR 2 5 
7. TAILOR 2 5 
8. HOME MAKER 23 57.5 
9. AGRICULTURE 1 2.5 
 
 
 
Chart - 7: Occupational status 
 
      
 
 
Inference: 
Among 40 cases, 23 cases (57.5%) were Home maker and 6 cases (15%) 
were  Employee. 
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SOCIO – ECONOMIC STATUS: 
 
 Table – 5.26: Socio – Economic Status 
 
S.NO SOCIO – ECONOMIC STATUS NO OF CASES PERCENTAGE(%) 
1. POOR 20            50 
2. MODERATE 14            35 
3. HIGH 6       15 
 
 
Chart - 8: Socio – Economic Status 
 
 
 
 
 
Inference: 
Among 40 cases, 20 cases (50%) were poor, 14 cases (35%) were 
moderate and 6 Cases (15%) were from high class. 
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DIET: 
 
Table – 5.27: Diet 
 
 
S.NO DIET NO OF CASES PERCENTAGE(%) 
1. VEGETARIAN 8 20 
 
2. 
NON 
VEGETARIAN 
 
32 
 
80 
[ 
 
                   
 
 
 
           Chart - 9: Diet 
 
 
 
   
 
Inference: 
   Among 40 cases, 32 cases (80%) were non-vegetarian and 8 cases (20%) were 
vegetarian. 
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DURATION OF ILLNESS: 
 
                                   Table – 5.28: Duration of illness 
 
S.NO 
DURATION OF 
ILLNESS 
 
NO OF CASES 
 
PERCENTAGE(%) 
1. UPTO 6 MONTHS 6 15 
2. 6 MONTH – 1 YEAR            8 20 
3. 1 – 2 YEAR            4 10 
4. 2 – 3 YEAR 9 22.5 
5. 3 – 4 YEAR            2   5 
6. 4 – 6 YEAR 7 17.5 
7. 6 – 10 YEAR            4 10 
 
                                      
      Chart - 10: Duration of illness 
 
 
 
Inference: 
Among 40 cases, 9 cases (22.5%) had 2-3 years of illness, 8 cases (20%) had 6 
months-1year of illness, 7 cases (17.5%) had 4-6 years of  illness, 6 cases (15%) had 
up to 6 months of illness, 4 cases (10%) had 1-2 year of illness,4 cases (10%) had 6-
10 years of illness and 2 cases(5%) had 3-4 years of chronic illness. 
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DISTRIBUTION AMONG PARUVAKAALANGAL 
Table –5.29:Paruvakaalangal 
S.No Paruvakaalam No of cases Percentage 
1. Ilavenilkaalam 14 35 
2. Muthuvenilkaalam 12 30 
3. Kaarkaalam 7 17.5 
4. Koothirkaalam 2 5 
5. Munpanikaalam 3               7.5 
6. Pinpanikaalam 2 5 
 
 
 
Chart – 11:Paruvakaalangal 
 
 
 
 
 
Inference: 
 Among 40 patients,  35%, 30%, 17.5%, 5%, 7.5% , 5% of patients 
came in Ilavenil kaalam, Muthuvenil kaalam, Kaar, koothir, Munipani, 
Pinpani. 
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DISTRIBUTION AMONG KAALAM 
 
Table –5.30:Distribution among kaalam 
S.No Kaalam No of patients Percentage 
1 Vatham 4 10 
2 Pitham 36 90 
3 Kabam 0 0 
 
Chart -112: Distribution among kaalam 
 
 
 
Inference: 
 Out of 40 patients, 10% of patients were belonged Vatha  kaalam and 90% 
belonged to Pitha kaalam. 
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10% 
Pitham 
90% 
Kabam 
0% 
DISTRIBUTION AMONG KAALAM 
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DISTRIBUTION OF UDARKATTUGAL 
Table –5.31:Distribution of udarkattugal 
S.No Udarkattugal No of Patients Percentage 
1 Saaram 40 100 
2 Senneer 18 45 
3 Oon 20 50 
4 Koluppu 0 0 
5 Enbu 40 100 
6 Moolai 0 0 
7 Sukkilam/Suronitham - - 
 
 
Chart -13: Distribution of udarkattugal 
 
 
Inference: 
 Out of 40 Patients, were affected in all the patients. Saaran and senneer, 
Oon, Enbu were affected in 100% , 45%, 50%, 100% of patients respectively. 
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DISTRIBUTION OF VATHAM 
                  Table –5.32:Distribution of vatham 
Vatham No of Patients Percentage 
Pranan 0 0 
Abanan 25 62.5 
Udanan 0 0 
Vyanan 40 100 
Samanan 40 100 
Naagan 0 0 
Koorman 0 0 
Kirukaran 0 0 
Devadhathan 0 0 
Dhananjeyan - -  
 
                 Chart -14: Distribution of vatham 
                     
Inference: 
 Out of 40 Patients, Udanan and Samanan were affected in all the patients.  
abanan were affected in 62% of patients respectively. 
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DISTRIBUTION OF PITHAM 
 
Table –5.33:Distribution of pitham 
S.No Pitham No of Patients Percentage 
1 Analagam 0 0 
2 Ranjagam 18 45 
3 Saathagam 40 100 
4 Alosagam 0 0 
5 Prasagam 0 0 
 
 
Chart -15: Distribution of pitham 
                        
Inference: 
 Out of 40 patients, Ranjaga pitham was affected in 45% of patients and 
Saathaga pitham was affected in all the patients (100%). 
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DISTRIBUTION OF KABAM 
                                         Table –5.34:Distribution of kabam 
S.No Kabam No of Patients Percentage 
1 Avalambagam 40 100 
2 Kilethagam 0 0 
3 Pothagam 0 0 
4 Tharpagam 0 0 
5 Santhigam 40 100 
 
 
Chart -16: Distribution of kabam 
                     
 
Inference: 
Out of 40 patients, Avalambagam and Santhigam were affected in all patients (100%)  
 
 
 
 
 
 
 
0
20
40
60
80
100
120
Avalambagam Kilethagam Pothagam Tharpagam Santhigam
DISTRIBUTION OF KABAM 
RESULTS AND OBSERVATIONS / 2019 
146 
 
 
DISTRIBUTION OF ENVAGAITHERVU 
                                 Table –5.35:Distribution of envagaithervu 
S.No Envagaithervu No of Patients Percentage 
1 Naa 18 45 
2 Niram 0 0 
3 Mozhi 0 0 
4 Vizhi 18 45 
5 Sparism 0 0 
6 Malam 25 62.5 
7 Moothiram 0 0 
8 Naadi   
Vathapitha naadi 12 30 
Pithavatha naadi 28 70 
 
                                                      Chart -17:Distribution of envagaithervu 
                             
Inference: 
Out of 40 patients, Naa were affected in 45% of patients, Mozhi were 
affected in 45% of patients and Malam were affected in 62.5% of patients. 
Naadinadai seen in Uthiravatha suronitham  patients were Vathapitham 30% and  
Pithavatham 70%. 
0 10 20 30 40 50 60 70
NAA  
NIRAM 
MOZHI 
VIZHI 
SPARISM 
MALAM 
MOOTHIRAM 
VATHA PITHA NAADI 
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DISTRIBUTION OF ENVAGAI THERVU 
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NEERKURI/NEIKKURI 
                          Table –5.36:Neerkuri/Neikkuri 
S.No Neikkuri No of Cases Percentage 
 
               1 
 
Neerkuri 
“Vaikkolniram” 
(Straw yellow) 
40 
 
 
100  
 
 
               2 VathaNeer 
“Aravenaneelal” 
 
15 
 
37.5                        
3 .PithaNeer 
“Azhipolparaval” 
19 47.5 
4 KabaNeer 
“Muthuthothunitral” 
06 15 
 
                              Chart -18:Neerkuri/Neikkuri 
                         
Inference: 
 Out of 40 patient’s urine sample vathaneer were present in 37.5% of 
patient’s urine sample, Pithaneer were present in 47.5% of patient’s urine sample 
and Kabaneer were present in 15% of urine sample. 
Vadha neer 
37% 
Pitha neer 
48% 
Kabha neer 
15% 
NEIKKURI 
Vadha neer Pitha neer Kabha neer
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MODE OF ONSET: 
Acute onset: upto 6 months 
Sub-acute: 6 months – 3 years 
Chronic: 4 – 10 years 
Table – 5.37: Mode of Onset 
 
S.NO MODE OF ONSET NO OF CASES PERCENTAGE(%) 
1. ACUTE 6            15 
2. SUB ACUTE 21 52.5 
3. CHRONIC 13            32.5 
 
 
 
Chart - 19: Mode of Onset 
 
 
 
Inference: 
Among 40 cases, 6 cases (15%) were suffering from acute illness, 21 cases 
(52.5%) were suffering from sub-acute illness, 13 cases (32.5%) were suffering from 
chronic illness. 
ACUTE 
15% 
SUB ACUTE 
52% 
CHRONIC 
33% 
MODE OF ONSET  
ACUTE SUB ACUTE CHRONIC
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          CLINICAL FEATURES: 
Table – 5.38: Clinical Features 
 
S.NO CLINICAL FEATURES NO OF CASES PERCENTAGE(%) 
1. PAIN 40 100 
2. SWELLING 25            62.5 
3. TENDERNESS 22 55 
4. MORNING STIFFNESS 28 70 
5. LOW GRADE FEVER 10 25 
6. POLYARTHRALGIA 34 85 
7. RESTRICTED MOVEMENTS 18 45 
8. LOSS OF APPETIDE 16 40 
 
    
 
 Chart -20: Clinical features 
                                       
 
 
 
Inference 
Among 40 cases, 40 cases(100%) had pain, 25 cases(62.5%) had swelling, 
28cases(70%) had morning stiffness, 34 cases (85%) had polyarthralgia, 22 cases 
0 20 40 60 80 100
PAIN 
SWELLING 
TENDERNESS 
MORNING STIFFNESS 
LOW GRADE FEVER 
POLYARTHRALGIA 
RESTRICTED MOVEMENTS 
LOSS OF APPETIDE 
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45 
40 
CLINICAL FEATURES 
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(55%) had tenderness, 18 cases (45%) had restriction of movements, 16 cases 
(40%) had loss of appetite, 10 cases (25%) had low grade fever. 
 
INVOLVEMENT OF JOINTS: 
 
 
Table -5.39: Involvement of Joints 
 
 
S.NO 
 
INVOLVEMENT OF JOINTS 
NOOF 
CASES 
 
PERCENTAGE(%) 
1. CERVICAL VERTEBRAE 1 2.5 
 
2. 
METACARPO PHALANGEAL 
JOINT(MCP) 
 
36 
 
90 
 
3. 
PROXIMAL 
INTERPHALANGEAL JOINT(PIP) 
 
34 
 
85 
4. WRIST JOINT 28 70 
5. ELBOW JOINT 10 25 
6. SHOULDER JOINT 8 20 
 
7. 
METATARSAL PHALANGEAL 
JOINT(MTP) 
 
15 
 
37.5 
8. KNEE JOINT 22 55 
9. ANKLE JOINT 20 50 
10. HIP JOINT 3 7.5 
11. LUMBOSACRAL JOINT 1 2.5 
 
Chart - 21: Involvement ofJoint 
 
 
 
Inference: 
Among 40 cases, high involvement of joints were MCP and 
PIP joints, 36 cases (90%) and 34 cases (85%) respectively. 
0 20 40 60 80 100
CERVICAL VERTEBRAE 
PIP 
ELBOW JOINT 
MTP 
ANKLE JOINT 
LUMBOSACRAL JOINT 
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RESULTS AFTER TREATMENT: 
IMPROVEMENT OF GROUP I SUBJECTS: 
Improvement in subjects treated with internal trial drug “RAJALOGA   
NAATHARASA  PARPAM” in group I subjects 
 
     Table –5.40: Improvement of group I subjects 
 
S.NO CLINICAL 
FEATURES 
BEFORE TREATMENT AFTER TREATMENT 
SUBJECTS PERCENTAGE SUBJECTS PERCENTAGE 
1. PAIN AND 
SWELLING OF 
PIP JOINT 
14 70% 3 15% 
2. MORNING 
STIFFNESS > 1 hr 
12 60% 2 10% 
3. TENDERNESS 8 40% 1 5% 
4. LOW GRADE 
FEVER 
4 20% 1 5% 
5. ARTHRITIS OF 
MORE THAN 3 
JOINTS 
19 95% 4 20% 
6. RESTRICTION OF 
MOVEMENTS 
11 55% 2 10% 
7. LOSS OF  
APPETITE 
6 30% 1 5% 
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                                       Chart-22:Improvement of group I subject 
 
Inference: 
Among 20 cases, 14 cases (70%) had pain and swelling of PIP joints, 
12 cases (60%) had morning stiffness > 1hr, 8 cases (40%) had tenderness, 4 
cases (20%) had low grade fever, 19 cases (95%) had arthritis of more than 3 
joints, 11 cases (55%) had restriction of movements, 6 cases (30%) had loss 
of appetite before treatment. But after treatment only 3 cases (15%) had pain 
and swelling of PIP joints, 2 cases (10%) had morning stiffness>1hr, 1 cases 
(5%) had tenderness, 1 cases (5%) had low grade fever, 4 cases (20%) had 
arthritis of more than 3 joints, 2 cases (10%) had restriction of movements, 1 
cases (5%) had loss of appetite. 
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AFTER TREATMENT BEFORE TREATMENT
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IMPROVEMENT OF GROUP II SUBJECTS: 
Improvement in subjects treated with internal & external trial drug 
“RAJALOGA NAATHARASA PARPAM, PARUTHI THYLAM & 
MARIKOZHUNTHU OTTRADAM” in group II subjects. 
 
 
 Table – 5.41: Improvement of group II subjects 
 
 
S. 
N O 
CLINICAL 
FEATURES 
BEFORE TREATMENT AFTER TREATMENT 
SUBJECTS PERCENTAGE SUBJECTS PERCENTAGE 
1. PAIN AND 
SWELLING OF PIP 
JOINT 
11 55% 2 10% 
2. MORNING 
STIFFNESS > 1 hr 
16 80% 3 15% 
3. TENDERNESS 14 70% 2 10% 
4. LOW GRADE FEVER 6 30% 1 5% 
5. ARTHRITIS OF MORE 
THAN 3 JOINTS 
15 75% 4 20% 
6. RESTRICTION OF 
MOVEMENTS 
7 35% 1 5% 
7. LOSS OF APPETITE 10 50% 2 10% 
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           Chart – 23: Improvement of group II  subjects 
 
 
 
 
Inference: 
Among  20 cases, 11 cases (55%) had pain and swelling of PIP joints,16 cases (80%) 
had morning stiffness > 1hr, 14 cases (70%) had tenderness, 6 cases (30%) had low grade 
fever, 15 cases (75%) had arthritis of more than 3 joints, 7 cases (35%) had restriction of 
movements,10 cases (50%) had loss of appetite before treatment. But after treatment only 2 
cases (10%) had pain and swelling of PIP joints, 3 cases (15%) had morning stiffness >1hr, 
2 cases (10%) had tenderness, 1 cases (5%) had low grade fever, 4 cases (20%) had arthritis 
of more than 3 joints, 1 cases (5%) had restriction of movements, 2 cases (10%) had loss of 
appetite. 
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REDUCTION OF PAIN: 
SEVERE PAIN: PAIN SCORE 7 – 10  
MODERATE PAIN: PAIN SCORE 4 
MILD PAIN: PAIN SCORE 1 – 3 
NO PAIN: PAIN SCORE 0 
 
Table – 5.42: Reduction of pain 
 
 
S.NO REDUCTION 
OF PAIN 
BEFORE TREATMENT AFTER TREATMENT 
SUBJECTS PERCENTAGE 
(%) 
SUBJECTS PERCENTAGE 
(%) 
1. SEVERE 18 45% 6 15% 
2. MODERATE 15 37.5% 5 12.5% 
3. MILD 7 17.5% 20 50% 
4. NO PAIN 0 0 9 22.5% 
 
 
Chart – 24: Reduction of pain 
 
 
 
Inference: 
Among 40 cases, 18 cases (45%) had severe pain, 15 cases (37.5%) had 
moderate pain and 7 cases (17.5%) had mild pain before treatment. But after 
treatment only 6 cases (15%) had severe pain, 5 cases (12.5%) had moderate 
pain, 20 cases (50%) had mild pain and 9 cases (22.5%) had no pain. 
0%
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20%
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SEVERE MODERATE MILD NO PAIN 
REDUCTION OF PAIN 
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FUNCTIONAL ABILITY GRADATION: 
GRADE I – FIT FOR ALL ACTIVITIES 
GRADE II – MILD RESTRICTION  
GRADE III – MODERATE RESTRICTION 
GRADE IV – CONFINED TO CHAIR OR BED RIDDEN 
 
Table – 5.43: Functional ability gradation 
 
S.NO GRADE BEFORE TREATMENT AFTER TREATMENT 
SUBJECTS PERCENTAGE 
(%) 
SUBJECTS PERCENTAGE 
(%) 
1. GRADE I 6 15% 31 77.5% 
2. GRADE II 15 37.5% 8 20% 
3. GRADE III 18 45% 1 2.5% 
4. GRADE IV 1 2.5% 0 0 
 
Chart – 25: Functional ability gradation 
 
 
 
Inference: 
Among 40 cases, 6 cases (15%) was fit for all activities, 15 cases (37.5%) 
had mild restriction in movements, 18 cases (45%) had moderate restriction in 
movements and 1 cases (2.5%) had confined to chair on before treatment. 
But after treatment, 31 cases (77%) became fit for all activities, 8 cases 
(20%) had mild restriction in movements, 1 cases (2.5%) had moderate restriction 
in movements and no one was confined to chair. 
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OVERALL RESULT: 
IMPROVEMENT OF RA 
Table – 5.44: Improvement of RA 
 
S.NO IMPROVEMENT NO OF PATIENTS PERCENTAGE(%) 
1. GOOD 32 80% 
2. MODERATE 4 10% 
3. MILD 4 10% 
4. NO IMPROVEMENT 0 0 
 
 
 
 
 
Chart – 26: Improvement of RA 
 
 
 
  
 
Inference: 
           Among 40 cases, 32 cases (80%) had good improvement, 4 cases (10%). 
                   
 
 
 
[PERCENTAGE] 
[PERCENTAGE] 
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Table – 5.45: Treatment details of Subjective parameters of Group I: 
 
 
S.NO 
OP/IP 
NO 
 
Name 
 
Age/ 
Sex 
 
Occupation 
Duration 
of illness 
 Date of 
starting 
treatment 
  Date of 
withdrawal 
treatment 
 
Results 
01 3301 HEMAVATHI 32/F 
Employe 2-3years 7-5-2018 28-5-2018 Good 
Improvement 
02 3895 MOHANA 35/F 
Employe 1-2years 8-5-2018 29-5-2018 Good 
Improvement 
03   4500 SUNAITHA 
41/M 
Homemaker 1-2years 10-5-2018 1-6-2018 Moderate  
Improvement 
04   6534 PREMAVATHI 47/M 
Homemaker 6-10years 18-5-2018 9-6-2018 Good 
Improvement 
05 7482 MANI 38/M 
Employe 6 months-
1year 
22-5-2018 13-6-2018 Good 
Improvement 
06 2890 SATHYA 
35/F 
Employe Upto 6 
months 
12-6-2018 9-7-2018 Good 
Improvement 
07 6584 RASAKUMARI 26/F 
Homemaker 2-3years 26-6-2018 17-7-2018 Good 
Improvement 
08 4393 SUNDARI 46/F 
Homemaker 1-2years 23-7-2018 13-8-2018 Good 
Improvement 
09   4685 BARATHY 44/M 
Employe 4-6years 24-7-2018 14-8-2018 Good  
Improvement 
10 6776 SIVANESAN 47/M 
Engineer 6-10years 31-7-2018 21-8-2018 Good 
Improvement 
11 1140/ 
8659 
JAMUNA 
35/F 
Tailor 6 months-
1year 
26-5-2018 10-6-2018 Good 
Improvement 
12   1337/ 
  5662 
SHOBA 
48/F 
Homemaker 2-3years 25-6-2018 15-7-2018 Good 
Improvement 
13 1558/ 
4250 
KARNAN 
46/M 
Tailor Upto6 
months 
23-7-2018 14-7-2018 Good 
Improvement 
14 1581/ 
4659 
RAJALAKSHMI 
53/F 
Homemaker 2-3years 24-7-2018 15-8-2018 Good 
Improvement 
15 
 1635/ 
7245 
JAYASRI 
 34/F 
Teacher 6 months-
1year 
1-8-2018 21-8-2018 Good 
Improvement 
16 1734/ 
869 
SHANTHI 
53/F 
Homemaker 4-6 years 16-8-2018 5-9-2018 Good 
Improvement 
17   1810/ 
  4375 
VASANTHA 
40/F 
Homemaker 2-3years 29-8-2018 19-9-2018 Good 
Improvement 
18 2620/
4174 
MAHARANI 
41/F 
Teacher 6 months-
1year 
20-12-2018 7-1-2019 Good 
Improvement 
19   410/ 
8357 
SARASWATHI 
59/F 
Homemaker 6-10years 28-2-2019 9-3-2019 Mild 
Improvement 
20   553/ 
3908 
PUSHPA 
56/F 
Homemaker 4-6years 18-3-2019 14-4-2019 Mild 
Improvement 
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                     Table – 5.46: Treatment details of Subjective parameters of Group II: 
 
S.NO 
OP/IP 
NO 
 
Name 
 
Age/ 
Sex 
 
Occupation 
Duration 
of illness 
 Date of 
starting 
treatment 
  Date of 
withdrawal 
treatment 
 
Results 
01 4764 SUGANYA 30/F 
Tailor 6 months- 
1year 
11-5-2018 20-5-2018 Good 
Improvement 
02 6333 SAAVITHIRI 48/F 
Tailor 2-3years 17-5-2018 8-6-2018 Good 
Improvement 
03 1444 POONKODI 45/F 
Coolie 4-6 years 6-6-2018 27-6-2018 Moderate 
Improvement 
04  1534 RAJASEKAR 46/M 
Driver Up to 6 
months 
6-6-2018 27-6-2018 Good 
Improvement 
05    3163 BHARATHI 47/F 
Salesman 4-6 years  13-6-2018 23-6-2018 Good 
Improvement 
06  8747 VAANATHI 40/F 
Housewife 2-3 years 3-7-2018 24-7-2018 Good 
Improvement 
07  2837 ROSI 42/F 
Electrician Up to 6 
months 
17-7-2018 8-8-2018 Good 
Improvement 
08  2838 ASHOK 38/M 
Teacher Up to 6 
months 
17-7-2018 8-8-2018 Good 
Improvement 
09    4394 KASTHURI 57/F 
Driver 6-10 years 23-7-2018 14-8-2018 Mild 
Improvement 
10    6376  KRISHNAVENI 36/F 
Tailor  6 months-
1year 
30-7-2018 21-8-2018 Good 
Improvement 
11   1065/ 
   6134 
DEVI 
35/F 
Housewife 6 months- 
1 years 
16-5-2018 6-6-2018 Good 
Improvement 
12   1669/ 
   8898 
  ANANTHI 
47/F 
Electrician Up to 6 
months 
7-8-2018 28-8-2018 Good 
Improvement 
13   1727/ 
    727 
  POONKODI 
53/F 
Carpenter 4-6 years 16-8-2018 23-8-2018 Moderate 
Improvement 
14   1948/ 
    763 
  GEETHA 
48/F 
Driver  6 months-
1 years 
14-9-2018 2-10-2018 Good 
Improvement 
15   2086/ 
  6178 
  MANIVANAN 
54/M 
Housewife 3-4 years 1-10-2018 18-10-2018 Mild 
Improvement 
16   2140/ 
  8720 
  ASRAFNISHA 
45/F 
Tailor 1-2 years 10-10-2018 28-10-2018 Good 
Improvement 
17   2498/ 
  7705 
  KANIMOZHI 
20/F 
Housewife 2-3 years 3-12-2018 16-12-2019 Good 
Improvement 
18   2529/ 
  9500 
  GANESAN 
53/F 
Teacher 4-6 years 8-12-2018 30-1-2018 Good 
Improvement 
19     127/ 
  6121 
  KOMALA 
52/F 
IT sector 3-4 years 25-1-2019 15-2-2019 Moderate 
Improvement 
20     484/ 
  1729 
  KARTHIK 
38/M 
Tailor 2-4 years 11-3-2019 30-3-2019 Good 
Improvement 
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LABORATORY INVESTIGATION 
 
 
GROUP I SUBJECT : LAB INVESTIGATION 
 
 
 
 
 
GROUP II SUBJECT : LAB INVESTIGATION 
 
 
S. 
NO 
 
 
OP/IP 
NO 
 
 
 
NAME 
TC (Cells/ 
Cu.mm) 
 
DC (%) 
 
ESR (mm/ Hr) Hb (gm%) 
 
BT 
 
AT 
N B E M L ½ hr 1 hr  
BT 
 
AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. 4764 SUGANYA 9200 8100 71 70 0 0 2 2 5 3 22 25 27 26 42 40 10 10.5 
2. 6333 SAAVITHIRI 8900 8300 56 60 1 0 5 4 2 1 36 35 17 16 24 25 12 11.5 
3. 1444 POONKODI 7700 8200 70 71 1 0 6 4 1 0 22 25 11 10 19 21 12 11.5 
4.  1534 RAJASEKAR 8400 78600 58 63 0 1 4 3 3 1 35 32 10 12 25 24 10 13 
  5.    3163 BHARATHI 11000 10500 63 67 2 1 6 5 1 0 28 27 24 20 42 35 9.8    11 
6.  8747 VAANATHI 9400 9100 58 63 0 0 6 4 0 0 36 33 20 19 20 22 11 10.5 
7.  2837 ROSI 8500 8600 62 65 0 0 6 5 0 0 32 30 12 11 32 28 10.4 10 
8.  2838 ASHOK 9600 9400 70 69 0 0 5 3 0 0 25 28 16 16 42 32 10.2 11.4 
9.    6376 KRISHNAVENI 8900 8550 55 61 0 0 8 5 0 0 37 34 18 15 38 30 9.8 10 
10.    4394 KASTHURI 8100 8000 59 62 0 0 7 6 0 0 34 32 14 15 32 29 11.2 12 
11.   1065 DEVI 9200 11000 47 62 1 1 7 4 3 2 42 31 11 13 34 32 10.3 10 
12.   1669 ANANTHI 8200 8300 61 61 0 0 6 5 0 2 33 32 16 18 22 22 11.5 11 
13.   1727 POONKODI 9500 9440 71 64 0 0 5 4 0 1 24 31 25 25 45 42 10.2 12 
14.   1948 GEETHA 8400 8400 65 63 1 1 3 3 4 2 27 31 11 10 35 30 10.6 12.4 
15.   2086 MANIVANAN 3400 5000 47 55 1 0 7 5 4 2 41 38 12 10 34 35 10.4 13.2 
16.   2140 ASRAFNISHA 6900 7100 64 60 2 1 3 2 4 1 27 36 15 13 34 28 10.5 11.5 
17.   2498 KANIMOZHI 6800 6400 66 67 0 0 6 4 2 1 26 28 30 29 60 54 10.7 11.8 
18.   2529 GANESAN 7300 7200 69 68 0 0 6 3 0 0 25 29 16 15 31 30 9.6 10.5 
19     127 KOMALA 8700 9200 49 55 1 0 6 4 0 0 44 41 22 20 45 43 10.5 11.4 
20.     484 KARTHIK 8600 7600 70 67 0 1 2 2 8 4 20 26 9 10 26 24 11.3 12 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
NO 
 
 
OP/IP 
NO 
 
 
NAME 
TC (Cells/ 
Cu.mm) 
 
DC (%) 
 
ESR (mm/ HR) 
HB 
(gm%) 
 
BT 
 
AT 
N B E M L ½ HR 1 HR  
BT 
 
AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
 1. 3301 HEMAVATHI 8000 8700 65 65 1 0 5 5 3 1 26 29 4 4 10 13 11.1 12.3 
 2. 3895 MOHANA 7500 7800 58 60 1 0 5 4 1 0 35 36 12 11 30 26 13.3 14 
 3.   4500 SUNAITHA 9610 9700 65 64 0 0 7 6 1 0 27 30 25 23 51 48 9.2 10.1 
 4.   6534 PREMAVATHI 6200 6420 50 56 0 0 5 4 2 2 43 38 20 18 45 40 9.1 10.3 
 5. 7482 MANI 10400 10000 79 73 0 0 2 2 0 0 19 25 36 38 59 56 12.5 14 
 6. 2890 SATHYA 9250 9500 57 64 1 0 6 5 1 1 35 30 16 15 37 35 12.6 13 
 7. 6584 RASAKUMARI 8200 8400 68 68 0 0 5 5 2 1 25 26 21 15 44 30 15.1 15.5 
 8. 4393 SUNDARI 8700 9100 64 60 2 0 5 4 2 1 27 35 45 40 83 76 9.5 10 
   9.   4685 BARATHY   8800   9200 54 59 1 0 7 5 2 1 36 35   10     9   22    18   15   16 
  10. 6776 SIVANESAN 10500 9000 53 60 1 0 8 6 1 0 37 34 18 15 38 30 12.1 13 
11. 1140 JAMUNA 7800 8000  75   71   0   0   8   6    0   1   17   22 14 12 29 25 10.3 11.5 
12.   1337 SHOBA 8300 8500 66   65 1 0 5 5 2 0 26 30 22 21 46 44 9.6 10.2 
13. 1558 KARNAN 7700 8500 51 59 0 0 2 1 2 0 45 40 15 15 32 30 10.9 11.5 
14. 1581 RAJALAKSHMI 8600 9000 61 67 0 0 6 4 0 0 33 29   5   5 18 15 11.8 13 
  15.   1635 JAYASRI   8800   9200 54 58 0 0 7 4 0 0 39 38   18   14   42   37   11.4   13 
16. 1734 SHANTHI 9500 9600 70 68 0 1 5 3 0 2 25 26 10 9 21 18 11.3 12 
17.   1810 VASANTHA 9622 9800 56 56 1 1 6 7 6 1 31 35 25 23 42 38 10.4 11 
18. 2620 MAHARANI 8200 8000 67 66 0 1 7 7 0 1 26  25 20 20 38 30 12 14.2 
19   410 SARASWATHI 8400 8600 63 59 1 0 7 8 2 0 27 33 10 8 24 16 10.2 11 
20.   553 PUSHPA 5600 6300 50 56 1 0 5 4 4 0 40 40 6 6 15 12 11.8 12.4 
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                                GROUP I SUBJECT : LAB INVESTIGATION 
 
 
 
 S. 
NO 
   
OP/IP 
   NO 
 
 
 
     NAME 
 
 
BLOOD SUGAR 
 
 
PLT(103 
×mm3) 
 
 
  S.CHOLETEROL 
(mg/dl) 
 
 S.URIC ACID 
      (mg/dl) 
FBS PPBS  
BT 
 
AT 
 
BT 
 
AT 
 
BT 
 
AT BT AT BT AT 
1.  3301 HEMAVATHI 78 82 126 130 236 305 170 181 2.2 2.3 
2.  3895 MOHANA 80 84 125 132 234 266 189 192 3.5 3.4 
3.  4500 SUNAITHA 76 81 120 126 319 330 152 147 2.2 2.0 
4.  4764 PREMAVATHI 102 100 141 135 280 310 160 151 2.7 2.5 
5.  6333 MANI 81 78 161 150 241 275 146 158 2.6 2.4 
6.  6534 SATHYA 96 90 137 130 234 260 186 183 2.3 3.0 
7.  7482 RASAKUMARI 94 85 135 126 221 239 179 166 4.8 4.4 
8.  1444 SUNDARI 98 100 143 145 296 306 231 224 4.1 4.0 
9.  1534 BARATHY 77 80 138 140 429 419 179 184 3.5 3.5 
10.  2890 SIVANESAN 88 92 129 130 313 316 216 215 3.4 3.4 
11.  1140 JAMUNA 107 110 207 212 293 310 185 191 2.9 3.0 
12.  1337 SHOBA 84 90 143 145 243 251 174 180 4.8 4.9 
13.  1558 KARNAN 79 85 128 133 194 215 169 164 2.6 2.5 
14.  1581 RAJALAKSHMI 88 85 137 130 296 303 173 170 2.4 2.3 
15.  1635 JAYASRI 96 100 145 145 322 353 176 171 5.8 5.5 
16.  1734 SHANTHI 101 110 152 150 242 290 187 184 4.1 4.0 
17.  1810 VASANTHA 89 84 131 120 214 247 193 190 3.5 3.4 
18.  2620 MAHARANI 95 90 134 138 247 294 193 205 3.8 3.7 
19.    410 SARASWATHI 83 80 125 126 212 260 200 205 2.4 2.2 
20.    553 PUSHPA 77 70 148 145 264 308 185 190 4.2 4.4 
 
 
                                GROUP II SUBJECT : LAB INVESTIGATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  S. 
NO 
 
OP/IP. 
   NO 
 
 
      NAME 
 
BLOOD SUGAR 
 
PLT(103 
×mm3) 
 
 
S.CHOLESTEROL 
           (mg/dl) 
 
S.URIC ACID 
      (mg/dl) 
FBS PPBS  
BT 
 
AT 
 
BT 
 
AT 
 
BT 
 
AT BT AT BT AT 
1.   4764 SUGANYA 77 80 126 130 236 305 170 181 2.2 2.3 
2.   6333 SAAVITHIRI 82 86 125 132 234 266 189 192 3.5 3.4 
3.   1444 POONKODI 76 81 120 126 319 330 152 147 2.2 2.0 
4.   1534 RAJASEKAR 102 100 141 135 280 310 160 151 2.7 2.5 
5.   3163 BHARATHI 81 78 161 150 241 275 146 158 2.6 2.4 
6.   8747 VAANATHI 96 90 137 130 234 260 186 183 2.3 3.0 
7.   2837 ROSI 94 85 135 126 221 239 179 166 4.8 4.4 
8.   2838 ASHOK 98 100 143 145 296 306 231 224 4.1 4.0 
9.   6376 KRISHNAVENI 77 80 138 140 429 419 179 184 3.5 3.5 
10.   4394 KASTHURI 85 90 129 130 313 316 216 215 3.4 3.4 
11.   1065 DEVI 107 110 207 212 293 310 185 191 2.9 3.0 
12.   1669 ANANTHI 84 90 143 145 243 251 174 180 4.8 4.9 
13.   1727 POONKODI 79 85 128 133 194 215 169 164 2.6 2.5 
14.   1948 GEETHA 88 85 137 130 296 303 173 170 2.4 2.3 
15.   2086 MANIVANAN 96 100 145 145 322 353 176 171 5.8 5.5 
16.   2140 ASRAFNISHA 101 110 152 150 242 290 187 184 4.1 4.0 
17.   2498 KANIMOZHI 89 84 131 120 214 247 193 190 3.5 3.4 
18.   2529 GANESAN 95 90 134 138 247 294 193 205 3.8 3.7 
19.   127 KOMALA 83 80 125 126 212 260 200 205 2.4 2.2 
20.   484 KARTHIK 77 70 148 145 264 308 185 190 4.2 4.4 
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 GROUP I SUBJECT : LAB INVESTIGATION 
 
 
 
S. 
NO 
 
OP/IP 
NO 
 
 
 
 NAME 
 
                                 LIVER FUNCTION TEST     RENAL FUNCTION TEST 
T.BILIRUBIN 
    (Mg/dl) 
ALKALINE 
PHOSPHATASE       
       (U/L) 
 
 
SGOT(U/L) 
 
SGPT(U/L) 
 
CREATININE 
       (mg/dl) 
 
UREA 
(mg/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 3301 HEMAVATHY 0.38 0.36 193 181 29.9 33 26.4 24 22 21 0.8 0.7 
2. 3895 MOHANA 0.4 0.3 139 135 37 36 31 31 20 19 0.3 0.4 
3. 4500 SUNAITHA 0.2 0.2 204 202 31 30 33 31 14 14 0.6 0.5 
4. 6534 PREMAVATHI 0.4 0.3 173 173 22 20 17 18 23 22 0.4 0.4 
5. 7482 MANI 0.7 0.5 194 189 36 33 30 26 20 20 0.6 0.5 
6. 2890 SATHYA 0.5 0.6 196 200 23 25 20 22 32 28 0.7 0.5 
7. 6584 RAJAKUMARI 0.8 0.6 147 143 19 19 22 20 19 19 0.5 0.4 
8. 4393 SUNDARI 0.44 0.38 96 82 15.4 14 11.9 11.9 22 21 0.4 0.4 
9. 4685 BHARATHY 0.7 0.5 158 148 20 15 22 19 19 20 0.7 0.6 
10. 6776 SIVANESAN 0.7 0.6 159 154 24 22 27 25 24 23 0.6 0.5 
11. 1140 JAMUNA 0.4 0.5 188 188 25 26 20 22 24 20 0.8 0.7 
12. 1337 SHOBA 0.6 0.4 167 162 28 25 22 19 15 16 0.3 0.4 
13. 1558 KARNAN 0.5 0.6 110 106 19 19 23 23 18 17 0.6 0.4 
14. 1581 RAJALAKSHMI 0.5 0.3 190 183 23 20 19 15 21 19 0.7 0.5 
15. 1635 JAYASRI 0.7 0.5 215 212 35 34 30 28 20 21 0.6 0.4 
16 1734 SHANTHI 0.3 0.4 68 65 22 21 16 15 19 18 0.5 0.4 
17. 1810 VASANTHA 0.4 0.3 155 152 21 19 17 15 24 20 0.4 0.4 
18. 2620 MAHARANI 0.4 0.3 196 193 23 21 20 19 14 15 0.6 0.5 
19.   410 SARASWATHI 0.5 0.4 168 168 27 25 24 24 21 20 0.4 0.4 
20   553 PUSHPA 0.4 0.4 195 194 17 15 19 16 33 29 0.7 0.6 
 
GROUP II SUBJECT : LAB INVESTIGATION 
 
 
 
 
 
 
 
 
S. 
NO 
 
OP/IP 
NO 
 
 
 
 NAME 
 
                                 LIVER FUNCTION TEST     RENAL FUNCTION TEST 
T.BILIRUBIN 
    (Mg/dl) 
ALKALINE 
PHOSPHATASE       
       (U/L) 
 
 
SGOT(U/L) 
 
SGPT(U/L) 
 
CREATININE      
       (mg/dl) 
 
     UREA  
    (mg/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 4764 SUGANYA 0.6 0.6 100 96 16.8 16.4 23.6 22.2 21 20 0.7 0.6 
2. 6333 SAAVITHIRI 0.4 0.4 192 193 43.3 32 36.8 25 19 18 0.4 0.5 
3. 1444 POONKODI 0.3 0.4 90 90 13 14 17 16 15 14 0.5 0.4 
4. 1534 RAJASEKAR 0.3 0.3 163 164 24 24 21 19 16.9 15 0.93 0.8 
5. 3163 BHARATHI 0.6 0.4 211 186 51.2 35 79.5 70 22 22 0.7 0.5 
6. 8747 VAANATHI 0.5 0.5 156.1 143 24.3 20 14.7 12.8 31 27 0.5 0.4 
7. 2837 ROSI 0.3 0.3 152 149 19 20 24 22 20 19 0.8 0.7 
8. 2838 ASHOK 0.5 0.4 154 150 20 19 23 20 24 23 0.5 0.4 
9. 6376 KRISHNAVENI 0.4 0.4 98 100 13 14 18 15 20 18 0.4 0.6 
10. 4394 KASTHURI 0.3 0.4 125 124 15 14 9 9 23 22 0.6 0.5 
11. 1065 DEVI 0.2 0.2 138 137 24 22 28 24 24 20 0.6 0.5 
12. 1669 ANANTHI 0.3 0.3 183 184 25 22 23 22 15 16 0.8 0.7 
13. 1727 POONKODI 0.5 0.5 178 179 13.7 13 11 11 19 18 0.6 0.4 
14. 1948 GEETHA 0.6 0.5 165 163 15 15 19 18 22 19 0.6 0.4 
15. 2086 MANIVANAN 0.3 0.3 147 145 25 24 21 20 20 21 0.6 0.5 
16 2140 ASRAFNISHA 0.3 0.4 188 183 31 27 34 30 17 18 0.5 0.4 
17. 2498 KANIMOZHI 0.7 0.5 176 171 30 28 26 23 24 20 0.5 0.5 
18. 2529 GANESAN 0.6 0.6 195 188 21 16 19 13 15 16 0.6 0.5 
19.   127 KOMALA 0.5 0.5 187 185 25 24 20 20 21 20 0.7 0.6 
20   484 KARTHIK 0.6 0.4 191 185 33 30 35 27 32 28 0.4 0.4 
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 GROUP I SUBJECT : LAB INVESTIGATION 
 
 
GROUP II SUBJECT : LAB INVESTIGATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
NO 
 
OP/IP 
NO 
 
 
 
 NAME 
 
                        SPECIAL IVESTIGATION                          URINE TEST 
  ANTI-CCP      CRP 
 
       RA ALBUMIN 
 
   SUGAR 
 
         DEPOSITS 
        (PUS CELLS) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 6534 HEMAVATHY 220 214 38 4.8 164.2 148 NIL NIL NIL NIL 1 - 4 cells 1 – 2 cells 
2. 3895 MOHANA 110 102 13.5 9 16 10 NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
3. 4500 SUNAITHA 52 40 6.2 2.5 240 228 NIL NIL NIL NIL 6– 8cells 2– 4 cells 
4. 6534 PREMAVATHI 124 112 15.7 9 574 520 NIL NIL NIL NIL 2 – 3 cells 1 – 2 cells 
5. 7482 MANI 130 122 16 12 14 11 NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
6. 2890 SATHYA 45 35 8.7 6 12 7 NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
7. 6584 RAJAKUMARI 62.70 58 21.4 18.8 52.1 42.8 NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
8. 4393 SUNDARI 124 114 20.2 18.6 80.6 74.2 NIL NIL NIL NIL 1 – 3 cells 1 – 4 cells 
9. 4685 BHARATHY 24 15 6.27 5.2 18 12.9 NIL NIL NIL NIL 2 – 4 cells 1 – 3 cells 
10. 6776 SIVANESAN 200 184 12.90 10.4 26 18 NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
11. 1140 JAMUNA 33.9 30 8.3 4 592 458 NIL NIL NIL NIL 4 – 6 cells 2 – 5 cells 
12. 1337 SHOBA 76 71 18 7 37 33.6 NIL NIL NIL NIL 2 – 4 cells 2 – 3 cells 
13. 1558 KARNAN 100 98 16.2 12.5 20.4 18.1 NIL NIL NIL NIL 2 – 6 cells 2 – 4 cells 
14. 1581 RAJALAKSHMI 18 11 37 32 16.5 14 NIL NIL NIL NIL 1 – 4 cells 1 – 3 cells 
15. 1635 JAYASRI 69 61 5.8 4 204 182 NIL NIL NIL NIL 0 – 1 cells 1 – 2 cells 
16 1734 SHANTHI 96 88 20 18 20 17.8 NIL NIL NIL NIL   2 – 3 cells 0 – 1 cells 
17. 1810 VASANTHA 162.3 155 8.4 6 16 12.7 NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
18. 2620 MAHARANI 192.8 188 6.8 5.8 117 108 NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
19.   410 SARASWATHI 123 116 10.4 7.2 24 20.2 NIL NIL NIL NIL 2 – 6 cells 2 – 4 cells 
20   553 PUSHPA 28 18 7.2 5 86.3 78.7 NIL NIL NIL NIL 1 – 4 cells 0 – 2 cells 
 
 
S. 
NO 
 
OP/IP 
NO 
 
 
 
 NAME 
 
                        SPECIAL IVESTIGATION                          URINE TEST 
  ANTI-CCP           CRP 
 
        RA  ALBUMIN 
 
   SUGAR 
 
       DEPOSITS 
     (PUS CELLS) 
BT AT BT AT BT AT BT AT BT AT BT AT 
1. 4764 SUGANYA 30.75 28.1 51 4.8 692 458 NIL NIL NIL NIL 1 – 4 cells 1 – 2 cells 
2. 6333 SAAVITHIRI 188.6 180.4 10.5 8 37 33.6 NIL NIL NIL NIL 1 – 2 cells 0 – 1cells 
3. 1444 POONKODI 205 201 5.2 1.5 20.4 18.1 NIL NIL NIL NIL 1 – 4cells 0 – 1cells 
4. 1534 RAJASEKAR 200 198.6 15.7 9 16.5 14 NIL NIL NIL NIL 2 – 3 cells 1 – 2 cells 
5. 3163 BHARATHI 30.2 28.4 15 13 209 185 NIL NIL NIL NIL 1 – 4cells 1 – 2 cells 
6. 8747 VAANATHI 10.3 7.5 6.7 5 21 18.8 NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
7. 2837 ROSI 68 61.3 20.4 17.8 18 14.7 NIL NIL NIL NIL 0 cells 0 – 2 cells 
8. 2838 ASHOK 34.6 32.1 21.2 20.6 117 108 NIL NIL NIL NIL 1 – 2cells 1 – 2 cells 
9. 6376 KRISHNAVENI 61.33 58.8 5.37 4.8 24 20.2 NIL NIL NIL NIL 2 – 4 cells 1 – 3 cells 
10. 4394 KASTHURI 12 8 11.90 9.4 89.3 80.7 NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
11. 1065 DEVI 110.2 94.78 7.3 5 168.2 150 NIL NIL NIL NIL 4 – 6 cells 2 – 4 cells 
12. 1669 ANANTHI 154.6 160 16 8 14 9 NIL NIL NIL NIL 2 – 4 cells 2 – 3 cells 
13. 1727 POONKODI 199.2 203.2 14.2 13.5 243 238 NIL NIL NIL NIL 2 – 6 cells 2 – 4 cells 
14. 1948 GEETHA 10.56 6.8 35 30 584 570 NIL NIL NIL NIL 1 – 4 cells 1 – 3 cells 
15. 2086 MANIVANAN 38 30 5.3 5 15 12 NIL NIL NIL NIL 0 – 1 cells 1 – 2 cells 
16 2140 ASRAFNISHA 209 216 19 17 10 4 NIL NIL NIL NIL 2 – 4 cells 0 – 1 cells 
17. 2498 KANIMOZHI 26.43 19.4 9.6 9 50.1 42.8 NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
18. 2529 GANESAN 471.2 479 5.8 5.5 80.6 74.2 NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
19.   127 KOMALA 140.7 150 9 7.5 17 11.9 NIL NIL NIL NIL 2 – 4cells 1 – 2cells 
20   484 KARTHIK 15 9 7.8 5 28 20 NIL NIL NIL NIL 1 – 4 cells 0 – 2 cells 
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STATISTICAL ANALYSIS - CLINICAL PROGNOSIS 
 
IMPROVE MENT OF GROUP I SUBJECTS:  
 
 Improvement in subjects treated with internal trial drug “RAJA LOGA NAATHA RASA PARPAM 
(INT)” in group I subjects. 
The most popular non parametric statistical tool, namely, McNemar Test analysis has been employed to 
analyses the effectiveness with the help of a hypothesis. 
 
IMPROVE MENT OF GROUP I SUBJECTS:  
 
S. No Clinical features Before Treatment After Treatment 
n% n% 
1. PAIN AND SWELLING OF PIP JOINT 14(70) 3(15)** 
2. MORNING STIFFNESS > 1 hr 12(60) 2(10)** 
3. TENDERNESS 8(40) 1(5)** 
4. LOW GRADE FEVER 4(20) 1(5)* 
5. ARTHRITIS OF MORETHAN 3 JOINTS 19(95) 4(20)** 
6. RESTRICTION OF MOVEMENTS 11(55) 2(10)** 
7. LOSS OF APPETITE 6(30) 1(5) 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference: Since the p value is significant in all clinical features. So there is significant reducing of clinical 
features among the patients for the treatment of Uthiravadha Suronitham (Rheumatoid Arthritis). Hence it is 
concluded that the treatment was effective and significant. 
 
IMPROVEMENT IN GROUP II SUBJECTS:  
Improvement in subjects treated with Internal & external trial drug “RAJA LOGA NAATHA RASA 
PARPAM [internal], PARUTHI THYLAM [external] and OTTRADAM [therapy]” in group II subjects.  
The most popular non parametric statistical tool, namely, McNemar Test analysis has been employed to 
analyses the effectiveness with the help of a hypothesis. 
 
IMPROVE MENT OF GROUP II SUBJECTS:  
 
 
 
 
 
 
 
 
 
 
 
 
S. No Clinical features Before Treatment After Treatment 
n% n% 
1. PAIN AND SWELLING OF PIP JOINT 11(55) 2(10)** 
2. MORNING STIFFNESS > 1 hr 16(80) 3(15)** 
3. TENDERNESS 14(70) 2(10)** 
4. LOW GRADE FEVER 6(30) 1(5)** 
5. ARTHRITIS OF MORE THAN 3 JOINTS 15(75) 4(20)** 
6. RESTRICTION OF MOVEMENTS 7(35) 1(5)** 
7. LOSS OF APPETITE 10(50) 2(10)** 
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McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing of clinical features 
among the patients for the treatment of  Uthiravadha  Suronitham (Rheumatoid Arthritis). Hence it is 
concluded that the treatment was effective and significant. 
GROUP I SUBJECTS : LIVER FUNCTION TEST 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 SGOT 24.86±6.23 23.60±6.63 <0.05 
2 SGPT 22.51±5.58 21.19±5.38 <0.05 
3 Alkaline 
Phosphatase 
165.55±38.43 161.5±39.92 <0.001 
4 T.Bilirubin 0.49±0.15 0.42±0.12 <0.05 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
 
GROUP II SUBJECTS : LIVER FUNCTION TEST 
 
 
 
 
 
 
 
 
 
 
C.I: 95%; Paired 
samples t test. Where p<0.001, p<0.05 represents statistically significant 
 
GROUP I SUBJECTS : RFT 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 21.20±4.89 20.10±3.65 <0.05 
2 Creatinine 0.56±0.15 0.48±0.10 <0.05 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant.  
 
GROUP II SUBJECTS : RFT 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 21.04±4.62 19.70±3.55 <0.05 
2 Creatinine 0.59±0.14 0.51±0.12 <0.05  
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
 
 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
      1 SGOT 24.11±9.98 21.47±6.51 <0.05 
      2 SGPT 25.13±14.70 21.95±12.53 <0.001 
      3 Alkaline 
Phosphatase 
159.45±34.63 155.75±32.61 <0.05 
      4 T.Bilirubin 0.44±0.14 0.41±0.10 0.234 
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GROUP I SUBJECTS:BLOOD INVESTIGATION 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.46±1.70 12.40±1.75 <0.001 
2 ESR1hr 36.30±16.84 31.85±15.96 <0.001  
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
 
 
GROUP II SUBJECTS : BLOOD INVESTIGATION 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 12.30±7.54 9.97±6.90 <0.001 
2 ESR1 hr 110.78±114.14 108.61±117.48 0.134 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
 
GROUP I SUBJECTS: SPECIAL INVESTIGATIONS 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Anti CCP 99.53±60.65 91.60±60.42 <0.001  
2 CRP 14.84±9.29 9.89±7.18 <0.05 
3 RA 116.50±173.18 100.75±147.37 <0.05 
 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
 
GROUP II SUBJECTS: SPECIAL INVESTIGATIONS 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Anti CCP 110.78±114.14 108.61±117.48 0.134 
2 CRP 14.59±11.28 9.97±6.90 <0.05 
3 RA 122.70±189.94 104.15±155.59 0.0120 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
 
  
6. discussion 
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DISCUSSION 
Rheumatoid arthritis (RA) is a chronic inflammatory syndrome with a strong 
autoimmune component (autoantigens) are neither tissue nor organ-specific, but comprise 
a broad collection of post-translational modified proteins, such as citrullinated proteins. 
Both innate and adaptive mechanisms will closely interplay to promote chronic 
inflammation in peripheral joints (PIP,MCP, MTP & Wrist joints) more often and very 
rarely after the larger joints. 
The disease Rheumatoid arthritis signs and symptoms were correlates with the 
symptoms of Uthiravadha Suronitham mentioned in the siddha literature Yugi 
Vaithiya Chindhamani. 
The drugs in the RAJALOGA NAATHARASA PARPAM  and PARUTHI 
THYLAM possesses anti-vadha and anti-spasmodic actions as indicated in the siddha 
literature Gunapadam-Mooligai & Thadhu SeevaVagupu were selected as Internal and 
External medicines respectively for the clinical evaluation on Uthiravadha Suronitham 
(Rheumatoid arthritis). 
After getting proper Authentication from the Head of the Department of 
Gunapadam (Pharmacology) and after conducting the proper analysis of Toxicological  
& Pharmacological study for the Internal trial medicine (Rajaloga naatharasa parpam), 
the medicine was administered to the patients. 
          20 patients were admitted for the trial in the outpatient ward & 20 patients were 
admitted for the trial in the inpatient ward. Out of which 20 patients was treated with 
Internal medicine alone (Group I), 20 patients was treated with Internal, External 
medicine & Ottradam (Group II) and guided by the Head of the Department of Sirappu 
Maruthuvam, GSMC, Chennai-106. 
          Progress of the patients was followed and documented regularly. Various criteria 
like Distribution of Gender, Age, Diet, Occupational & Socio-Economic status were 
assessed. Clinical manifestation and assessment of the enhancement in the prognosis of 
the disease (RA) with the trial drugs along with ottradam were taken into account for 
evaluating the Efficacy of the trial drugs. 
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GENDER: 
22.5% of Patients were in the gender of male 
77.5% of Patients were in the gender of female 
AGE: 
2.5% of Patients were in the age group of 18-20 
5% of Patients were in the age group of 21-30 
32.5% of Patients were in the age group of 31-40 
42.5% of Patients were in the age group of 41-50 
17.5% of Patients were in the age group of 51-60 
 
OCCUPATIONAL STATUS: 
57.5% of Patients was Homemakers were affected 
15% of Patients was Employees were affected 
7.5% of Patients was Labours were affected 
Mostly Homemakers and Employees were affected 
 
SOCIO-ECONOMIC STATUS: 
50% of Patients were affected in the socio-economic status of lower income 
groupbecause of the low nutrition, poor hygiene and poor immunity. 
 
DIET: 
80% of Patients were Non-vegetarian and only 20% of Patients were Vegetarian. 
 
DURATION OF ILLNESS: 
22.5% of Patients had illness for 2-3 years 
15% of Patients had illness upto 6 months 
17.5% of Patients had illness for 4-6 years 
10% of Patients had illness for 1-2 years 
20% of Patients had illness for 6 months – 1 year 
5% of Patients had illness for 3-4years 
10% of Patients had illness for 6-10 years 
 
MODE OF ONSET: 
52.5% of Patients were in the Sub-acute stage of the disease (6 month – 3 years) 
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CLINICAL FEATURES: 
80% of Patients merely have all the above said clinical features of the 
presentingillness. 
CLINICAL PROGRESS WITH INTERNAL MEDICINE: 
80% of Patients got relief from Pain, Morning stiffness, Inflammation and 
Restriction of movements. 
About 70-75% of Patients had the progress in their clinical features when treated 
with providing Internal medicine alone. 
CLINICAL PROGRESS WITH INTERNAL, EXTERNAL MEDICINE AND 
OTTRADAM: 
80% of Patients got relief from Pain, Morning stiffness, Inflammation and 
Restriction of movements. 
About 70-75% of Patients had the progress in their clinical features when treated 
with providing Internal medicine, External medicine and Ottradam. 
 
RESULTS: 
GROUP I SUBJECTS (INTERNAL MEDICINE): 
Among 20 cases, 14 cases (70%) had pain and swelling of PIP joints, 12 cases 
(60%) had morning stiffness > 1hr, 8 cases (40%) had tenderness, 4 cases (20%) had low 
grade fever, 19 cases (95%) had arthritis of more than 3 joints, 11 cases (55%) had 
restriction of movements, 6 cases (30%) had loss of appetite before treatment. But after 
treatment only 3 cases (15%) had pain and swelling of PIP joints, 2 cases (10%) had 
morning stiffness > 1hr,1 cases (5%) had tenderness, 1 cases (5%) had low grade fever, 4 
cases (20%) had arthritis of more than 3 joints, 2 cases (10%) had restriction of 
movements, 1 cases (5%) had loss of appetite. 
 
GROUP II SUBJECTS (INTERNAL, EXTERNAL MEDICINE AND 
OTTRADAM): 
Among 20 cases, 11 cases (55%) had pain and swelling of PIP joints, 16 cases 
(80%) had morning stiffness > 1hr, 14 cases (70%) had tenderness, 6 cases (30%) had 
low grade fever, 15 cases (75%) had arthritis of more than 3 joints, 7 cases (35%) had 
restriction of movements, 10 cases (50%) had loss of appetite before treatment. But after 
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treatment only 2 cases (10%) had pain and swelling of PIP joints, 3 cases (15%) had 
morning stiffness > 1hr, 2 cases (10%) had tenderness, 1 cases (5%) had low grade fever, 
4 cases (20%) had arthritis of more than 3 joints, 1 cases (5%) had restriction of 
movements, 2 cases (10%) had loss of appetite. 
 
OVERALL RESULTS: 
Among 40 cases, 34 cases (80%) had good improvement, 4 cases (10%) had 
moderate improvement and 4 cases (10%) had mild improvement. 
 
GRADING OF RESULTS: 
There is certainly marked improvement noted in the grading of the result before 
and after treatment. 
 
STATISTICAL REPORT: 
Inference: 
Since the p value is significant in all clinical features, so there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid arthritis). Hence it is concluded that the treatment was 
effective and significant. 
  
7. summary 
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SUMMARY 
The primary purpose of the study is to analyse my trial drugs in the disease 
Uthiravadha Suronitham (Rheumatoid Arthritis). 
Many literature reviews in both siddha and modern textbooks has been collected 
for the disease Uthiravadha Suronitham and Rheumatoid Arthritis respectively. Literature 
reviews has also been collected from siddha and modern textbooks as well as from 
various articles for the ingredients in the trial drugs. 
The trial drugs Internal and External medicine along with Ottradam has been 
approved by Institutional Ethics Committee (IEC No: GSMC-CH-ME-2/014/2017). 
After getting proper permission from the Institutional Animal Ethics 
Committee No: (IAEC No: LV/07/CLBMCP/2018). The clinical trial is also registered 
in Clinical Trial Registry of India (CTRI/2018/05/01360). 
Acute and Sub-acute Toxicity for the trial drug RAJALOGA NAATHARASA 
PARPAM was carried out in Wistar albino rats. 
Standardization and Quality Evaluation(NRS/AS/0202/01/2019) for the trial 
drug RAJALOGA NAATHARASA PARPAM was carried out in several methods which 
includes Organaoleptic characters, Qualitative and Quantitative Analysis, Heavy 
Metal Analysis, Phytochemical analysis. 
Pharmacological study (Immunomodulator activity) for the trial drug 
RAJALOGA NAATHARASA PARPAMwas done in-vitro method by using RAW 264.7 
Cell line. 
The patients with raised CRP, Anti-CCP along with the clinical symptoms 
mentioned in inclusion criteria were included in my clinical trial. 
Before conducting the clinical trial, the details about the trial drug and my study 
was informed to the patients in their vernacular language and their signature were 
obtained in the consent forms. Separate Proforma was maintained for each and every 
patient. 
After completing all the above studies and procedures, the clinical study was 
conducted in 40 patients. Out of which 20 were treated with Internal medicine (Group I) 
and 20 patients were treated with Internal and External medicine with Ottradam therapy 
(Group II). 
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The trial drugs RAJALOGA NAATHARASA PARPAM at the dose of 60 mg 
(twice daily) and PARUTHI THYLAM of 60 ml (per week) with OTTRADAM were 
administered to the above said group patients for 21days. 
The Efficacy of the trial drugs were assessed by Reduction in Inflammation of 
joints, Morning stiffness, CRP and Anti-CCP. 
The Safety of the trial drugs were assessed by comparing the safety parameters 
LFT & RFT before and after treatment.  
Hence the Statistical Analysis helps to evaluate the EFFICACY and SAFETY 
of the trial drug RAJALOGA NAATHARASA PARPAM (Internal), PARUTHI 
THYLAM (External) with MARIKOZHUNTHU OTTRADAM (External therapy) 
in Uthiravadha Suronitham (Rheumatoid Arthritis). 
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CONCLUSION 
As expressed before, various studies have conducted to evaluate whether the trial 
drug Rajaloga naatharasa parpam (Internal) along with Paruthi thylam (External) and 
Marikozhunthu Ottradam (External therapy) is Efficacy and Safety for the disease 
Uthiravadha suronitham (Rheumatoid Arthritis). 
Heavy Metal Analytical study clearly shows that sample has permitable limit the 
traces of heavy metals such as Mercury, Arsenic and lead. Further there is no trace of 
cadmium in the sample Rajaloga naatharasa parpam. Thus the drug Rajaloga naatharasa 
parpam is recommended for the clinical trial. 
Phytochemical study indicates the presence of rich Phenol, Tanin, Protein and 
Saponins. This analysis clearly proves that the ingredients of Rajaloga naatharasa parpam 
has possess Anti inflammatory and Immunomodulator  activity which helps to reduce the 
inflammation in RA. 
Acute oral toxic study and Repeated dose 28-day oral toxic study was done in 
Wistar Albino Rats for the sample Rajaloga naatharasa parpam and hence no other 
significant changes were observed in their behavior, body weight, water intake, food 
intake, LFT, RFT.  It proves that the trial drug Rajaloga naatharasa parpam is safe for 
animal models. 
In Pharmacological study, 25μg/ml concentration of Rajaloga naatharasa parpam 
has rich level of nitrate (446.49μg) and thus proven to be a potent IMMUNO 
MODULATOR  drug. 
Overall clinical study with the trial drugs (Internal, External medicine with 
Therapy) for 21days reveals that 80% cases have Good improvement, 10% cases have 
Moderate improvement and 10% cases have mild improvement in patients with 
Uthiravadha suronitham (RA). 
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Name and Address of the Researcher Dr.D.Suganya  
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 
Sample –ID Raja Loga Naatharasa Parpam – RLNP 
Parameter Requested  for Analysis Phytochemical Analysis 
Sample Received In Person 
Method of Analysis PLIM- Protocol – ASU Formulations 
Analysis Type Physicochemical Analysis  
Result of Analysis Test and Analytical Reports Attached As 
Annexures 
Phytochemical Analytical Report 
S.NO TEST OBSERVATION 
1 ALKALOIDS   - 
2 FLAVANOIDS   - 
3 GLYCOSIDES   - 
4 STEROIDS   - 
5 TRITERPENOIDS   - 
6 COUMARIN   - 
7 PHENOL   + 
8 TANIN   + 
9 PROTEIN   + 
10 SAPONINS   + 
11 SUGAR   - 
12 ANTHOCYANIN   - 
13 BETACYANIN   - 
 
+ -> Indicates Positive and - -> Indicates Negative 
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Project ID 
NRS/AS/0202/01/2019 
Name and Address of the Researcher 
Dr.D.Suganya  
Government Siddha Medical College, 
Chennai, Tamil Nadu, India 
Parameter Requested for Analysis 
Heavy Metal analysis by AAS 
Sample Received 
In Person 
Sample –ID 
Raja Loga Naatharasa Parpam – RLNP 
Description of the Sample Solid 
Method of Analysis                                                                                          
Instrument 
Extraction Solvent 
                                    
Model: AA 240 Series                                                                          
HCl and HNO3 
Analysis Type Third Party Analysis  
Date of Analysis 28/4/2019 
Result of Analysis Test Report Attached as Annexure 
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HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for detecting 
metals and metalloids in environmental samples. The total heavy metal content of the sample 
was performed by Atomic Absorption Spectrometry (AAS) Model AA 240 Series. In order to 
determination the heavy metals such as mercury, arsenic, lead and cadmium concentrations in 
the test item. 
Sample Digestion 
Test sample was digested with 1mol/L HCl for determination of arsenic and mercury. 
Similarly for the determination of lead and cadmium the sample were digested with 1mol/L of 
HNO3. 
Standard reparation 
 As & Hg- 100 ppm sample in 1mol/L HCl 
 Cd & Pb- 100 ppm sample in 1mol/L HNO3 
 
Test Report 
Name of the Heavy 
Metal 
Absorption Max 
Λ max 
Result Analysis Maximum Limit 
Mercury 253.7 nm 1.04 ppm 1 ppm 
Lead 217.0 nm 5.11 pm 10 ppm 
Arsenic 193.7 nm 0.04 ppm 3 ppm 
Cadmium 228.8 nm BDL 0.3 ppm 
BDL- Below Detection Limit 
 
Report and Inference 
 Results of the present investigation have clearly shows that the sample has traces of 
heavy metals such as Mercury, Arsenic and lead.  Further there is no trace of cadmium in 
the sample presented for analysis. 
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Project ID NRS/AS/0202/01/2019 
Name and Address of the Researcher Dr.D.Suganya  
Government Siddha Medical College, Chennai 
Tamil Nadu, India 
Parameter Requested by the Customer for Analysis Elemental Analysis 
Sample Received In Person 
Sample –ID Raja Loga Naatharasa Parpam – RLNP 
Description of the Sample Solid 
Method of Analysis 
Instrument 
 
 
EDAX Elemental Analysis 
Analysis Type Third Party Analysis  
Date of Analysis 19/02/2019 
Result of Analysis Test Report Attached 
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Methodology 
Sample subjected for particle size and elemental analysis using FE- SEM- SUPRA 55.,CARL ZEISS, 
Germany. The EDX detector system performs a simultaneous display of all mid-energy (1-20 keV) X-rays 
collected during any individual analysis period and the energy of the X-rays is reproduced as a spectrum, 
which is a histogram plot of number of counts against X-ray energy. The spectrum contains both semi-
qualitative and semi quantitative information. The position of a peak in the spectrum, its energy, identifies 
the element; the area under the peak is proportional to the number of atoms of the element in the irradiated 
area. 
                     Elemental Analysis Report 
Element Weight% 
C 12.44 
O 52.38 
Na 1.04 
S 0.88 
Ca 33.27 
Total 100.00 
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Spectrum of Elemental Composition of the Test Sample 
 
Electron Microscopic Observation of Particle Size for the Test Sample 
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Mean 
26.37 
Std. Deviation 
5.343 
Std. Error 
2.39 
 
REPORT 
Microscopic observation of the particle size analysis reveals that the average particle size of the sample 
was found to be 26.37 ± 5.3 nm  
Reference 
1.Morgan AJ. X-ray microanalysis in electron microscopy for biologists. Oxford University Press; 1985 
2.Takashi Hiroi. Measurement of Particle Size Distribution in Turbid Solutions by Dynamic Light Scattering 
Microscopy. J Vis Exp. 2017; (119): 54885. 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                                   CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
An open clinical evaluation on “Uthiravadha suronitham (Rheumatoid 
arthritis)” with  Siddha trial drug “RAJALOGA  NAATHARASA  PARPAM” 
(Internal), “PARUTHI  THYLAM” (External) and “MARIKOZHUNTHU 
OTTRADAM” (External therapy). 
 
FORM l - SCREENING AND SELECTION PROFORMA 
1. OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………                                              4.GENDER: …………....... 
5. OCCUPATION: ………………………………..   6.INCOME:   ………………… 
7. ADDRESS:    ……………………………………    
…………………………………… 
…………………………………… 
8. CONTACT NO:    ……………………………………              
 INCLUSION CRITERIA: 
 Age : 18-60 years                                                                   YES/NO 
 Sex : both male & female                                                       YES/NO 
 Low grade fever                                                                     YES/ NO 
 Morning stiffness>1hours                                                       YES/NO 
 Arthritis of ≥3 joint area of the possible 28 joints                   YES/NO    
 Arthritis of hand joints[MCPs , PIPs , WRISTs]                     YES/NO      
 Symmetric swelling –same joints on both sides                      YES/NO 
 Redness of joints                                                                      YES/NO 
 Rheumatoid nodules                                                                YES/NO 
 Serum rheumatoid factor [RA factor] +ve / –ve                      YES/NO 
 Anti ccp  +ve                                                                            YES/NO 
 CRP                                                                                           YES/NO 
 Patient willing to sign the cosent form                                      YES/NO 
 
   EXCLUSION CRITERIA 
 Systemic lupus erythematosis 
 Sub acute bacterial endocarditis 
 Rheumatic fever 
 Gouty arthritis 
 Carries spine 
 Ankylosing spondylitis 
 Psoriatic arthritis 
 Osteomyelitis 
 Renal failure 
 Tumours 
 History of long term intake of steroid 
 HIV 
 Progressive systemic sclerosis 
 Pregnancy&lactation 
 Chickungunya 
 
ADMITTED TO TRIAL:                          YES                        NO   
 
 
If yes,       OPD/IPD 
 
 
 
Date:          
Station: 
 
 
 
Signature of the Guide:                                              Signature of the Investigator:   
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA  NAATHARASA  PARPAM” (Internal), 
“PARUTHITHYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                     FORM lI -HISTORY TAKING PROFORMA 
1. SERIAL NO OF THE CASE: …….           
2.OP / IP NO: ...........................................  
3. NAME: …………………………………………  
4. AGE: ……..                                                      5. GENDER: …….. 
5. OCCUPATION: …………………………     6. INCOME:   ………………….. 
7.COMPLAINTS & DURATION:   
 
 
 
8.CHIEF COMPLAINTS WITH DURATION 
                                                                  Presnt                   Absent                    
Duration 
 
Low grade fever 
Pain in the joints 
Tenderness & swelling of joints 
I. MCP 
II. PIP 
III. Wrist 
IV. Ankle 
V. Knee 
    Morning stiffness 
    Restriction of joint movements 
    Loss of appitite 
   Rheumatoid nodules 
   Deformities 
9.HISTORY OF PRESENT ILLNESS 
  1.Onset of disease              :          Acute                             Insidious 
  2.Duration of disease          : 
  3.Treatment given so far     :   Ayurvedic medicine              Modern medicine 
                                    
                                                      Unani                               Homeopathy 
 
10.PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES, SPECIFY 
DURATION/QUANTITY 
Smoking    
Tobacco Chewing    
Alcoholism    
Narcotic drugs    
 
11. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY 
 
 
12. DIETARY HABIT:     
             1.Vegetarian                                               2.Non-vegetarian 
13. FAMILY HISTORY: 
      Whether this problem runs in family? 
            1. Yes                               2.No         
  If yes, mention the relationship of affected person(s) --------------------- 
  History of previous investigations if any ------------------------------ 
14.MENSTURAL AND OBSTETRIC HISTORY: 
 
 
Date:          
Station: 
 
                               
Signature of the Guide:                                                          Signature of the 
Investigator:   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
   POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM  
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA NAATHARASA PARPAM”(Internal), 
“PARUTHI THYLAM”(External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                                                              FORM III  
         CLINICAL  ASSESSMENT  ON  ENROLLMENT  AND  ON  VISITS  
1. SERIAL NO: …………………   
2. OP  NO        :    ………………….. 
3. IP NO           :  …………………….. 
4. BED NO      :    ……………………….   
5. NAME         : ……………………………   6.AGE: ……     7.GENDER: 
.................   
 
8. RELIGION: H/C/M/O 
 
9. SOCIAL STATUS :  ……………………… 
 
10. OCCUPATION   :  ………………………… 
 
11.  DATE OF INITIAL ASSESSEMENT  
 
 
SIDDHA SYSTEM OF EXAMINATION 
 
1. THEGI  (BODY CONSTITUTION): 
1. Vathaudal 
            2. Pithaudal 
            3. Kabaudal 
            4. Thonthaudal 
 
 
 
 
 
 2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji 
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai  
 
3. KAALAM: 
            1. Kaarkaalam (Aavani-Puratasi) 
            2. Koothirkaalam (Ippasi-Kaarthigai) 
            3. Munpanikaalam (Maargazhi-Tai) 
            4. Pinpanikaalam (Maasi-Panguni) 
            5. Ilavenilkaalam (Chithirai-Vaigasi) 
            6. Muthuvenilkaalam    (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
 
5. PORI PULANGAL (SENSORY ORGANS):                  
   Normal     Affected   
1. Mei                         ................................................................... 
2. Vaai(Naaku)   ............................................................. 
3. Kan                                  ................................................................. 
4. Mookku                          ................................................................. 
5. Sevi                                      ................................................................. 
 
6. KANMENDRIYAM (MOTOR ORGANS) :         
  Normal    Affected  
1. Vaai                                    ................................................................. 
2. Kaal                                  ................................................................. 
3. Kai                                     ................................................................. 
4. Eruvaai                                 ................................................................. 
5. Karuvaai                               .................................................................    
 
7. KOSANGAL (SHEATH):          
 Normal    Affected  
1. Annamaya kosam  .      ....                  ........................................................... 
2. Pranamaya kosam                                  .......................................................... 
3. Manomaya kosam          ....................................................... 
4. Vignanamaya kosam     ....                    ................................................... 
5. Anandhamaya kosam     ...         .................................................... 
 
8. UYIR THATHUKKAL (THREE HUMOURS): 
       8a.VALI:              Normal   Affected 
1. Praanan                                      .............................................................. 
2. Abaanan                                ................................................................. 
3. Viyaanan                                .............................................................. 
4. Uthaanan                                 ................................................................. 
5. Samaanan                                 ................................................................. 
6. Naagan                                     ................................................................. 
7. Koorman                                  ................................................................. 
8. Kirukaran                                 .............................................................. 
9. Devathathan                              ............................................................. 
10. Dhananjayan  .            .......................................................... 
 
8b. AZHAL:              Normal    Affected 
1. Analam                                     ................................................................. 
2. Ranjagam                              ............................................................... 
3. Saathagam                              ................................................................. 
4. Aalosagam                               ................................................................. 
5. Praasagam                                ................................................................. 
 
 
  8c.IYAM:                  Normal    Affected 
1. Avalambagam                         ................................................................. 
2. Kilethagam                              ................................................................. 
3. Pothagam                                 ................................................................. 
4. Tharpagam                               ................................................................. 
5. Santhigam                                ................................................................. 
9. EN VAGAI THERVU (EIGHT FOLDS OF EXAMINATION): 
   1.Naadi  :                 ………………………................. 
   2.Parisam :                ………………………................. 
   3.Naa            :               ............……………….................. 
   4.Niram           :               .....……………………................. 
   5.Mozhi    :               .....……………………................. 
   6.Vizhi            :                ...................................................... 
   7.Malam        :               ..................................................... 
   8. Moothiram :               …………………………………. 
         8a.Neerkuri: 
Niram      :       1.Whitish                                2. Yellowish      
                        3.Straw coloured                     4. Crystal clear 
Edai   :       1.Present                        2.Absent 
Manam:                1.Nil                     2.Reduced                    3. Increased 
Nurai :                 1. Normal             2. Increased                  3. Decreased  
Enjal : 
 
          8b: Neerkuri (Oil –in urine sign): 
                                 VathaNeer                           PithaNeer             KabaNeer 
 
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS):                                  
                                               Normal      Affected   
 1. Saaram                                               ....................................................... 
2. Senneer    ..          ..................................................... 
3. Oon                                                  ...................................................... 
4. Kozhuppu                                      ..................................................... 
5. Enbu                                      .....................................................
 6.Moolai                                                         ..................................................... 
           7. Sukkilam / Suronitham                     ...................................................... 
 
GENERAL EXAMINATION: 
 
1. Body weight [Kg]    :                      
2. Height [cm]                        :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mmHg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.  :   
                                                                Yes              No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
VITAL ORGAN EXAMINATION:                                                      
      Normal          Abnormal 
1.  Heart  
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION: 
     Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Genital urinary system     
6.  Endocrine system        
 
CLINICAL  ASSESSMENT AND PROGRESS 
 
S.NO CLINICAL  
FEATURES 
BEFORE  
TREATMENT 
AFTER  TREATMENT 
7
th 
 DAY 
14
th 
 DAY 
21
th
 
DAY 
1. Pain in the joints     
2. Morning stiffness     
3. 
 
 
 
 
 
 
Swelling and tenderness  
of joints 
 MCP 
    
 PIP     
 Wrist     
 Ankle     
 Knee     
4. Fever     
5. Loss of appetite     
6. Anaemia     
7. 
 
Restriction of joint 
Movements 
    
8. Subcutaneous nodules     
9. Deformities     
 
0 – nil 
+ - mild 
++ - moderate 
+++ - severe 
 
 
 
 
PAIN ASSESMENT: VISUAL ANALOGUE PAIN SCALE; 
 
 
 
 
CLINICAL EXAMINATION 
 
I . INSPECTION: 
 
 
1st 
 
Day 
7
th 
 Day 
14
th
 day 21
th
 
day 
Skin over 
joints 
Normal/ 
Affected 
   
Swelling Mild/ 
Moderate/ 
Severe 
   
Deformities Present/ 
Absent 
   
Muscle 
wasting 
 1.Proximal 
 2.Distal 
Present/ 
Absent 
   
 
 
  
 
 
 
 
 
 
II. PALPATION: 
 
 1st  day 7
th
 day 14
th
 day 21
th
  day 
Local temperature     
Tenderness Mild/ 
Moderate/ 
Severe 
   
Evidence of intra articular 
fluids 
Present/ 
Absent 
   
Rheumatoid vasculitic lesions Present/ 
Absent 
   
Local lymphadenopathy 
 
Present/ 
Absent 
   
Pitting oedema Present/ 
Absent 
   
Subcutaneous nodules Present/ 
Absent 
   
 
III. MOVEMENTS: 
 
 1
st
 
 Day 
7
th
 
Day 
14
th
 day 21
th
  day 
Stiffness Present/ 
Absent 
   
Rotation Normal/ 
Affected 
   
Flexion Normal/ 
Affected 
   
Extension Normal/ 
Affected 
   
 
 
Date :      
 
Station: 
 
 
Signature of the Investigator: 
 
 
Signature of the guide: 
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An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA  NAATHARASA  PARPAM”(Internal), 
“PARUTHI THYLAM”(External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                        FORM IV: LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE: …………………   
2.IP/OP  NO: ......................................   
3. NAME: ……………………………    
4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS: 
BLOOD INVESTIGATIONS NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gm/dL) M:12-15 
F:11.5-14 
  
T.RBC (millions cells / Cu.mm) M:4.0-5.5 
F:3.5-4.5 
  
ESR (mm) ½ hr. M:6-12 
F:7-18 
  
1 hr   
T.WBC (Cells / Cu.mm) 4000-11000   
Differential Count 
(%) 
Polymorphs      40-75   
 
Lymphocytes      20-40   
 
Monocytes       2-10   
 
Eosinophils        1-6   
 
Basophils         0-1   
 
BLOOD INVESTIGATIONS NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood glucose (mg/dl) Fasting 70-100   
 
PP 80-140   
Serum Cholesterol(mg/dl) < 200   
Renal Function Test(mg/dl) 
 
Blood urea   7-20   
Serum creatinine   0.6-1.2   
Liver function test 
 Alkaline phosphatase  
(IU/L) 
  44-147   
 SGOT (mg/dl)   5-40   
SGPT (mg/dl)   7-56   
Specific Investigation 
RA factor (IU/ml)    < 15   
Anti CCP(u/ml)     < 20   
CRP (mg/dl)      < 3    
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
               Sugar   
Deposits   
Date:          
Station: 
 
Signature of the Guide:                                           Signature of the Investigator:   
 
 
 
 
                          GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
          POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM  
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA  NAATHARASA  PARPAM”(Internal), 
“PARUTHI THYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                                    FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction. 
            I   consent voluntarily to participate in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
"I have received a copy of the information sheet/consent form" 
Date: 
Signature of the participant:                                       Signature of the Investigator                                     
In case of  illiterate participant: 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and  the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.”        
          Date: 
                                                         
                                                                                  Left thumb Impression of the Participant 
        Signature of a witness: 
(Selected by the participant bearing no  
connection with the survey team)                   
                                                                                 Signature of participant:                                
Date:                                                 Signature of the Investigator:   
Station:                                                                     Signature of the Guide: 
                                
                       ,     -600 106 
                                                   , 
                    . 
                                      . 
                                           
                           . 
    :                                                                                                             :                       
   :                                                                                                          : 
                                      
                                   ,            
                                                 
         ,                                    
                                              
            . 
                                                  
                                         
                     .                           
                                                    
          ,                                            
                                       . 
                                                                                           
    :                                                           : 
   :                                              :  
 
    :                                                       :                           
   :                                         :  
 
                                                                                                                   
                 GOVERNMENT SIDDHA MEDICAL COLLEGE  
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                                             CHENNAI-600 106 
              POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM  
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with siddha trial drug “RAJALOGA  NAATHARASA  PARPAM”(Internal), 
“PARUTHI THYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                        FORM VI - WITHDRAWAL FORM 
SI NO:                  
OP /IP NO:                                               
NAME: 
AGE / GENDER :                
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                    Yes/ No 
• Irregular treatment:                                               Yes/ No 
• Shift of locality :                                                   Yes/No 
• Increase in severity of symptoms:                        Yes/No 
• Development of severe adverse drug reactions:     Yes/No 
 
 
Date:    
Station: 
 
Signature of the Guide:                                              Signature of the Investigator:   
 
 
 
                               GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA NAATHARASA PARPAM”(Internal), 
“PARUTHI THYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                               FORM VII – PATIENT INFORMATION SHEET 
Name of  Investigator: Dr.D.SUGANYA 
Name of the college:  Govt. Siddha Medical College, Arumbakkam, Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       D.Suganya studying M.D (Siddha) at Govt.Siddha Medical College, Chennai,  
is doing a clinical trial on ‘‘Uthiravadha suronitham (Rheumatoid arthritis)”. It is 
becoming a most common disease, occurring throughout the world. In this regard, I 
am in need to ask you few questions. I will maintain confidentiality of your comments 
and data obtained. There will be no risk of disclosing your identity and no physical, 
psychological or professional risk is involved by taking part in this study. Taking part 
in this study is voluntary. No compensation will be paid to you for taking  part in this 
study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
              If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine 
         GOVERNMENT SIDDHA MEDICAL COLLEGE 
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
with Siddha trial drug “RAJALOGA  NAATHARASA  PARPAM”(Internal), 
“PARUTHI THYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
                                                               FORM VIII 
             DIETARY ADVICE FORM 
               : 
     : கத்திரி ஧ிஞ்சு, முருங்கக ஧ிஞ்சு, அயகப ஧ிஞ்சு ஆகினகய  
         சேர்க்க சயண்டும். 
 ீ    : கரிோக஬, ப஧ான்஦ாங்கண்ணி, நணத்தக்கா஭ி, முருங்கககீகப,   
   ஧ேக஬கீகப, ேிறுகீகப, க஫ிசயப்஧ிக஬ ஆகினகய சேர்க்க சயண்டும். 
     : நாதுக஭, ஆப்஧ிள், யாகம, ச஧ரீச்கே, அத்தி, திபாட்கே, பகாய்னா,  
         ஆபஞ்சு, எலுநிச்கே, ஥ாயல், தக்கா஭ி ஆகினகய சேர்க்க சயண்டும். 
       : சகாதுகந, ஓட்ஸ், சோனா஧னீ்ஸ், ஧ட்டாணி, பகாண்கடகடக஬,  
              எள், ஧ாதாம் ஆகினகய சேர்க்க சயண்டும். 
     : பயள்஭ாட்டு க஫ி, ஈபல், எலும்பு நஜ்கை ஆகினகய சேர்க்க   
           சயண்டும். 
     : ப஥ய்,஧ால் 
              : 
 நந்தப் ப஧ாருள் 
 உருக஭க் கிமங்கு 
 அகத்திக் கீகப 
 பு஭ிப்பு 
 புககனிக஬ 
 நது அருந்துதல் 
                           GOVERNMENT SIDDHA MEDICAL COLLEGE 
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
An open clinical evaluation on Uthiravadha suronitham (Rheumatoid arthritis) 
Siddha trial drug “RAJALOGA NAATHARASA PARPAM”(Internal), 
“PARUTHI THYLAM” (External) and “MARIKOZHUNTHU OTTRADAM” 
(External therapy). 
 
                         FORM IX   - ADVERSE REACTION FORM 
SERIAL NO:                                                                                                           
OP/IP  NO:  
NAME:                                                            
AGE:                                         GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:    
TIME: 
DESCRIPTION OF ADVERSEREACTION: 
 
 
 
 
 
                                                                        SIGNATURE OF THE INVESTIGATOR 
    DATE        : 
    STATION  : 
                                                                                       SIGNATURE OF THE GUIDE 
 
 
 
 
 
 
